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Introduction
1

General Introduction
Part of the introduction has been published, entitled
An overview of different systems: The Bone-Anchored Hearing Aid. 
In: Implantable bone conduction hearing aids. 
Advances in Oto-Rhino-Laryngology.
Dun CAJ
Faber HT
de Wolf MJF
Cremers CWRJ
Hol MKS
Adv Otorhinolaryngol. 2011;71:22-31.
1.1
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General introduction
The bone anchored hearing aid (Baha) has been developed in Gothenburg, Sweden
by Håkansson, Tjellström and coworkers.1 Tjellström reported the application of extra-
oral implants in the temporal bone region in 1977.2 Up until that moment, titanium
implants were used as a fixture for an intraoral dental bridge in an edentulous jaw.3
The implantation of an implant in the temporal bone gave way for the application of a
hearing aid in the form of a bone conductor. Since the first application of the Baha,
bone anchored hearing implants (BAHI) have been developed into a means of hearing
rehabilitation for patients with conductive and mixed hearing loss. Nowadays, Baha
(Cochlear) and Ponto (Oticon) devices are commercially available.
Anatomy and physiology of the hearing ear
The ear and its auditory system consists of three sections; the outer ear, middle ear
and the inner ear. The outer ear contains the auricle, or pinna and the external
acoustic meatus. The middle ear contains the tympanic membrane, the ossicles and 
their associated muscles. The inner ear holds the cochlea and the auditory nerve
(Figure 1). The cochlea is a snail like organ which consists of three curled up canals.
The upper canal, the scala vestibuli and lower canal, the scale tympani contain
perilymph. In between these two is the scala media situated filled with endolymph
(Figure 2). These scalae are separated by membranes; the scala vestibuli and scala 
media are separated by the Reissner’s membrane and the scala media and scala 
tympani is separated by the basilar membrane.
Sound is a pressure wave which is defined by a frequency in Hertz and an
amplitude in decibels. The sound reaches the auricle which directs the sound into the
external acoustic meatus. From there the sound reaches the tympanic membrane,
ossicles and then the cochlea at the oval window as vibrations.
These vibrations cause a pressure wave of the perilymph in the scala vestibuli
and because the perilymph cannot be compressed, the wave passes through to the
scala tympani onto the round window. This pressure wave causes the basilar
membrane to vibrate; the stiffness of the basilar membrane dictates at what distance
from the oval window the basilar membrane moves as a function of frequency. 
The basilar membrane holds the organ of Corti. This organ contains two types of hair
cells, called stereocilia (Figure 3). The inner hair cells are sensory cells that are 
attached caudal on the basilar membrane and cranial to the tectoral membrane. 
When a pressure wave causes the basilar membrane to vibrate a relative motion occurs
between the basilar and the tectoral membrane. The sensory stereocilia will 
subsequently move and bend which causes a depolarisation. The more displacement,
the more depolarisation is sent through the cochlear nerve to the brain where it is
12
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Figure 1 Anatomy of the ear and the components for hearing and vestibular function.
(Courtesy of Scott & White Healthcare Community)
Figure 2 Transmission of sound from the external acoustic meatus to the cochlear
nerve. (Courtesy of Drake: Gray’s Anatomy for Students, 2nd edition)
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interpreted as sound. This typically works for loud sounds of approximately 60 dB HL 
or louder. The outer hair cells have a supportive role for the sensory cells. They have
an active mechanism to increase the vibrations of the basilar membrane for low level
sounds. With this mechanism an increased movement will activate the sensory inner 
hair cells. As a consequence the input dynamic range of the ear is extended from
60-110 dB HL to 0-110 dB HL.
Figure 3 The cochlea contains three spiraled canals, the middle canal containing the
organ of Corti. This organ converts mechanical energy into electrical energy as the 
inner hair cells create a pulse when stimulated. (Courtesy of Answers Magazine)
14
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Physiology of bone conduction 
The physiological concept behind the bone conduction (BC) pathway is still not
entirely understood. Tonndorf (1966) described, from studies primarily in cats, several
modes stimulating the basilar membrane during bone conduction excitation.4 In more 
recent years, an update was published by Stenfelt and Goode in which they describe 
seven different pathways for the perception of sound by bone conduction.5 The most
important pathways for patients with conductive hearing loss are: 1.Inertia of the
cochlea fluids; 2.compression of the cochlear walls; and 3.pressure transmission
from the intracranial fluids through the third window of the cochlea.
The importance of these components for bone conduction perception depends
on the frequency. Stenfelt et al. showed that up to 4 kHz the most important way in
which the basilar membrane is stimulated seems to be the first pathway; fluid inertia
within the cochlea.5,6 As these fluids are incompressible, they will vibrate as a whole
and in phase with the bone. However, the cochlea has two mobile windows, the oval
and round window. Therefore, inertia of the inner ear fluids will result in longitudinal
fluid waves traveling from one window to the other, which causes the basilar
membrane to vibrate. The second pathway seem to play a role above 4 kHz because 
of asymmetric compression of the cochlear walls.5
The third cochlear window refers to all connections between the cochlea and the
intracranial space. As mentioned before, fluid movement is only possible when two
mobile windows are present. The third window will become of importance if one the 
two windows between cochlea and middle ear is obstructed as is the case in
otosclerosis.7
Von Békésy showed that the basilar membrane responds equally to air-conducted
as to bone conducted sound.8 Distinction between air conduction and bone 
conduction stimulation at the basilar membrane level is not possible. However, the
bone conduction route towards the basilar membrane is less efficient than the air 
conduction route. Therefore, bone conduction hearing aids are primarily used for 
hearing loss where air conduction hearing aids are contraindicated.  
Osseointegration
The BAHI consists of three elements: the sound processor, abutment and a titanium
implant. The titanium implant is surgically placed in the temporal bone where it is 
fixed in a natural process called osseointegration. The definition of osseointegration
is the process of a direct structural and functional connection between a titanium
fixture (implant) and the surrounding living bone.10 Successful osseointegration relies 
on several factors, concerning the implant as material, design and surface of the 
implant. The degree of stability in surrounding bone can be altered by the status of 
the bone, the surgical technique and loading conditions.11 This combination of factors
determines osseointegration. 
15
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Implant stability is an important factor in the success of the BAHI. Clinicians would
like an objective measure as an indication for safe loading of the implant with the
sound processor. The application of a simple, clinically applicable, non-invasive test
to assess implant stability and osseointegration is considered highly desirable. If an
absolute measure peroperatively would indicate a safe loading, patients might benefit
from their hearing rehabilitation sooner by an earlier loading of the implant with the
hearing device. Next to that, it might be indicative for possible implant loss.
Resonance frequency analysis
Albrektsson has studied ways to determine the level of osseointegration by percussing
a metal instrument against the implant and analyse the transmitted sound.12 This
method had its pitfalls since there was no typical sound diagram for osseointegrated
implants to acquire a level bone resorption or implant stability. Computed tomography
(CT) is a way of evaluating bone anatomy but the metal implants produce artifacts
which renders the CT to limited use.13 The cone beam CT might provide valuable 
information in implants by scanning the bone around the implant.14
Figure 4 Illustration of the Baha as a semi-implantable percutaneous bone conduction
hearing device coupled to the skull by an osseointegrated titanium fixture. (Courtesy
of Advances in Oto-Rhino-Laryngology9).
16
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In 1996 Meredith et al. published a method to evaluate the level of osseointegration
with resonance frequency analysis (RFA).15 The change in stiffness observed in bone
surrounding an implant during healing was modeled by embedding implants in 
self-curing polymethylmethacrylate and measuring the resonance frequency at
periods during polymerisation. An increase in resonance frequency was observed
related to the increase of stiffness. After the first studies on RFA by Meredith et al. in
1996, Integration Diagnostics AB (Savedalen, Sweden) launched the Osstell® system 
in 2000. In the initial studies published by Meredith et al., the units of measurement
used were Hertz in a range from 3.5 to 8.5 kHz.15,16 The Implant Stability Quotient 
(ISQ) was subsequently developed, converting kHz units to ISQ values on a scale of 
1 to 100, with high values indicating high stiffness. The Osstell® system now features 
the Osstell Mentor®. It is a portable, hand-held device that emits signals by a 
transducer that is screwed directly onto the implant or its abutment. The resonance
frequency is determined and expressed as an ISQ value. The RFA has since been 
applied to monitor changes over time in terms of stability.17,18
At the recent OSSEO 2013 conference held in Newcastle upon Tyne in June 2013,
many oral reports were presented on outcomes over time with RFA-measurements
after implantation in adults and even children. These outcomes seem to improve over
time after implantation. Early loading series have been followed with RFA measurements.
Overview of bone anchored hearing implants
The Baha, a percutaneous Bone Anchored Hearing Aid was developed in Gothenburg,
Sweden as an inter-university research project between Chalmers University and the
Sahlgrenska University Hospital of Gothenburg. Their industrial partner was Nobel
Biocare, part of NobelPharma. Later on, the company became independent and
was renamed Entific Medical Systems. In 2005, Cochlear Company acquired Entific 
Medical Systems and has continued its activities as Cochlear BAS.
The device is a semi-implantable percutaneous bone conduction hearing device 
coupled to the skull by an osseointegrated titanium implant without interference from
intermediate tissue (Figure 4, Figure 5). A skin-penetrating abutment is attached to the
implant to facilitate coupling of the Baha sound processor. The direct coupling for the
mechanical vibrations to the skull provides effective sound transmission of around 5-15 dB 
higher than the transcutaneous coupling of conventional bone conduction devices.19
In 2008 the William Demant Foundation in Copenhagen started their Oticon
Medical company to develop implantable hearing solutions. Their first activity became 
the development of an imlpantable percutaneous bone anchored hearing device,
named Ponto.
Conventional transcutaneous bone conduction devices could give complications
because of the pressure of the transducer against the skin. The pressure can result
in headaches or skin reactions and insufficient pressure will reduce the gain of the
17
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device. On the other hand, the disadvantages of percutaneous implants include loss
because of poor osseointegration or trauma and skin reactions around the skin
penetrating part of the implant.
Until the mid eighties of the last century, the transcutaneous bone conduction
hearing aids were the only option available for bone conduction hearing. Its transducer
was attached to a steel spring, mostly driven by a body-worn hearing aid. A less powerful
option was a hearing aid as part of spectacles and this provided a bilateral application.
At present a.o. the Starkey company is providing updated classical bone conduction
solutions, including spectacle mounted solutions. The softband transcutaneous
bone conduction solution was initiated and introduced in 2001 in Nijmegen especially
to serve the very young children and to help overcome the delay for surgery for a
percutaneous bone anchored solution. At present this softband solution is available 
along a.o. Cochlear BAS, Oticon Medical and Starkey.20,21
An early semi-implantable transcutaneous bone anchored hearing solution was
introduced in the mid eighties of the last century. It was named Audiant. The output of 
that device was low compared to the available percutaneous Baha option at that time.
At present there are new transcutaneous semi-implantable bone conduction
solutions available like the Alpha 2 device by Sophono, the Bonebridge by Med-El
and the Cochlear Baha 4 system. Other solutions are on their way to become
commercially available like the Bone Conduction Implant developed by Håkansson
and his team in Gothenburg. An intra-oral system Soundbite is an alternative to these
options.
Figure 5 Coupling of the sound processor on the abutment.
(Courtesy of Oticon Medical)
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History of the bone conduction hearing aid
The first bone conduction hearing aid was described in 1876 by Professor Paladino
at the University of Napels.22 The device was a metal rod called the Fonifero. One end
was placed on the speakers’ larynx and the other end on the teeth or mastoid of the
listener. Various instruments later used the concept of conduction via the mastoid or
teeth. In the 1920s, with the development of the electric hearing aid, a conventional 
bone conductor was created with a microphone and vibrating transducer attached to
a steel headband. The separate location of microphone and transducer created 
problems with sound localisation. Many patients also found the steel headband 
uncomfortable and unsightly which led to a cosmetic alternative in the form of hearing
spectacles in 1954. The Baha, introduced in the mid 1980, has rendered these 
spectacles to limited use.
The first patients to be fitted with the Baha in the Netherlands had Baha surgery
in June 1988 in Nijmegen. It was a starting point for the development and spread of 
the Baha system in the Netherlands, and since, quite some research has been 
conducted in this field of bone conduction hearing. Up till 2013 more than 1500 
implants have been implanted in Nijmegen with a titanium implant for the use of 
hearing rehabilitation.
Indications
Bilateral mixed or conductive hearing loss (acquired/congenital)
The BAHI system is typically beneficial in patients with bilateral mixed or conductive
hearing loss who cannot be fitted with conventional acoustic hearing aids (behind the
ear or in the ear), including those with chronic otitis and those with congenital aural
atresia.23-25 In patients for whom reconstructive surgery is no longer considered a
feasible option and for whom a conventional bone conduction hearing aid has proven
to be inadequate, the BAHI has been shown to be of great benefit.26-31
Whereas most bilateral hearing-impaired patients with sensorineural hearing loss,
using acoustic hearing aids prefer binaural amplification over monaural amplification, 
binaural use of the BAHI in bilaterally impaired patients is not yet widely applied.32
There are several well-documented advantages of binaural hearing: (a) hearing 
sensitivity and speech recognition are improved due to bilateral summation when 
inputs received by the two cochleae are added together33-36, (b) speech recognition
is improved in noisy situations with spatially separated speech and noise sources,
and (c) directional hearing will be enabled in the horizontal plane.37 It has been
reported that bilateral BAHI use in adults has both significant subjective and objective
benefits.29-31,33,34,38,39 A disadvantage is cross stimulation: owing to the low damping of 
vibrations in bone, stimulation on one site of the head stimulates not only the ipsilateral
cochlea but also the contralateral one.40 That might hinder proper binaural hearing.
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Unilateral Conductive Hearing Loss
Unilateral conductive hearing loss (UCHL) in patients with a contralateral normal
hearing ear may involve the typical problems associated with unilateral hearing (i.e.,
poor sound localisation abilities and poor speech recognition performance in
noise).41-43 Agterberg et al.37 reported on sound localisation in patients with acquired 
UCHL fitted with a bone conduction device on their impaired side. Using varied
several stimulus characteristics, they demonstrated that BAHI users with acquired 
UCHL were able to localise sounds on the basis of restored binaural hearing.
However, some UCHL patients show fairly good directional hearing abilities in an 
unaided monaural condition.44,45
Single-sided deafness
In patients with unilateral sensorineural deafness, a BAHI positioned near the deaf ear
works as a transcranial CROS (contralateral routing of signal). Sounds received by the
BAHI system are transmitted to the functional contralateral cochlea via bone conduction
(cross stimulation). In principle, this will not result in stereophonic hearing, but the
negative effects of acoustic head shadow (poor understanding of a person who is
talking on the deaf side of the patient) might be decreased.46-49 The BAHI CROS
generates benefit when the speaker is located on the impaired side but background
noise on the impaired side can give a distraction and be a drawback. The degree of 
success seems to depend on the motivation of the patient, the listening demands
imposed by their lifestyle and working environment, and the level of transcranial
attenuation. In literature, it is reported that 25-30% of the patients finally apply for
implantation of the BAHI system after a trialperiod with the device on a headband.47,50
BAHI use in children
In part, BAHI application in children addresses different issues than in adults. Children
are known to have more immature and thinner bone. When implanted, they have a 
higher risk of soft tissue overgrowth, and, compared to adults, more implants are lost
within the first year after implantation.51 Furthermore, cleaning problems have been
reported.52,53 A considerable number of the children scheduled for implantation have
major congenital (syndromal) malformations of the ear, sometimes combined with
skull deformities, making surgery more challenging.54-57 For BAHI surgery in children,
there are additional considerations and precautions, including (a) at what age is
implantation possible, (b) what should be the minimal thickness of the skull bone, (c)
what is the best implant position, (d) is there a need to place a second sleeping
fixture, and (e) what can be done to prevent post surgery soft tissue reactions. It is of 
the utmost importance that children with bilateral conductive hearing loss be
rehabilitated early in life. Early and consistent stimulation is critical for optimal
development of speech and language.58
20
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For children who are too young for application of a percutaneous BAHI, and to
overcome the risks associated with BAHI surgery in specific syndromal cases, a
conventional transcutaneous bone conductor can be used like a BAHI Softband.20,21
This BAHI Softband comprises the BAHI sound processor connected to a soft elastic 
headband. Aided sound field thresholds with the BAHI Softband are almost equivalent 
to those obtained with a transcutaneous conventional bone conduction hearing aid.20
Speech and language development are greatly facilitated by the early use of bone
conductors like the BAHI Softband21, and currently, the BAHI Softband is generally
accepted as the first option and as the most convenient treatment for the very young
children with a bilateral conductive hearing impairment.
Lieu59 and Lieu et al.60 found that several children with unilateral hearing loss
demonstrate increased rates of school year failure and that they needed additional 
educational assistance. The Paediatric Workgroup on Hearing Aid Amplification61
summarised the literature in 2000 and stated that in children with unilateral conductive or
sensorineural hearing loss, amplification should be considered on a case-by-case basis,
centered on the child’s audiometric data, development, and communication needs.
BAHI use in patients with mental retardation
Initially, potential BAHI patients with mental retardation were excluded from treatment
due to doubts concerning care for the percutaneous implant and surrounding skin. 
Recently, however, patients with moderate mental retardation and conductive or
mixed hearing loss have received BAHI treatment. Use of the BAHI in this specific
patient group has been shown to be beneficial, improving both listening and learning
capabilities.62-64 Following these results, use of the BAHI has also been extended as
a valuable treatment option for this special patient group.
This indication of moderate mental retardation is now extended to the group of 
severe mental retardation and severe behavioural problems by the paediatric Birmingham
bone anchored hearing study group.65
BAHI surgery
Several types of surgery have been advocated in the past for the placement of the
titanium fixture. The main focus on these types of surgery has been to minimise the
occurrence of implant loss and skin reactions. To minimise implant loss, osseointe-
gration of the implant has to be as optimal as possible. This requires from the surgeon
a steady drilling technique where the bone should be traumatised as little as possible.
The occurrence of soft tissue reactions was considered to become less by reduction
of subcutaneous tissue. Hair follicles in an area of approximately 1 to 3 cm surrounding
the implant should be removed to avoid debris accumulating around the abutment.
In this period only titanium abutments with a 5.5 mm length were available to the
surgeon.66,67
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Figure 6 A-F. Presentation of the surgical technique applied to implant the BAHI
implant. A, Implantation location. B, Exposure of the periosteum. C, Drilling procedure
HUKWSHJLTLU[VM [OLÄ_[\YL\UKLYZHSPUL PYYPNH[PVU D, Area of subcutis reduction.
E, Subcutis reduction procedure. F, Healing cap and position of the yankauer (courtesy
of Otology Neurotology70).
22
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The surgical technique has been simplified over the years reducing the surgical
procedure from a 2-stage procedure to a 1-stage procedure in 1989.68,69 In the early 
nineties Cremers developed a simplified technique remaining a longitudinal incision 
to facilitate wide subcutaneous tissue reduction as illustrated in Figure 6. The implant
is nowadays subsequently being placed automatically into the mastoid with sufficient
cooling by saline irrigation. The skin is then placed back over the implant en stitched
back together to capsule the implant in a paramedian positioning. With a puncture in
the skin, the implant is retrieved through the puncture and a healing cap is placed
around which a gauze is draped for local pressure.70
Development of sound processors
;OLÄYZ[KL]PJLH]HPSHISL^HZ[OL)HOH/*TPKLPNO[PLZ-YVT[OH[TVTLU[VU
more sophisticated devices have been introduced, while taking the aesthetical
aspect into consideration. The size of the processor was minimised and different
colours were made available. The Baha HC100 was followed by the Baha HC200 and 
subsequently the Baha HC300, also known as the Baha Classic. The sound
WYVJLZZVYJVU[HPUZ[OLTPJYVWOVULHTWSPÄLYHUK]PIYH[PVU[YHUZK\JLYPUVULJHZPUN
The following Baha, the Baha HC 220, comprised a conventional powerful 
hearing aid (body worn) and a separate transducer. This device was called the
Superbass HC220. In 1998, that device was replaced by the Baha Cordelle. The
Baha Cordelle is still the most powerful body-worn bone conduction device on the
market, for patients with sensorineural hearing loss components between 35 and 60
dB hearing loss.71 The Baha Compact was developed in 1998 and had a more 
aesthetic appearance by being smaller than the Baha Classic. In 2005, the Baha
Compact was followed by the Baha Divino. This device has a digital sound processor
and a directional microphone. The Baha Divino is suitable for patients with a bone
conduction threshold of 35 dB hearing loss or better.72 The Baha Intenso, launched
in 2007, was more powerful than the Baha Divino, but less powerful than the Cordelle. 
The latest devices from Cochlear are the Baha BP100 and Baha BP110, which 
replaces the Baha Divino and Baha Intenso. These devices make use of advanced
signal processing.
5V^HKH`Z[OLYLHYLÄ]L[`WLZVM)HOHZV\UKWYVJLZZVYZJVTTLYJPHSS`H]HPSHISL
produced by the Cochlear Company: the Baha Divino, BP100, BP110, Intenso and
the Cordelle II. The updated Baha Cordelle II is the strongest member of the Baha 
family, developed particularly for patients who need a high gain.
In recent years, Oticon Medical entered the market with an alternative BAHI and
introduced the percutaneous Ponto® system.73 Oticon Medical produces three
sound processors: the Ponto, Ponto Pro and the Ponto Pro Power. While the Ponto 
is suitable for the same type and degree of hearing loss as Ponto Pro, Ponto Pro
Power targets more severe hearing losses and has slight differences in sound 
23
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WYVJLZZPUNHUKÄ[[PUNMLH[\YLZV]LY[OLYLN\SHY7VU[V(UL^KPYLJ[PVU^HZ[HRLUPU
2010 by Sophono Company who created a non-percutaneous semi-implantable 
bone conduction device, called the Alpha 1 and Alpha 2 bone conduction hearing
system.74 The implanted part is a magnet, The Alpha 1 sound processor has an 
additional magnet that couples the device magnetically to the implanted magnet,
Therefore, the Sophono device is a passive transcutaneous bone conductor, without 
a skin penetrating implant. The sound processor can also be used with a softband or 
a headband for those not ready to commit to surgery or for patients under 5.75  
Recently, the MED-EL company developed an active transcutaneous bone
conduction implant, called the Bonebridge. The Bonebridge is a partially implantable 
bone conduction system and consists of an external part, the audio processor with 
transmitter and an implanted part, comprising a subcutaneously placed receiver 
coupled to an implanted bone conduction transducer. The processor is worn 
externally over the skin and contains the microphones, a digital signal processor, and 
H IH[[LY ` ;OL PTWSHU[ PZ JVTWVZLK VM HU HJ[P]L LSLJ[YVTHNUL[PJ ÅVH[PUN THZZ
transducer, an electrical demodulator and a receiver coil.76
Complications
The application of the BAHI requires surgery and trauma is conducted to the bone to
secure the implant. Intraoperative complications are rare, mainly consisting of 
bleeding from the scalp, muscle or emissary veins. The post implantation 
complications of BAHI surgery can roughly be divided into two main categories: The
bone tissue and soft tissue complications in the form of skin reactions.
Skin reactions
;OLZVM[[PZZ\LYLHJ[PVUZPUJS\KLZRPUÅHWULJYVZPZ^V\UKKLOPZJLUJLISLLKPUNVY
hematoma formation and persistent pain.77 The short term complications mainly 
PU]VS]LPUHKLX\H[L^V\UKOLHSPUNHUKZRPUÅHWULJYVZPZ78-80:RPUÅHWULJYVZPZ\ZLK
to occur in 0-10% of patients at areas with inadequate blood supply but advances in 
Z\YNPJHS[LJOUPX\LOH]LYLZ\S[LKPUHKLJYLHZLKPUJPKLUJLVMWHY[PHSVY[V[HSZRPUÅHW
necrosis.70 Nowadays skin necrosis is negligible with gentle soft tissue handling,
gentle postoperative packing and the use of a single incision.
*VTWSPJH[PVUZ VU [OL SVUN [LYT HYL THPUS` ZRPU PUÅHTTH[PVU HUK PUMLJ[PVU
around the abutment, and hypertrophic skin overgrowing the abutment.70,81-83 Holgers 
et al. developed a grading system to categorise the skin reactions (Table 1).84,85 Skin
reactions around the implant should be avoided because they can result in skin
overgrowth, extrusion and severe wound infection. The majority of skin reactions are
/VSNLYZNYHKLHUKKVUVYTHSS`UV[ULLKHU`TLKPJHS[YLH[TLU[4VYLZPNUPÄJHU[
infections (grade 2-4) respond well to topical therapy with an antibacterial/steroid
ointment (grade 2) or may require oral antibiotics (grade 3 or 4).
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Hypertrophic skin
Patients with inadequate skin thinning may develop soft tissue overgrowth. This
overgrowth of skin can cover the abutment and make that the processor cannot be
used adequately. Conservative treatment consists of good local hygiene and a local
antibacterial/steroid ointment. When conservative treatment is not adequate, a higher
abutment can be placed nowadays. Revision surgery may be required if previous
options fail and the skin can be reduced.
Implant loss
)VUL JVTWSPJH[PVUZ SLHKPUN [V PTWSHU[ SVZZ HYL JSHZZPÄLK HZ LHYS` VY SH[L ,HYS`
complications are due to failure of osseointegration, while late complications are 
\Z\HSS`[OLYLZ\S[VMLP[OLYJOYVUPJPUMLJ[PVUVY[YH\TH0TWSHU[SVZZJHUILPUÅ\LUJLK
by bone status, surgical technique and implant characteristics as design, material
HUKÄUPZO12 The bone status can be altered by radiotherapy, diabetes mellitus, chronic
steroid use and smokers.86-90 The reported rates for implant loss vary greatly between
BAHI clinics. The incidence in adults range from 3.5% to 17.4%.2,66,70,79,91,92 In children
these numbers are higher with reported rates ranging from 5.3% to 26%.52,53,93,94
Single sided deafness
An important part of the conducted studies concerned single-sided deafness (SSD). 
SSD implies severe or profound sensorineural hearing loss in one ear with (sub)
normal hearing in the contralateral ear. Common causes of SSD include acoustic 
neuroma (untreated, treated with surgery or radiotherapy), sudden sensorineural
hearing loss, congenital hearing loss and Ménière’s disease. SSD patients experience
T\S[PWSLH\KPVSVNPJHSKPMÄJ\S[PLZ^ OLU[OLZV\UKPZSVJH[LKVU[OLUVUOLHYPUNZPKLVY
in the presence of competing sounds. Treatment options are scarce.
Table 1/VSNLYZJSHZZPÄJH[PVUVMZRPUYLHJ[PVUZHYV\UKZRPUWLUL[YH[PUN[P[HUP\T
implants.85
Holgers Grading Description
Grade 0 No reaction
Grade 1 Reddish discoloration of the skin around the implant
Grade 2 Red and moist surface of the skin around the implant
Grade 3 Formation of granulation tissue around the implant
Grade 4 Extensive soft tissue reaction that requires implant removal or
leads to implant loss
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1.1
Audiological aspects
;OL ILULÄ[Z VM IPUH\YHS OLHYPUN HYL NHPULK [OYV\NO [OL HIPSP[` [V \[PSPZL SV\KULZZ
summation and sound localisation, whilst eliminating head shadow effect, optimising
both speech intelligibility in noise and spatial balance.95 Patients with SSD have 
functional hearing for speech, education and vocational skills but experience 
KPMÄJ\S[PLZHZZV\UKPZKPMMYHJ[LKI`[OLOLHKHUKJYLH[LZHOLHKZOHKV^LMMLJ[;OL
HTV\U[VMLMMLJ[PZPUÅ\LUJLKI`[OL^H]LSLUN[OVM[OLZV\UK0M[OLVIZ[HJSLPZSHYNLY
than the wavelength, the sound will be blocked. A sound with a higher frequency has 
a shorter wavelength and the head shadow effect will therefore be more pronounced 
at a higher frequency.95,96 The attenuation at 1 kHz is about 10-16 dB. As a result, 
WH[PLU[Z^P[O::+L_WLYPLUJLKPMÄJ\S[PLZ^OLU[OLZV\UKZV\YJLPZWVZP[PVULKVU[OL
side of impairment. Furthermore, hearing problems especially arise in environments 
where the sound is positioned on the impaired side or when reverberations or 
background corrupt speech perception.97
Subjective handicap
Hearing handicap can widely differ between patients.98 Reactions to minimal hearing 
impairment not only vary greatly among patients, the perceived communication and 
psychosocial handicap cannot easily be determined from the audiogram alone.
Several quality of life (QoL) questionnaires have been used to assess the audiological
OHUKPJHWHUKILULÄ[ZVMZ\YNPJHSYLOHIPSP[H[PVUVM::+I`)0
Questionnaires used in this thesis
The Speech, Spatial, and Qualities of Hearing (SSQ) questionnaire was developed by
Stuart Gatehouse and William Noble.99 It is designed to measure self-reported
H\KP[VY`KPZHIPSP[`HJYVZZH^PKL]HYPL[`VMKVTHPUZYLÅLJ[PUN[OLYLHSP[`VMOLHYPUNPU
the everyday world. It covers the domains speech in several scenarios (listening in a
variety of challenging and real life situations), the domain spatial (covering directional 
hearing, distance and movement assessment) and quality (assessing segregation of 
sounds, attending to simultaneous speech streams, the naturalness, clarity and 
PKLU[PÄHIPSP[`VMZV\UKZ
;OLHIIYL]PH[LKWYVÄSLVMOLHYPUNHPK(7/()PZHZLSMYLWVY[KPZLHZLZZWLJPÄJ
questionnaire. Four domains are distinguished viz. hearing in Background Noise (BN)
and in Reverberant conditions (RV), Ease of Communication (EC) and Aversiveness
to sound (AV). The APHAB scores can be related to norm data and other studies. The 
APHAB gives an indication of the improvement achieved with a hearing aid by
JVTWHYPUNIHZLSPULHUKWVZ[PU[LY]LU[PVUV\[JVTLZ(OPNOLYJHSJ\SH[LKILULÄ[MVY
the domains EC, RV and BN is more likely to be associated with satisfaction.
;OL.SHZNV^/LHYPUN(PK)LULÄ[7YVÄSL./()7PZHZLSMYLWVY[X\LZ[PVUUHPYL
for assessing aspects of auditory disability, auditory handicap, and hearing-aid use. 
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The questions cover scales of initial disability, handicap, hearing aid use, hearing aid
ILULÄ[ZH[PZMHJ[PVUHUKYLZPK\HSKPZHIPSP[ `
;OL.)0PZHX\LZ[PVUUHPYL^OPJOHZZLZZLZ[OLILULÄ[VMZ\YNPJHSPU[LY]LU[PVUZ
on the health status of the patients. The GBI assess changes in psychological, social,
and physical condition, post-intervention.
;OL ZWLJPÄJ ZWLJPHSS` KL]LSVWLK::+X\LZ[PVUUHPYL^HZ ÄYZ[ \ZLK PU JSPUPJHS
study in 200395 and was designed to be administered after BAHI implantation for
::+0[^ HZKL]LSVWLKI`[OLMVYTLY,U[PÄJ4LKPJHS:`Z[LTZ*VTWHU`HUKW\ISPZOLK
in the product’s audiology manual.100
Conventional hearing rehabilitation
In the past audiological rehabilitation of individuals with SSD was carried out with an
air-conduction device used as contralateral routing of sound (CROS) hearing aids.
The microphone is positioned at the deaf ear and the rest of the hearing aid on the 
contralateral side. Such CROS devices have been optimised. A new application was
the BAHI CROS, which implies a BAHI at the deaf side which stimulates the
contralateral ear by cross stimulation, as described by a.o. Wazen et al. in 2003.95
Air conduction contralateral routing of sound
The conventional CROS hearing aid is the least expensive option, easy to use without
surgery. It consists of two devices: a microphone which is worn on the deaf side and
HUHTWSPÄLY^P[O[LSLWOVULVU[OLIL[[LYOLHYPUNLHY;OL[^VKL]PJLZHYLJVUULJ[LK
by a wire or an FM-link. Drawback of a conventional CROS device is (partly) occlusion 
of the better ear canal by an earmould.97 There is evidence that patients perceive
ILULÄ[ HUK JVU[PU\L [V \ZL [OLPY JVU]LU[PVUHS HJV\Z[PJ*96:KL]PJL101 With the
PU[YVK\J[PVUVM [OLKPNP[HS*96:OLHYPUNHPKZ [OLILULÄ[ PUOLHYPUN PTWHPYTLU[ PZ
increased. Hill et al. reported an acceptance rate of 72.5%.101
Transcranial air conduction hearing aid
To provide a contralateral routing of sound, a transcranial CROS, or t-CROS hearing
aid can be applied. A t-CROS device only comprises an air-conduction device in the
deaf ear.102  That device must be very powerful so that enough output is produced to 
vibrate the bony structures of the ear canal and, thus, stimulate the contralateral ear 
by bone conduction. Such application requires a deep insertion of the ear mould of 
the hearing device into the ear canal, what can feel uncomfortable. Hol et al.
investigated these options, conventional CROS and a headband BAHI in patients
with SSD.103+LZWP[LVIQLJ[P]LHUKZ\IQLJ[P]LILULÄ[UV[VULVM[OLWH[PLU[ZJOVZL
a t-CROS device.
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Intraoral bone conduction device
The SoundBite Hearing System is a new device, a non-surgical and removable 
hearing solution to transmit sound via the teeth. The SoundBite system consists of 
two components: a removable in-the-mouth bone conduction vibrator and a
behind-the-ear device with microphone worn on the impaired ear. The bone
conduction vibrator is coupled to the teeth in the upper jaw, ipsilateral to the normal
hearing ear. These two parts of the SoundBite are connected wireless and work as a
*96:KL]PJL0U[OLSP[LYH[\YLHILULÄ[MVYWH[PLU[Z^P[O::+PZZ\NNLZ[LK104-106
BAHI application
The majority of recent studies on SSD rehabilitation compare CROS hearing options.
Multiple studies support the use of BAHI CROS to other CROS hearing aids.49,97,107-109
,HJOZ[\K`WYV]PKLZT\S[PWSLVIQLJ[P]LHUKZ\IQLJ[P]LILULÄ[TLHZ\YLZ 0TWYV]LK
hearing and speech perception in noise if the speaker is standing at the patient’s deaf 
side and questionnaires show increased patient satisfaction.
Audiological results
;VJYLH[LHYLHSPZ[PJL_WLJ[H[PVUVMILULÄ[^P[OH)(/0*96:KL]PJL PUNLULYHSH
prolonged trial of 1-2 weeks with a BAHI on a headband trial is advised. Attenuation
of the BAHI sound  by soft tissue will occur (approximately 10-15dB), asking for a trial
with a powerful BAHI.110
Patient satisfaction
;OL ZH[PZMHJ[PVU HM[LY )(/0*96: Ä[[PUN PZ PUÅ\LUJLK I` [OL L_WLJ[H[PVUZ ILMVYL
Ä[[PUN-V\YLSLTLU[ZHYLKPZ[PUN\PZOLKPU[OLHJX\PZP[PVUVMH)(/0*96:UHTLS`
OLSW ZLLRPUN \W[HRL HJX\PYL [OL KL]PJL \ZL VM [OL KL]PJL HPK HUK ÄUHSS` [OL
satisfaction with the device.111 :L]LYHS MHJ[VYZ Z\JO HZ WYLÄ[[PUN OLHYPUN HPK
expectations, counseling and personality items as coping and acceptance of the
OLHYPUNWYVISLTZ^PSSPUÅ\LUJL[OLZLLSLTLU[Z:H[PZMHJ[PVU^P[OH)(/0*96:JHU
alter over time as for instance habituation takes place. A trend is seen in patients with 
::+^OV OH]L OHK )(/0 *96: Z\YNLY` [OH[ ZH[PZMHJ[PVU HUK ILULÄ[ WLYJLW[PVU
outcomes tended to regress over time.49,112(S[OV\NO[PTLZLLTZ[VILVMPUÅ\LUJLPU
the satisfaction of a BAHI in patients with SSD, long-term studies on patient subjective 
ILULÄ[HYLYHYL49,107,112-114
Scope of this thesis
The overall objectives of this thesis are to describe the basic characteristics of the
BAHI implant and attempt to optimise them. The consequences for the patient are
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described in terms of complications and best loading moment of the implant. Another
objective is to assess patients’ opinion and satisfaction with the BAHI CROS for 
patients with single sided deafness.
Chapter 1.1 provides an introduction into the BAHI system with an overview of history
and development of the BAHI considering implant and sound processor. Processes
of osseointegration and bone conduction are discussed and the indications for the 
application of the BAHI.
Chapter 1.2 focuses on the indication of single sided deafness. The drawbacks in
audiological and subjective handicap are described together with the possible
treatment modalities.
Chapter 2 creates an insight into implant characteristics and complications of BAHI
surgery. The relation between the location of the implant and skin reactions is
described in chapter 2.1. Implant loss is investigated in chapter 2.2 and its relation
with diabetes mellitus. The stability of the implant is described in chapter 2.3 and
whether loading of the implant is safe at three weeks. Chapter 2.4 gives an overview
of the results in Nijmegen of a large set of 1000 implants.
*OHW[LY  HZZLZZLZ [OL ILULÄ[ VM [OL )(/0 *96: PU ::+ WH[PLU[Z *OHW[LY 
ZOV^Z[OLILULÄ[PULSKLYS`WH[PLU[Z;OLWYLPUJS\ZPVU[YPHS^ P[OH)(/0VUHOLHKIHUK
is evaluated in chapter 3.2 and shows factors that might predict the success of the
test. Chapter 3.3 looks at patient characteristics that might determine patient
satisfaction and the long term results.
In chapter 4 the general discussion is presented and a summary of the thesis is
presented in chapter 5.
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Abstract
In the past 30 years, a large amount of clinical and audiological research on bone
conduction hearing devices has been performed. In this review, we give a brief history
of the developments in indications, surgical techniques and sound processors with
respect to implantable bone conduction devices like the bone anchored hearing aid
or Baha. Starting with the use of Baha in patients with bilateral conductive or mixed
hearing loss, the indications for such devices have been extended to patients with
unilateral hearing loss (HL), children and moderate mentally retarded patients.
)PSH[LYHS Ä[[PUN OHZ ILLU ZOV^U [V IL ILULÄJPHS PU YLZ[VYPUN IPUH\YHS OLHYPUN PU
patients with bilateral acquired or congenital conductive HL. In addition, the surgical
[LJOUPX\LZ \ZLK [V PTWSHU[ [OL [P[HUP\T Ä_[\YL MVY )HOH HWWSPJH[PVU OH]L ILLU
TVKPÄLKHUKM\Y[OLYKL]LSVWLK[VYLHJO[^VTHPUNVHSZ!HVW[PTHSVZZLVPU[LNYH[PVU
and (b) preparation of the implant site to minimize the occurrence of soft tissue
YLHJ[PVUZ*\YYLU[S `[OLTVZ[\ZLK[LJOUPX\LZHYL[OLWLKPJSLKZRPUÅHWKLYTH[VTL
and linear incision techniques. Several generations of the Baha® sound processor
OH]LILLUKL]LSVWLKI`*VJOSLHY [VWYV]PKL Z\MÄJPLU[ HTWSPÄJH[PVU PUKPMMLYLU[
hearing situations. Improvements in sound quality, aesthetics and handling have
been major points of interest. The Baha sound processors most often used today are 
[OL)HOH+P]PUV[OL)HOH0U[LUZVHUK[OL)HOH*VYKLSSL9LJLU[S `[OLTVYLÅL_PISL
Baha BP100 sound processor was launched.
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Introduction
In 1984, the bone-anchored hearing aid (Baha), which was developed by Håkansson,
Tjellström and coworkers in Gothenburg, Sweden, became commercially available.1
Currently, the Baha is a well-established device for hearing rehabilitation for
conductive hearing loss (HL), and over 250 papers have been published worldwide
VU[OPZOLHYPUNKL]PJL0U1\UL [OLÄYZ[[OYLL5PQTLNLUWH[PLU[Z^LYLÄ[[LK^P[O
a Baha device2, setting off more than 20 years of clinical and audiological research
HUK YLZ\S[PUN PU TVYL [OHU  W\ISPJH[PVUZ PU ]HYPV\Z )HOHYLSH[LK ÄLSKZ 0U [OPZ
review, we give an overview of current knowledge about the Baha in general, with 
special attention given to research performed over the past several years in our clinic.
Physiology of bone conduction
The physiological concept behind the bone conduction (BC) pathway is still not
entirely understood. Tonndorf (1966) described, from studies primarily in cats, several
modes stimulating the basilar membrane during BC excitation.3;OLZPNUPÄJHUJLVM
the different modes depends on the frequency. For humans at hearing frequencies
the most important way in which the basilar membrane is stimulated seems to be the
LMMLJ[VMÅ\PKPULY[PH^ P[OPU[OLJVJOSLHY4,5 In short, BC sound is made up of vibrations
[YHUZTP[[LK[OYV\NO[OLZR\SS[V[OLJVJOSLH;OPZ[OLUJH\ZLZ[OLÅ\PKZPU[OLJVJOSLH
[V]PIYH[LHZ^LSS(Z[OLZLÅ\PKZHYLPUJVTWYLZZPISLPUWYPUJPWSL[OL`^PSS]PIYH[LHZH
whole and in phase with the bone. However, the cochlea has two mobile windows,
[OL V]HS HUK YV\UK^PUKV ^ ;OLYLMVYL PULY[PH VM [OL PUULY LHY Å\PKZ^PSS YLZ\S[ PU
SVUNP[\KPUHS Å\PK^H]LZ [YH]LSPUN MYVTVUL^PUKV^ [V [OLV[OLY^OPJOJH\ZLZ [OL
basilar membrane to vibrate. 
Von Békésy showed that the basilar membrane responds equally to both
air-conducted (AC) and BC sound.6 Distinguish between AC and BC stimulation at
the basilar membrane level is not possible. However, the BC route towards the basilar
TLTIYHULPZLULYN`^PZLSLZZLMÄJPLU[[OHU[OLHPYJVUK\J[PVUYV\[L;OLYLMVYL)*
hearing aids are primarily used for HL where air conduction hearing aids are contra-
indicated. 
Description of the Baha system
The Baha® is a semi-implantable percutaneous BC hearing device coupled to the
ZR\SSI`HUVZZLVPU[LNYH[LK[P[HUP\TÄ_[\YL-PN\YL;OL[P[HUP\TÄ_[\YL\ZLKPZH
standard Brånemark type of implant with an as-machined surface, developed by
Cochlear™ Bone Anchored Solutions, Gothenburg, Sweden. Recently, as there have
ILLU Z\IZ[HU[PHS KL]LSVWTLU[Z VM [P[HUP\T Ä_[\YLZ MVY [OL KLU[HS PUK\Z[Y ` H UL^
Baha® BI300 implant has been designed to improve stability and to enhance
osseointegration. The new Baha® BI300 implant features a wider diameter (4.5 mm
38
CHAPTER 1.2
compared to 3.75 mm for the standard implant), small sized threads at the implant
neck, and a moderately rough TiOblast™ surface on the intraosseous portion of the
implant. 
Figure 1 Illustration of the Baha as a semi-implantable percutaneous BC hearing
KL]PJLJV\WSLK[V[OLZR\SSI`HUVZZLVPU[LNYH[LK[P[HUP\TÄ_[\YL.
Figure 2 Illustration of the standard titanium implant (left) and the new BI300 titanium
implant (right).
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Figure 2 illustrates the standard titanium implant and the new BI300 implant (Figure
2). A skin-penetrating abutment is attached to the implant to facilitate coupling of the
Baha sound processor. Compared to the standard abutment, the BI300 abutment is 
a concave shaped abutment. The direct coupling for the mechanical vibrations to the
skull provides effective sound transmission of around 5-15 dB higher than the
transcutaneous coupling of conventional BC devices.7
Because the Baha sound processor is coupled directly to the skull without
interference from intermediate tissue, some drawbacks of conventional transcutaneous
bone conduction devices are avoided. These drawbacks include pressure of the
transducer mounted on a spring or in the sidepiece of spectacles against the temporal
ZRPU^OPJOJHUYLZ\S[PUOLHKHJOLZVYZRPUYLHJ[PVUZHUKPUZ\MÄJPLU[WYLZZ\YL^OPJO
reduces the gain of the device. Furthermore, when the classical bone conductor is
used with a headband, mostly, the positioning of the microphone and vibrational
transducer are contralaterally on the skull, resulting in unnatural listening conditions.
;OLZHTLKYH^IHJRZHWWS`[VJVU]LU[PVUHS)*KL]PJLZ^P[O[OLHTWSPÄLY^VYUVU
the body. On the other hand, the disadvantages of percutaneous implants include
loss of osseointegration and skin reactions around the implant.
Indications
Bilateral mixed or conductive hearing loss (acquired/congenital)
;OL)HOHZ`Z[LTPZ[`WPJHSS`ILULÄJPHSPUWH[PLU[Z^P[OIPSH[LYHSTP_LKVYJVUK\J[P]L
/3^OVJHUUV[ILÄ[[LK^P[OJVU]LU[PVUHSHJV\Z[PJOLHYPUNHPKZILOPUK[OLLHYVYPU
the ear), including those with chronic otitis and those with congenital aural atresia.8-10
In patients for whom reconstructive surgery is no longer considered a feasible option
and for whom a conventional BC hearing aid has proven to be inadequate, the Baha
OHZILLUZOV^U[VILVMNYLH[ILULÄ[11-16
Whereas most bilateral hearing-impaired patients with sensorineural HL, using
HJV\Z[PJ OLHYPUN HPKZ WYLMLY IPUH\YHS HTWSPÄJH[PVU V]LY TVUH\YHS HTWSPÄJH[PVU
binaural use of the Baha in bilaterally impaired patients is not yet widely applied.
There are several well-documented advantages of binaural hearing: (a) hearing
sensitivity and speech recognition are improved due to bilateral summation when
inputs received by the two cochleae are added together17,18, (b) speech recognition is
improved in noisy situations with spatially separated speech and noise sources19, and
(c) directional hearing will be enabled in the horizontal plane. It has been reported that
IPSH[LYHS)HOH\ZLPUHK\S[ZOHZIV[OZPNUPÄJHU[Z\IQLJ[P]LHUKVIQLJ[P]LILULÄ[Z14-20
Unilateral Conductive Hearing Loss
Unilateral conductive HL (UCHL) in patients with a contralateral normal hearing ear 
may involve the typical problems associated with unilateral hearing (i.e., poor sound
localisation abilities and poor speech recognition performance in noise). Agterberg et
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al.21 YLWVY[LKVUZV\UKSVJHSPZH[PVUPUWH[PLU[Z^P[OHJX\PYLK<*/3Ä[[LK^P[OH)*
device on their impaired side. Using varied several stimulus characteristics, they 
demonstrated that BCD users with acquired UCHL were able to locali se sounds on 
the basis of restored binaural hearing.However, some UCHL patients show fairly 
good directional hearing abilities in an unaided monaural condition.22,23
Single-sided deafness
In patients with unilateral sensorineural deafness, a Baha positioned near the deaf 
ear works as a transcranial CROS (contralateral routing of signal). Sounds received
by the Baha system are transmitted to the functional contralateral cochlea via BC. In
principle, this will not result in stereophonic hearing, but the negative effects of 
acoustic head shadow (poor understanding of a person who is talking on the deaf 
side of the patient) might be decreased.24,25 Before implantation, a trial should be
arranged with a Baha device on a steel headband placed on the mastoid of the deaf 
ear.26 The degree of success depends on the motivation of the patient and the 
listening demands imposed by their lifestyle and working environment. In literature, it 
is reported that 25-30% of the patients apply for implantation of the Baha system 
after trial on a headband.24,27
Baha use in children
In part, Baha application in children addresses different issues than in adults. Children 
are known to have more immature and thinner bone. When implanted, they have a 
higher risk of soft tissue overgrowth, and, compared to adults, more implants are lost
^P[OPU[OLÄYZ[`LHYHM[LYPTWSHU[H[PVU28 Furthermore, cleaning problems have been
reported, especially among adolescents.29,30 A considerable number of the children
scheduled for implantation have major congenital (syndromal) malformations of the 
ear, sometimes combined with skull deformities, making surgery more challenging.31-
34 For Baha surgery in children, there are additional considerations and precautions,
including (a) at what age is implantation possible, (b what should be the minimal
thickness of the skullbone, (c) what is the best implant position, (d) is there a need to
WSHJLHZLJVUKZSLLWPUNÄ_[\YLHUKL^ OH[JHUILKVUL[VWYL]LU[WVZ[Z\YNLY`ZVM[
tissue reactions. It is of the utmost importance that children with bilateral conductive
hearing loss be rehabilitated at the earliest age possible as early and consistent 
stimulation is critical for optimal development of speech and language.35
-VYJOPSKYLU^OVHYL[VV`V\UN[VILÄ[[LK^P[OH)HOHWLYJ\[HULV\ZS `HUK[V
V]LYJVTL [OL YPZRZ HZZVJPH[LK^P[O )HOH Z\YNLY` PU ZWLJPÄJ Z`UKYVTHS JHZLZ H
conventional transcutaneous bone conductor can be used or the more recently
introduced Baha® Softband (Cochlear Bone-Anchored Solutions, Gothenburg,
Sweden). This Baha Softband comprises the Baha sound processor connected to a
ZVM[ LSHZ[PJ OLHKIHUK (PKLK ZV\UK ÄLSK [OYLZOVSKZ ^P[O [OL )HOH :VM[IHUK HYL
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almost equivalent to those obtained with a transcutaneous conventional bone
conduction hearing aid.36 Speech and language development are greatly facilitated
by the early use of bone conductors like the Baha Softband37, and currently, the Baha
Softband is generally accepted as the treatment for children under 3 years of age.
Lieu38 and Lieu et al.39 found that several children with unilateral HL demonstrate
increased rates of school year failure and that they needed additional educational
assistance. ;OL7HLKPH[YPJ>VYRNYV\W VU/LHYPUN (PK (TWSPÄJH[PVU40 summarized 
the literature and stated that in children with unilateral conductive or sensorineural
/3HTWSPÄJH[PVUZOV\SKILJVUZPKLYLKVUHJHZLI`JHZLIHZPZJLU[LYLKVU[OL
child’s audiometric data, development, and communication needs.
Baha use in patients with moderate mental retardation
Initially, potential Baha patients with mental retardation were excluded from treatment
due to doubts concerning care for the percutaneous implant and surrounding skin. 
Recently, however, patients with moderate mental retardation and conductive or
TP_LK/3 OH]L YLJLP]LK)HOH [YLH[TLU[<ZL VM [OL)HOH PU [OPZ ZWLJPÄJ WH[PLU[
NYV\W OHZ ILLU ZOV^U [V IL ILULÄJPHS PTWYV]PUN IV[O SPZ[LUPUN HUK SLHYUPUN
capabilities.41-43 Following these results, use of the Baha has also been extended as
a valuable treatment option for this special patient group.
Baha surgery
Goals of surgery
Independent of the surgical technique used, there are two major goals of Baha
surgery: placement of an implant capable of optimal osseointegration and preparation
of an implant site that minimizes the occurrence of future soft tissue reactions
surrounding the implant. For adequate osseointegration, trauma to the surrounding 
bone should be minimized. The actual placement (drilling and placing) of the implant 
is mostly done using the technique reported by Tjellström.44 Subcutaneous tissue
reduction is carried out to reduce soft tissue movement and the subsequent
development of scar tissue and infection around the implant. In addition, hair follicles
surrounding the implant should be removed to avoid skin irritation and accumulation
of debris. If all of these precautions are taken into consideration and therapy-resistant
skin reactions still occur, recent studies have shown that changing to a larger 8.5-mm
HI\[TLU[JHUILILULÄJPHS45-47 A recent study by Faber et al.48 showed that implant
location was not correlated with the frequency and severity of skin reactions around 
the abutment in 248 randomly selected Baha patients.
Handling soft tissue (surgical techniques)
The surgical techniques used to handle soft tissue vary among surgeons. Initially, a
MYLLYL[YVH\YPJ\SHYZRPUNYHM[^HZ\ZLK^OPJOSH[LYILJHTLHSVJHSWLKPJSLKZRPUÅHW
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predominantly.33,49,50;VZ[HUKHYKPaL[OLZ\YNPJHSÅHW[LJOUPX\LHZWLJPHSKLYTH[VTL
^HZKL]LSVWLK[VJYLH[LHOHPYMYLL[OPUZRPUÅHW49,51An alternative surgical technique, 
using a linear incision, has been developed at the Radboud University Nijmegen 
Medical Center.52-54 Both the dermatome technique and linear incision technique
provide safe alternatives in Baha surgery and are recommended in the Baha®
Surgery Guide (Cochlear).55
Loading time
Another point of interest in previous studies has been osseointegration of the titanium 
implant. Osseointegration of the implant is key to the success of the Baha implant
before loading the implant with the Baha sound device. In 2005, Snik et al. 26 published
HJVUZLUZ\ZYLWVY[I`L_WLY[ZPU[OLÄLSKYLJVTTLUKPUNHSVHKPUN[PTLVMIL[^LLU
4 and 6 weeks in adults and at least 3 months in children under 10 years of age. In
accordance with this report, the current protocol for Baha surgery (Cochlear) includes
^LLRZVM\USVHKLKOLHSPUN[VHSSV^MVYZ\MÄJPLU[VZZLVPU[LNYH[PVUHUKZ[HIPSP[`VM
the implant in adults.55 In children with bone thickness of 3-4 mm, two-stage surgery
is recommended and the Baha sound processor can be attached as soon as wound
healing has occurred after the second stage. Longer healing time before loading 
should still be used in adults being irradiated on the skull bone, in adults with bony
KPZVYKLYZHUK^OLUZVM[IVULPZVIZLY]LKK\YPUNPUP[PHSÄ_[\YLPTWSHU[H[PVU
Development of different generations of the Baha sound processors
Since the introduction, several Baha sound processors have been developed. The
ÄYZ[ JVTTLYJPHSS` H]HPSHISL KL]PJL ^HZ [OL /*  YLSLHZLK PU   :PUJL [OPZ
YLSLHZL\WKH[LZOH]LILLUTHKL[VHWWYVHJOTVYLZWLJPÄJOLHYPUNULLKZ(SZV[OL
aesthetical aspects were taken into consideration in these updates, the size of the
processor was minimized and different colours were made available. Nowadays there 
are four types of Baha sound processors (Cochlear) commercially available: the Baha® 
Divino, the Baha® BP100, the Baha® Intenso and the Baha® Cordelle (Figure 3). 
The Divino, Intenso and the BP100 are behind-the-ear devices containing microphone,
HTWSPÄLYHUK]PIYH[PVU [YHUZK\JLY PUVULJHZPUN;OL)HOH*VYKLSSLJVUZPZ[ZVMH
separate ear level vibration transducer connected to a body-worn microphone and
HTWSPÄLY0U  [OPZ)HOH*VYKLSSL^HZKLZPNULKV\[MYVTWYLJLKPUNWYVJLZZVYZ
as the HC Superbass, as an even more powerful successor.56 The Baha Divino was
launched in 2005. In contrast to its predecessor, the Baha Compact, this device 
MLH[\YLZ H KPNP[HS ZV\UK WYVJLZZVY HUK H KPYLJ[PVUHS TPJYVWOVUL :V\UKÄLSK
[OYLZOVSKZ HUK ZWLLJO [LZ[Z PU X\PL[ KPK UV[ YL]LHS HU` Z[H[PZ[PJHSS` ZPNUPÄJHU[
advantage (or disadvantage) of the Baha Divino when compared to the Baha 
Compact.57 However, speech understanding in noise presented at the rear was
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reported to be better with the Baha Divino, an effect assigned to the directional
microphone noise-reduction system. The Baha Intenso, launched in 2007, bridges
the gap between the Baha Divino and the Baha Cordelle. Of the ear-level Baha’s (i.e.
Cordelle not included), the Baha Intenso provides the most gain and the highest
maximum output.
;V KL[LYTPUL [OL Ä[[PUN YHUNL VM [OYLL TVZ[ \ZLK [`WLZ VM IVULHUJOVYLK
hearing aid devices, speech recognition data on three groups of Baha users were
obtained from the Nijmegen database. Figure 4 presents the (monaural) individual
aided phoneme scores in quiet at 65 dB SPL (sound pressure level; PS65) from 90
Baha Compact (predecessor Divino) users, 23 Baha Intenso users and 25 Baha
Cordelle users (Figure 4). 
All patients had conductive HL or mixed HL, with a sensorineural HL component of 
up to 70 dB HL. PS65 was presented as function of the mean sensorineural HL 
JVTWVULU[5VUSPULHYYLNYLZZPVUJ\Y]LZVM[OLZLJVUKVYKLY^LYLÄ[[LK[OYV\NO[OL
individual data and are also presented. Using these lines, it was concluded that for a
sensorineural HL component exceeding approximately 25 dB, scores were better
with the stronger Baha Intenso than with the Compact. At this threshold, the PS65 
line of the Baha Compact was 10% lower (arbitrary choice) than that of the Baha
Intenso and the discrepancy continued to increase with increasing sensorineural HL 
component. Therefore, assuming that the speech tests in quiet of the Baha Compact
and its successor Baha Divino are equally effective, it can be established that the
Baha Divino is a good choice for patients with a mild sensorineural HL component of 
up to 25 dB HL.
In a similar way, the upper limit of application for the Baha Intenso was set at 50
dB HL. At this threshold, the PS65 with a Baha Cordelle was likely to be at least 10%
Figure 3 Available Baha sound processors (left to right): Baha Divino, new Baha
BP100, Baha Intenso and Baha Cordelle with bodyworn receiver (not actual sizes).
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higher than with the Baha Intenso. The Baha Intenso is a good choice for patients
with an average sensorineural HL component of between 30 and 50 dB HL (Figure 4).58
Bosman et al.59 HZZLZLK [OL\WWLY SL]LSZÄ[[PUN YHUNLVM [OL)HOH*VYKLSSL PU
patients with severe to profound mixed HL. To reach a 50% score at 65 dB, the upper
SPTP[VM[OLÄ[[PUNYHUNLHZL_WYLZZLKPU)*[OYLZOVSKZ^HZZL[[VK)
/3H[HUK/a YLZWLJ[P]LS ` 0M [OLNHPU PZ PUZ\MÄJPLU[ MVYH
WHY[PJ\SHYWH[PLU[[OLUL_[HTWSPÄJH[PVUVW[PVUPZ[OLHWWSPJH[PVUVMHJVJOSLHYPTWSHU[
From a more recent study by Verhaegen et al.60 it was concluded that a CI takes 
preference over a Baha device in patients with mixed HL when the mean sensorineural
HL component is 65-70 dB or higher or when the PS65 with the Baha Cordelle is less 
than about 40%.
With the aid of information on the gain-frequency characteristics of Baha, as 
measured in patients, the straightforward application limits can be shaped into 
frequencies. The gain-frequency relations have been described in a group of patients 
using the Baha Intenso and Baha Cordelle.58,59 Using these frequency-gain data as
input and the National Acoustics Laboratory-Non-Linear (NAL-N-L) rule backwards, 
MYLX\LUJ`ZWLJPÄJOLHYPUN [OYLZOVSKZJHUILVI[HPULK PUZ[LHKVMHTLHUOLHYPUN
threshold. The NAL-N-L rule is a well-validated prescription method that prescribes 
desired gain based on hearing thresholds.61,62 -PN\YL  ZOV^Z [OL ÄUHS YLZ\S[ MVY
JOHUNLMYVT*VTWHJ[[V0U[LUZVHUKMYVT0U[LUZV[V*VYKLSSL-PN\YL;OLÄN\YL
can be used to choose the best Baha option for Baha candidates. The Baha Compact 
Figure 4 (Monaural) individual aided phoneme scores in quiet at 65 dB SPL (PS65)
from three groups of Baha users presented as function of their mean sensorineural 
OLHYPUNSVZZ;OL[OYLLSPULZHYLILZ[Ä[[LKUVUSPULHYYLNYLZZPVUSPULZ
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is not available anymore and application data can be used for its successors, the
Baha Divino and the Baha BP100.
 Towards the end of 2009, a new Baha sound processor was launched, the Baha
BP100. The BP100 is considered to be applicable in individuals with bone-conduc-
tion thresholds up to 35 dB. This device makes use of full digital processing. With this
device, sound is analyzed across 12 channels. It has several automatic systems that
VWLYH[LVU[OLPUJVTPUNZV\UKZPNUHSZ\JOHZHKHW[P]LHTWSPÄJH[PVUHUKH\[VTH[PJ
noise reduction. Another special feature is that hearing thresholds can be measured
directly by stimulation by pure tones generated by the BP100 sound processor such
[OH[ [OL NHPU JHU IL HKHW[LK PUKP]PK\HSS` HUK MYLX\LUJ` ZWLJPÄJ63 ( ÄYZ[ JSPUPJHS
evaluation showed that compared with the Baha Divino, speech understanding in
noise was on average 2.6 dB better with the Baha BP100.64 In this evaluation the
sound quality of the BP100, assessed by a patient’s questionnaire, was reported to 
be better compared to the Divino. Company-independent effectivity studies of the
Baha BP100 have not yet been published and should be awaited for.
Recently, alternative implantable BC devices produced by other companies entered
[OLÄLSK6[PJVU4LKPJHSYLJLP]LKJSLHYHUJLMYVT[OL<:-VVK+Y\N(KTPUPZ[YH[PVU
to market their percutaneous Ponto® system.In 2010, the Sophono, Inc and Otomag, 
GmbH companies have teamed together to pioneer the development a non-percuta-
neous implantable BC device, called the Otomag Alpha®.65
Figure 5 Audiological application range for three types of Baha devices. The Baha
Divino and the also the Baha BP100 are expected to have application ranges
comparable to their predecessor the Baha Compact.
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Abstract
Objective: To evaluate the effect of implant location and skin thickness on the frequency
and degree of adverse skin reactions around the abutment.
Design: Retrospective multivariate analysis of implant position related to skin thickness
and clinical variables.
Setting: Tertiary referral center.
Patients: Random sample of 248 patients with bone-anchored hearing aids.
Interventions: Bone-anchored hearing aid implant placement by means of the linear 
incision technique.
Mean Outcome Measures: Type and number of skin reactions and implant loss.
Results: The mean (SD) distance from the external auditory ear canal to implant was
48.8 (8.0) mm (range, 29-84 mm). The mean skin thickness was 5.5 (1.9) mm. Severe
ZRPUYLHJ[PVUZ/VSNLYZJSHZZPÄJH[PVU^ LYLZLLUPUVM[OLWH[PLU[Z
Implant loss occurred in 4 patients (1.6%). Three implants were lost owing to failed
osseointegration (1.3%), and another implant was removed because of deterioration
of cochlear function (0.9%). No implant was lost as a result of infection.
Conclusion: Implant location and skin thickness were not correlated with implant loss
or the frequency or degree of adverse skin reactions around the abutment.
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BAHA IMPLANT LOCATION IN RELATION TO SKIN REACTIONS
2.1
Introduction
Brånemark et al1ÄYZ[KLZJYPILK[OLWYPUJPWSLVMVZZLVPU[LNYH[LKPTWSHU[H[PVUPU[OL
dental region. On the basis of osseointegration between bone and titanium, a new
hearing device was introduced, the bone-anchored hearing aid (BAHA).2 Tjellström et 
al.3PUP[PH[LK[OLÄYZ[JSPUPJHSHWWSPJH[PVUVMH)(/(KL]PJLJV\WSLK[VHZRPUWLUL[YH[-
ing, bone-anchored titanium implant (anchored to the temporal bone of the skull).
The implant in the skull enables sound vibrations to be transmitted to the cochlea via
bone conduction. Since 1987, the BAHA system has been successfully introduced in 
many countries. In the Netherlands, the BAHA program was established at the 
University Medical Center in Nijmegen in 1988. In patients with conductive or mixed 
hearing loss, the BAHA has been a well-established treatment for over 25 years.4-5
One of the main concerns in BAHA surgery is to achieve a stable implant with a
zone of reaction-free skin around the percutaneous abutment. It has been reported
that movement of the tissue around the percutaneous implant it is a risk factor for
skin reactions.6 Surgical thinning of the skin around the abutment reduces the chance 
of epithelial debris or crusts being trapped between the abutment and the skin and 
acting as foreign bodies.
Regular cleaning is the most effective way to prevent skin reactions. If skin
reactions occur, they can usually be treated successfully with a medicated ointment.
Skin reactions should be avoided because they can have a more serious outcome,
such as skin overgrowth, implant extrusion, and severe wound infection.7-9 The
probability of losing an implant as a result of adverse skin reactions is fairly low.
However, if left untreated, a skin reaction may eventually lead to implant loss or
withdrawal.10 Also, preexisting skin impairment, such as dermatoses, thick skin,
previous radiotherapy, and poor hygiene, can impair the clinical outcome.6,11-12 Other
MHJ[VYZ [OH[TPNO[ PUÅ\LUJL [OL SVUN[LYT YLZ\S[Z HYL ZVM[[PZZ\L YLK\J[PVU K\YPUN
)(/(Z\YNLY`HUK[OLPTWSHU[SVJH[PVUVU[OLZR\SS^OPJOTPNO[HSZVPUÅ\LUJLZVM[
tissue in the long term. We evaluated the effect of the implant location and skin
thickness on the frequency and degree of adverse skin reactions around the
abutment.
Methods
Patients
Patients who were scheduled for their regular (yearly) follow-up visit to the BAHA 
outpatient clinic were invited to participate in the study. Inclusion criteria were age
older than 17 years, implant using the Nijmegen linear incision technique, unilateral 
application, and at least 1 year of BAHA use. Patients with syndromal features and
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skull deformities were excluded. The patients were informed about the study,
including the skin thickness measurement using a needle and the lateral skull
radiograph. A random sample of 248 patients agreed to participate in the study. They
had undergone implantation during the period of January 1, 1992, through December
31, 2006.
BAHA surgery
All the patients had received their BAHA using the Nijmegen linear incision technique.
In general, the Nijmegen linear incision technique consists of a longitudinal incision
approximately 3 cm long, 50 to 55 mm posterosuperiorly to the ear canal. After
removal of the periosteum, the titanium implant was placed according to the 1-stage
technique described by Tjellström and Granström.13 Subcutaneous tissue was
reduced extensively over an area of approximately 2 cm around the incision. After
wound closure, a pressure dressing provided hemostasis. The handling of the soft 
tissue is described by de Wolf et al.14HUK^HZUV[TVKPÄLKK\YPUN[OLZ[\K`WLYPVK
Skin thickness measurements
Skin thickness at the implant site was estimated by using a needle to penetrate the
skin up to the bone on the contralateral side at the matching position (relative distance
of the implant from the ipsilateral rim and pinna). The procedure was performed by 2
otolaryngologists (E.A.M.M. and M.K.S.H.). Measurements were recorded as the 
number of millimeters the needle penetrated the skin during the regular checkups.
Implant position
A standardized digital lateral conventional radiograph of the whole skull (Siemens,
Erlangen, Germany), taken of the ipsilateral side of the implant, was used to determine
the position of the implant on the skull. The side of the implant was always positioned
ULHYLZ[ [V [OL _YH` KL[LJ[VY [V H]VPK KPMMLYLUJLZ PU [OLTHNUPÄJH[PVU MHJ[VY ;OL
distance from the upper center of the external auditory ear canal to the implant was
measured using the ruler function in a radiological program, with the Frankfurter
horizontal plane (FHP) as a baseline (adopted at the 1884 Craniometrical Conference 
in Frankfurt am Main, Germany, cited in 1958 by Moorrees and Kean15). It consists of 
a straight line between the most superior point on the upper margin of the external
auditory ear canal and the most inferolateral point in the orbital cavity (Figure 1). The 
position of the implant was recorded as x- and y-coordinates (horizontal and vertical,
respectively) using the FHP as the x-axis.
Case analysis
Data were retrieved from the medical records. These include age, sex, indication for
a BAHA, surgical method, type of implant (3 or 4 mm), type of abutment (5.5 or 8.5
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mm), type of tissue at the end of the drilled hole, implant loss, duration until loss, skin
YLHJ[PVUZ HJJVYKPUN [V [OL JSHZZPÄJH[PVU W\ISPZOLK I` /VSNLYZ L[ HS16 hereinafter
/VSNLYZJSHZZPÄJH[PVU[PTLVMPTWSHU[H[PVUHUKK\YH[PVUVMMVSSV^\W
Follow-up
The tissue reactions around the abutment were evaluated according to the Holgers
JSHZZPÄJH[PVU!NYHKLUVYLHJ[PVU"NYHKLYLKKPZOKPZJVSVYH[PVUVM[OLZRPUHYV\UK
the implant; grade 2, red and moist surface of the skin around the implant; grade 3,
formation of granulation tissue around the implant; and grade 4, extensive soft-tissue
reaction that requires implant removal or leads to implant loss.16 The state of the skin
around the implant was also observed. Thick skin around the implant was noted 
when it was level with the top of most of the abutment. At each follow-up visit, the 
implant stability was checked manually with a torque wrench. All these data were
Figure 1 Frankfurt horizontal plane (FHP) coordinates of the implant (x- and
y-coordinates) used to measure the distance from the upper center of the external
auditory ear canal to the implant (l). x indicates the distance from the upper center of 
the external auditory ear canal (EAEC) to implant along the FHP; and y, the distance
from the upper center of the EAEC to the implant vertically perpendicular to the FHP.
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LU[LYLKPU[V[OLTLKPJHSÄSLZI`TLHUZVMHZ[HUKHYKPaLKZ[HTW0UP[PHSS `[OLWH[PLU[Z
attended the checkups at least once every 4 months. Later, the interval was prolonged
to 6 months, and currently, once a year is the standard interval.
Statistical analysis
Comparisons of categorical variables were made using multivariate correlation tests, 
1-way analysis of variance, and independent sample t tests. Time-to-event analyses 
were conducted using Kaplan-Meier curves. The analyses controlled for age at 
surgery, sex, duration of follow-up, and tissue type at the end of the hole drilled for
the abutment. SPSS software (version 16; SPSS Inc, Chicago, Illinois) and Prism
Graph Pad 5 (GraphPad Software, La Jolla, California) were used to perform statistical
HUHS`ZPZ;OLSL]LSVMZPNUPÄJHUJL^HZZL[H[P=.05.
Results
Description of population
Our population comprised 100 men and 148 women with a unilateral percutaneous
titanium implant. The mean (SD) age at implantation was 52.5 (14.7) years.
Figure 2 shows the age distribution. Implants had been placed on the left side
U$ HUK VU [OL YPNO[ ZPKL U$ 0UKPJH[PVUZ MVY )(/( Ä[[PUN ^LYL IPSH[LYHS
acquired conductive or mixed hearing loss (n=209 patients [86.7%]), congenital
conductive hearing loss (n=8 [3.8%]), and unilateral inner ear deafness (n=31 [12.5%]).
The latter group comprised 30 cases of acoustic neurinoma and 1 case of intracranial
rhabdomyoma. The etiology of the hearing loss in 1 patient (0.4%) was trauma. A total
VMWH[PLU[Z^LYLJSHZZPÄLKHZOH]PUNTLU[HSYL[HYKH[PVU
A 1-stage surgical procedure had been used to place 247 implants (99.6%). In 1
patient, the second stage (abutment placement and tissue reduction) was performed
separately.
During surgery, the drilled hole had ended in bone in 213 cases (85.9%), at the
dura mater in 21 cases (8.5%), and in the sinus in 8 cases (3.2%). Only 6 observations
were missing (2.4%). All of the implants were 4 mm except for 1. In 2 cases, the length
of the implant was not noted in the medical records. All the abutments were 5.5 mm
except for 1. This patient did not report any adverse skin reactions or thick skin. The
mean duration of follow-up was 67.7 (39.4) months (range, 12-215 months) with a 
mean of 7.4 (4.9) observations per implant.
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Figure 2 Age at time of surgery per implant (N=248 patients) and number of implants.
Figure 3 Scatterplot of the implant locations. The coordinates (0,0) = external
auditory ear canal (EAEC); x = distance from the upper center of the EAEC to implant
along the Frankfurt horizontal plane (FHP); y = the distance from the upper center of 
the EAEC to implant vertically perpendicular to the FHP.
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Implant location measurements on the lateral radiographs
The mean (SD) distance from the upper center of the external auditory ear canal to
the implant was 48.8 (8.0) mm (range, 29.0-84.0 mm), the mean distance of the 
x-component was 44.8 (8.5) mm (range, 22.0-82.0 mm), and the mean distance of 
[OL`JVTWVULU[^HZTTYHUNLò[VTT-PN\YLZOV^ZH
lateral representation of the scatter of implant positions.
In patients with congenital atresia (n=8), the mean distance of the y-component
was 21.3 mm. Compared with the mean distance of the y-component in the other
patients (18.5 mm) this was not a notable difference. Their x-component was 46.3 mm
JVTWHYLK^P[O [OL V[OLY WH[PLU[Z ^OPJO^HZ UV[ JSPUPJHSS` ZPNUPÄJHU[ ;OLTLHU
distance between the upper center of the external auditory ear canal and implant was
TT;OPZKPMMLYLUJLTT^HZUV[JSPUPJHSS`ZPNUPÄJHU[JVTWHYLK^P[O[OVZLVM
the other patients. The measurements in the patients with congenital atresia did not
notably affect the distances in the total group of patients. In the patients who had 
undergone translabyrinthine schwannoma surgery, the x-component of the implant
location did not differ from that in the patients who underwent “regular” BAHA surgery.
Implant loss
A total of 4 of the 244 implants (1.6%) were lost: 3 owing to failed osseointegration
(1.3%) and 1 that was removed owing to deterioration of cochlear function (0.9%). No
implants were lost as a result of infection. Statistical analysis did not show any
relationship between implant loss and the distance from the upper center of the ear
canal to the implant, the mean distance of the x-component, and the y-component.
Skin reactions
Skin reactions were observed in 130 patients (52.4%): in 84 patients the most severe
skin reaction was Holgers grade 1 (33.9%), in 32 patients this was Holgers grade 2
(12.9%), in 12 patients this was grade 3 (4.8%), and only 2 patients had a grade 4 skin
reaction (0.8%). In this group, 46 patients (18.5%) had a skin reaction that required
[YLH[TLU[JSHZZPÄLKHZ/VSNLYZNYHKL;OPZ[`WLVMYLHJ[PVUVJJ\YYLKVUS`VUJL
in 33 of the 46 patients (71.7%) (Table 1 and Table 2).
The mean intervals in months between implantation and the skin reactions were 42.5
months for grade 1, 37.8 months grade 2, 37.8 months for grade 3, and 76.5 months
MVYNYHKL;HISL;OLTLHUPU[LY]HS\U[PS[OLÄYZ[ZRPUYLHJ[PVUPYYLZWLJ[P]LVM[OL
grade, was 24.3 months (range, 0-129 months).
The distance from the upper center of the external auditory ear canal to the implant
was not correlated with Holgers grade 1 to 4 skin reactions or the total number of skin
reactions. Furthermore, there was no correlation between skin reactions or implant
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loss and the x- and y-components of the distance from the upper center of the ear
canal to the implant.
Skin thickness, measurements, observations and revision surgery
In 204 patients (82.3%), skin thickness was measured on the side contralateral to the
percutaneous implant. Skin thickness varied from 2.0 to 11.0 mm, with a mean (SD) 
Table 1 Clinical Data on Skin Reactions and Revision Surgery
No. (%)
Scale (skin reaction) Distribution
per observation
Most severe skin
reaction per implant
0 (No irritation)
1 (Slight redness)
2 (Red and moist tissue)
3 (Granulation tissue)
4 Infection leading to
   removal of abutment
1505 (84.7)
206 (11.6)
52 (2.9)
12 (0.7)
2 (0.1)
118 (47.6)
84 (33.9)
32 (12.9)
12 (4.8)
2 (0.8)
Total 1777 (100) 248 (100)
3According to the scale described by Holgers et al.16
Table 2 Frequency of Skin Reaction and Most Severe Skin Reaction Around the
Implant
No. (%)
Frequency of
skin reaction
follow-up, No.
Total adverse
skin reactions
per implant
Total skin reactions
rated as 2-4
per implanta
0
1
2
3
4
5
6
7
118 (47.6)
68 (27.4)
27 (10.9)
15 (6.1)
7 (2.8)
7 (2.8)
2 (0.8)
4 (1.6)
202 (81.5)
33 (13.3)
9 (3.6)
2 (0.8)
2 (0.8
0
0
0
Total 248 (100) 248 (100)
a According to the scale developed by Holgers et al.16
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[OPJRULZZ VM    TT (UHS`ZLZ KPK UV[ ZOV^ HU` Z[H[PZ[PJHSS` ZPNUPÄJHU[
correlations between skin thickness and implant loss (P=.58), or skin reactions of 
Holgers grades 1 and 2 (P=.48 and .65, respectively; there were too few cases of 
Holgers skin reactions of grades 3 and 4 for statistical comparison), or with the total
number of skin reactions (P$ ;OLYL^HZUVZPNUPÄJHU[JVYYLSH[PVUIL[^LLUZRPU
thickness and the vertical component (y) (P=.57). However, skin thickness was
ZPNUPÄJHU[S`JVYYLSH[LK^P[O[OLOVYPaVU[HSJVTWVULU[_TT"P<.002) and the
mean distance from the implant to the ear canal (0.2 mm; P<.001).
Next to the measurements of the thickness of the skin at the contralateral side to
the implant, the state of the skin level around the abutment was recorded during
follow-up in 192 patients. Thick skin, that is, skin reaching to the top of the 5.5-mm
abutment, had been noted in 81 patients (42.2%), with a mean rate of 2.4 observations
(range, 1-12 observations). Only 40 patients (16.1%) had 1 single observation of thick 
skin. The latter once-only events accounted for 49.4% of all the observations of thick 
ZRPU;OLTLHU:+ PU[LY]HS\U[PS [OLÄYZ[VIZLY]H[PVUVM[OPJRZRPU^HZ
months. In most of the cases, the thick skin was treated successfully with antibacterial
and steroid ointment or watchful waiting.
Tissue reduction surgery was performed on 23 implants (9.4%) at a mean period
of 34 months after implantation (range, 4-119 months) when thick skin persisted. One
patient required 1 subsequent tissue reduction surgery.
Comment
We evaluated the effect of the implant location and skin thickness on the frequency
and severity of skin reactions around the abutment. To evaluate this correlation, the
position of the implant (the mean distance from external auditory ear canal to the
implant) was measured (48.3 mm). This corresponds with the ideal site according to 
Table 3 Interval Between Implantation and Skin Reaction
Time to skin
Reaction
Type, mo
Implants
No. Range Mean (SD)
1
2
3
4
111
37
12
2
0-179
0-119
1-127
48-105
42.5 (34.0)
37.8 (35.5)
37.8 (39.8)
76.5 (40.3)
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the Nijmegen BAHA surgical procedure because it leaves enough space to
accommodate the BAHA transducer behind the auricle.14 No correlation could be 
found between implant location and the frequency and severity of skin reactions in 
this study.
To our knowledge, no previous studies have investigated a possible correlation
between implant location and skin reactions. Eeg-Olofsson et al,17 however, described
the position of the implant in relation to the external auditory ear canal. Their study 
was set up to determine the extent to which bone dampened sound transmission to 
the cochlea. They found that moving the vibrating stimulus closer to the cochlea
increased the velocity at the cochlear promontory. Combined with the results of our
study, the ideal implant site in terms of optimal sound transmission and low incidence
of skin reactions would be as close to the cochlea as possible.
It should be noted that skull dimensions can vary among individuals. Skull dimensions
also change with advancing age (eg, progressive decrease in the height of the 
neurocranium).18-19 Patil and Mody20KLZJYPILKZPNUPÄJHU[KPMMLYLUJLZPUJLWOHSVTL[YPJ
dimensions between men and women. In the current study, we adjusted the statistical
analyses for sex and age to address the differences in skull dimensions.
In BAHA surgery, special attention must be given to the handling of the soft
tissue in order to obtain thin hairless skin with optimal reduction of mobility. The
soft-tissue reduction technique used results in a gentle slope of the soft tissue in an
area of approximately 15 to 20 cm2 around the percutaneous implant, depending on
the length of the incision. At the basis of the abutment, postoperatively the skin
thickness varies from approximately 1 to 1.5 mm. Unfortunately, because skin
thickness measurements at the implant location were not performed in a structural
manner, a prospective analysis was not possible.
Implant loss is one of the major clinical outcome measures in BAHA surgery. In
our study, the total implant loss was 1.6% (4 of the 248 implants). Recent studies by
the Nijmegen BAHA team reported a 9.3% implant loss (14 of 150 implants) in a
consecutive series of 142 patients who had undergone BAHA surgery and in 6.5%
(14 of 248 implants) in 224 elderly patients who had undergone BAHA surgery.14,21 In
the literature, implant loss caused by failed osseointegration ranged from 0.4% to 7%,
whereas loss caused by infection ranged from 0.4% to 2.7%.5,7,9-10,22-23 The mean (SD) 
duration of follow-up in the current study was 78.4 (48.3) months (range, 12-220
months) compared with a range of 6 to 141 months in the literature.5,7,10,22 Rates of 
implant loss in these Nijmegen series are substantially lower than those described in
literature.
An explanation for the differences in implant loss might lie partly in the exclusion
of children from this study. Compared with the adult skull, the infant skull is less thick 
and has less mineral content and more water content. This is believed to be one of 
the causes of the higher risk of failed osseointegration in the younger population.7 In
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the study by Proops,22 implant loss occurred in 19 of 188 patients (10.1%); 10 of these
19 (52.6%) occurred in children. In the Nijmegen consecutive series of children,24
implant loss in children also accounted for a relatively large part of the percentage.
Overall implant loss in the Nijmegen series24 was 16.3% (21 of 129).
Another major clinical outcome measure in the follow-up after BAHA surgery is
skin reactions. Our data showed that 46 of the 248 patients (18.5%) had a severe skin 
reaction (Holgers grade, 2-4) at least once during follow-up. In this group of patients,
33 (71.7%) had a severe skin reaction only once. The rates of severe skin reactions in
the current study conform with those in the literature (3.4%-39.6%).5,10,16,25-27 These
data are also in line with those of previous studies performed within the BAHA 
program at the University Medical Centre. de Wolf et al14 found an incidence of 26.7%
(40 of 150) in a consecutive series of patients with BAHA implants.
Besides implant location, another potentially relevant variable is skin thickness.
Measurements found in this study varied from 2.0 to 11.0 mm, with a mean (SD) 
thickness of 5.5 (1.9) mm. No correlations were found between skin thickness and 
implant loss, Holgers grade 1 to 4 skin reactions, the y-component, or the total 
number of skin reactions. Measurements of the skin thickness were taken on the side
JVU[YHSH[LYHS[V[OLPTWSHU[:RPU[OPJRULZZ^HZZPNUPÄJHU[S`WVZP[P]LS`JVYYLSH[LK^P[O
the x-component and the distance between the implant and the ear canal (0.22 mm, 
P<.002; and 0.24 mm, P<.001, respectively). Thus, the greater the distance between
the implant and the ear canal, the thicker the skin. The procedure used for skin
thickness measurements was based on the assumption that the skin is of equal 
thickness on both sides.
In conclusion, no correlations were found between the distance from the superior
part of the external auditory ear canal to the implant nor between the horizontal and 
vertical positions of the implant and the type and number of skin reactions. Skin
thickness measured on the contralateral side was not correlated with the type and 
number of skin reactions. Comparatively, implant loss was not correlated with the 
distance from the superior part of the upper center of the external auditory ear canal
to the implant, the position of the implant, or skin thickness.
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Abstract
Objective: The aim of this study is to evaluate whether diabetes mellitus (DM) is a risk 
MHJ[VYMVY[P[HUP\TÄ_[\YLSVZZPUIVULJVUK\J[PVUKL]PJLZ)*+ZILJH\ZLVMVZZLV-
integration failure.
Study Design: Retrospective case study.
Setting: Tertiary referral center.
Patients: All patients who received a BCD at Nijmegen between January 1, 1988, and 
December 31, 2007, were analyzed. The analyses were performed on 833 patients 
(993 implants) and a subpopulation of patients aged 40 years or older consisting of 
641 patients (739 implants).
Methods: Patients received a questionnaire asking about the presence of DM at the
time of implantation. Data concerning implant loss were retrieved from medical 
records and the Nijmegen BCD database.
Results: The total survival rate of the BCD implant in this population was 90.6%. The
prevalence of DM was 9.3%. In the subpopulation of patients aged 40 years or older,
the non-DM group lost 5.1% of their implants versus 14% of Type 2 DM patients, a
Z[H[PZ[PJHSS`ZPNUPÄJHU[S`KPMMLYLUJLW$:WVU[HULV\ZSVZZSVZZK\L[VH.YHKL
4 Holgers skin reaction, and trauma accounted for 2.2% versus 4.7% (p = 0.13), 0.5%
versus 2.3% (p = 0.1), and 0.6% versus 4.7% (p = 0.007), respectively, of implant
losses in non-DM versus Type 2 DM patients.
Conclusion: The prevalence of DM among the Nijmegen BCD population is higher 
[OHU[OLNLULYHS+\[JOWYL]HSLUJL(Z[H[PZ[PJHSS`ZPNUPÄJHU[S`OPNOLYPTWSHU[SVZZ^HZ
observed during the study period for Type 2 DM patients than non-DM BCD wearers.
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Introduction
The bone-conduction device, BCD (formerly Bone-Anchored Hearing Aid [BAHA]) is
a semi-implantable percutaneous bone-conduction hearing aid. This device consists
of a titanium implant that is placed in the upper part of the mastoid portion of the
temporal bone, a skin penetrating titanium abutment and a sound transducer, which
the patient can attach on and remove from the abutment. The sound transducer
converts airborne sounds into vibrations. These vibrations are transmitted through
the skull by bone conduction directly to the cochlea, therefore bypassing the external
auditory canal and middle ear.1-5
Beginning in 1952, Brånemark (University of Göteburg, Sweden) began studying the
concept of tissue-integrated prostheses, which, after numerous animal studies, led
[V[OLÄYZ[KLU[HS[P[HUP\TÄ_[\YLPUO\THUZPU ;OLÄYZ[L_[YHVYHS[P[HUP\TÄ_[\YL
was implanted in 1977 by Tjellström (University of Göteburg, Sweden). Currently,
[OLZLV[VYOPUVSHY`UNVSVNPJÄ_[\YLZHYLZ[PSSILPUN\ZLK[VÄ[IV[OIVULJVUK\J[PVU
hearing aids and auricular epistheses.6
(JOPL]PUN PTWSHU[ Z[HIPSP[` PZ ULJLZZHY` [V ÄYTS` YVV[ [OL [P[HUP\T PU [OL [LTWVYHS
bone, allowing the vibrations to the cranium. The process of establishing new bone
formation that connects the implant and the surrounding bone, without intervening
connective tissue, is called osseointegration.5 There are 6 factors to consider to
achieve optimal osseointegration: implant material, implant design, surface quality, 
bone status, surgical technique, and implant loading conditions.7 There has been
continuous progress in these areas to improve osseointegration and the accompanying
survival rate of the BCD. Some of the latest improved implant designs, coated with
TiOblast, have shown increasingly promising results in the temporal bone.8
In Nijmegen, for more than 30 years, the BCD has been successfully used by patients
with conductive or mixed hearing loss for a wide range of external auditory canal and
middle ear disorders that prevent the use of a conventional air conduction hearing
aid. Although the BCD is a very successful treatment2,4,9, problems, such as adverse
skin reactions around the abutment, and implant loss either because of failure of os-
seointegration or trauma, have occasionally been described.3,10-12
Diabetes mellitus (DM) may be one of the factors that affect implant survival.7,13 Animal 
Z[\KPLZ PUKPJH[LZ\WWYLZZLKIVUL MVYTH[PVUZPNUPÄJHU[S` SLZZIVUL[VPTWSHU[JVU[HJ[
and woven bone instead of lamellar bone in animals with experimental Type 114-16 or Type
2 DM17,18 In Type 2 DM patients, both decreased biochemical markers for bone formation,
and elevated markers for bone resorption are found, indicating that these patients have 
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altered bone remodelling.19-23 Van de Berg et al.24 reported a DM prevalence of 9% in their
population of BCD wearers, well above the prevalence in the general Dutch population.25
Dun et al.8 also reported a prevalence of DM of 11%, the higher rate being predictable 
according to Baan et al.25 The only implant failure after 6 months of follow-up seen in the
present study group was observed in a patient with DM.8 These results have led to the
hypothesis that among the patients with DM, the implant failure rate might be higher
compared with non-DM patients. In Nijmegen, more than 1,000 patients have received a 
BCD since the beginning of the BCD program in 1988 under the guidance of Prof. Cremers.
This large study population is regarded suitable for investigating the hypothesis mentioned
above, as well as the prevalence of DM in our study population.
Patients and methods
Patients
At the Radboud University Medical Centre in Nijmegen, 974 patients received a total
of 1,150 implants during the period, which was from January 1, 1988, to December
31, 2007. Patients who passed away (117 patients; 12%), were unable to be contacted
during follow-up (12 patients; 1.2%), or did not want to participate in this study (12 
patients; 1.2%) were excluded. All analyses were conducted on the 833 remaining
patients with a total of 993 implants. In total, 106 patients (with 148 implants) were
younger than 18 years at the time of implantation.
Methods
All patients who received a BCD in Nijmegen during the 20-year study period were
sent a questionnaire in which they were asked whether they were diagnosed with
DM, the type of DM and the year of diagnosis. Prediabetes was not included in the
questionnaire. In addition, data concerning implant losses were retrieved from
medical records and the Nijmegen BCD database.
To discover whether implant loss occurs more frequently among patients with
DM, all patients younger than 40 years at the time of implantation were excluded from 
this analysis. Patients with DM Type 1 were excluded from the analysis to create 2 
comparable groups of patients over the age of 40 years.
Statistical Analysis
All data were analyzed using the Statistical Package for Social Sciences (SPSS, Inc.,
Chicago, IL, USA), version 16. The comparisons concerning age and sex were made 
using independent sample t tests. Statistical analysis regarding implant loss was
performed using Fisher’s exact test. The loss of implants was visualized with Kaplan–
4LPLYJ\Y]LZ=HS\LZVMW#^LYLJVUZPKLYLKZ[H[PZ[PJHSS`ZPNUPÄJHU[
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Results
The study population consisted of 833 patients with a total of 993 implants. All DM
patients were 40 years old and older. Two of these patients (0.2%) were diagnosed
with Type 1 DM, and 76 patients (9.1%) were diagnosed with Type 2 DM. Three
patients (0.4%) met the criteria for prediabetes, as was discovered by their general
practitioner. The remaining 752 patients (90.3%) did not have any type of diabetes.
The prevalence of diabetes in this study population was 9.3%. The mean age was 54
years in the total population, with a standard deviation of approximately 20 years. The
age distribution, categorized according to DM status, is presented in Figure 1. The
mean follow-up duration of the implants was 4 years and 9 months, ranging from 1
week to 22 years. The mean duration of disease for Type 2 DM patients was more
than 10 years, ranging from a few months to 63 years.
Overall, 93 of 993 implants were lost (9.4%). Divided in subcategories by the reason
for loss, 3.7% of the implants were spontaneously lost, 1.4% were lost because of 
trauma, and 1.2% were lost because of a Holgers Grade 4 skin reaction. The survival
YH[LVM[OLÄ_[\YLZMVY)*+ZHM[LY[OLÄYZ[`LHYZVM\ZLPU5PQTLNLU^HZ 
The group aged 40 years or older consisted of 641 patients, who received a total of 
739 implants. The baseline characteristics regarding patients, implants, indications
for BCD implantation, and implant loss are presented in Table 1.
In this subpopulation aged 40 years or older, 44 implants were lost (5.9%), resulting
in a survival rate of 94.1%. Separating the non-DM and Type 2 DM patients aged 40
`LHYZVYVSKLY[OLYL^ HZUVZPNUPÄJHU[KPMMLYLUJLIL[^LLUIV[ONYV\WZYLNHYKPUNZL_
Figure 1 Age distribution in study population.
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(t732$"W$;OLYL^HZHZPNUPÄJHU[KPMMLYLUJLPUYLNHYK[VHNL[123.6 = -7; 
p <= 0.001) as displayed in Table 1. However, the effect size was medium (r = 0.28).
In the non-DM patients 5.1% of the implants (n = 33 of 648) were lost, compared with 
14% of the implants (n = 12 of 86) in the Type 2 DM patients. This result was shown 
Z[H[PZ[PJHSS`ZPNUPÄJHU[W$I`-PZOLY»ZL_HJ[[LZ[(M[LYZLWHYH[PUN[OLPTWSHU[
SVZZYLHZVUPU[VZ\IJH[LNVYPLZ-PZOLY»ZL_HJ[[LZ[PUKPJH[LKHZPNUPÄJHU[KPMMLYLUJL
in implants lost because of trauma (p = 0.007) of 4.7% (n = 4) for patients with DM 
and 0.6% for non-DM patients. For spontaneous loss and implants lost because 
VM /VSNLYZ .YHKL  ZRPU YLHJ[PVUZ [OL KPMMLYLUJL ^HZ UV[ Z[H[PZ[PJHSS` ZPNUPÄJHU[
(p = 0.13 and p = 0.10, respectively). 
Table 1 )HZLSPULJOHYHJ[LYPZ[PJZWH[PLU[Z`LHYZ
Non-DM Type 2 DM
Characteristics Patients (n) 560 76
Implants (n) 648 86
Age (mean (± SD)) 61 (± 11.9) 69 (± 9.4)
Follow up (yrs (± SD)) 5 (± 4.4) 4,9 (± 3.7)
Indications Acquired CHL unilateral (n (%)) 372 (66.4%) 58 (76.3%)
Acquired CHL bilateral (n (%)) 72 (12.9%) 8 (10.5%)
Congenital CHL (n (%)) 26 (4.6%) 1 (1.3%)
SSD (n (%)) 90 (16.1%) 9 (11.8%)
Implant loss No loss (n (%)) 615 (94.9%) 74 (86%)
Spontaneous loss (n (%)) 14** (2.2%) 4 (4.7%)
Skin reaction grade 4 (n (%)) 3 (0.5%) 2 (2.3%)
Trauma (n (%)) 4 (0.6%) 4** (4.7%)
Other* (n (%)) 12 (1.9%) 2 (2.3%)
Months to
implant loss
Spontaneous loss (mean ((± SD)) 67,3 (±51,3) 50,6 (±35,3)
Skin reaction grade 4 (mean ((± SD)) 56,3 (±67,5) 83,5 (±14,8)
Trauma (mean ((± SD)) 26,3 (±17,7) 65,8 (±42,8)
CHL = conductive hearing loss, SSD = single sided deafness
*Implant lost by other causes, for instance removed due to chronic pain or esthetics, irradiated patient, etc.
**2 of the implants were lost in 1 patient
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Figure 2  A Spontaneous implant loss. Survival rate for spontaneous implant loss in 
patients with DM and non-DM patients. B Implant loss because of skin reaction 
Holgers Grade 4. Survival rate for implant loss because of skin reaction Holgers
Grade 4 in patients with DM and non-DM patients. C Implant loss because of trauma.
Survival rate for implant loss because of trauma in patients with DM and non-DM
patients.
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Figure 2 illustrates the survival curves of the implants, separated for spontaneous
loss, Holgers Grade 4 skin reactions, and trauma. The number of patients is displayed
(n (mean (±SD)).
Five patients were diagnosed with Type 2 DM within 5 years after implant loss. The data
regarding the time of the DM diagnosis in relation to implant insertion are presented
in Table 2.
Discussion
;OL[V[HSPTWSHU[Z\Y]P]HSYH[LPU[OLÄYZ[`LHYZVM[P[HUP\TPTWSHU[H[PVUMVY)*+ZPU
our study with patients who could be contacted and wanted to participate in the
study in Nijmegen is 90.6%, which is in accordance with the literature (82.5%–
96.6%).7,10-13,26 The literature mentions a failure of osseointegration found in 4%–13.6%
VMSVZ[Ä_[\YLZHUK[YH\THHJJV\U[LKMVY¶VM[OLPTWSHU[SVZZLZ10-12 These 
YH[LZHYL[HRLUMYVT[OLHSSHNLWH[PLU[WVW\SH[PVU6]LY[OL`LHYZ[OL[P[HUP\TÄ_-
[\YL )*+ Z\YNPJHS PTWSHU[H[PVU [LJOUPX\L ÄYZ[ PU[YVK\JLK I` ;QLSSZ[YT OHZ ILLU
YLÄULK12,24,27 ;OLZL YLÄULTLU[Z HYL NLULYHSS` JOHUNLZ PU ^H`Z [V YLK\JL [OL
subcutaneous tissue surrounding the implant.2 An analysis of these different surgical
techniques indicated no major differences in implant loss because of osseointegra-
tion failure24; therefore, no correction in the present study was made for the surgical 
technique used. The Nijmegen linear incision technique has been used for most of 
the implants (87%). Implants lost in patients with a history of irradiation, another 
known risk factor for implant loss7^LYL JSHZZPÄLK \UKLY [OL ¸V[OLY¹ JH[LNVY` MVY
implant loss (Table 1). None of the implants that were lost spontaneously due to 
/VSNLYZ.YHKLZRPUYLHJ[PVUVY[YH\TH^LYLTTÄ_[\YLZ"[OLYLMVYLUVJVYYLJ[PVU
Table 2 Diabetes Mellitus (DM) diagnosis in relation to implantation
DM years
before
implantation
DM same year 
as implantation
DM years after 
implantation
Total 38 (-10 (±11.8)) 5 33 (6.2 (±4.5))
Spontaneous loss 1 (-24) 3 (2.3 (±1.5))
Skin reaction grade 4 2 (-2 (±1.4))
Trauma 2 (-6 (±5.7)) 2 (3.5 (±2.1))
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for this well-known risk factor for implant loss had to be performed.10 Unfortunately,
UVJVUJS\ZP]LPUMVYTH[PVUVU[OLÄUHSRUV^UYPZRMHJ[VYZMVYPTWSHU[SVZZV]LYSVHK
and torsion forces can retrospectively be given.7.
Diabetes mellitus is a chronic disease characterized by hyperglycemia because of 
LP[OLY HIZVS\[L PUZ\SPUVWLUPH ;`WL +4 VY YLSH[P]L PUZ\SPU KLÄJPLUJ` HUK PUZ\SPU
resistance in the target organs (Type 2 DM). In year 2010, approximately 285 million
patients (20–79 yr) worldwide were affected, and without effective preventive
programs, this number is predicted to grow at least 50% over the next 20 years.28
Given these numbers, it is likely that the prevalence of DM will rise in the BCD patient
population as well, thereby increasing research interest in this group, especially in the
light of increased implant loss.
Currently, the prevalence of DM in the Dutch population is estimated to be
4.5%.25 Figure 3 shows the prevalence of DM according to age in the Dutch population
HUK PUV\YZ[\K`WVW\SH[PVU;OLKPMMLYLUJLZOV^U PU [OPZÄN\YL PZ PTWYLZZP]L-VY
almost all of the patients with DM, the indication for a BCD was recurrent otitis media
(71.1%), the patients with otitis externa account for 7.9%. A higher prevalence of these
diseases in DM patients is not found in the literature. However, because DM patients
are more prone to infection and poorer healing from infection29,30, theoretically, there 
might be an explanation for recurrent otitis externa, thus necessitating the use of 
BCD implantation instead of conventional hearing aids.
Prediabetes is a stage between normal glucose metabolism and diabetes, and it
covers the terms impaired glucose tolerance and impaired fasting glucose.31
Approximately, 30% of the Dutch population older than 60 years meets the criteria for
prediabetes. Within 6 years, 33% to 64.5% of these patients will change over to Type
2 DM24, as well as 5% of the normoglycemic population.32 In this study, 3 patients 
reportedly met the criteria for prediabetes as was discovered by their general
practitioner. In the group aged 60 years old and older, the patients with prediabetes 
account for only 0.8%. As this study was based on subjective reports of diabetes, this 
number was expected to be much higher. Therefore, prediabetes was not included in
this analysis.
The time between implant insertion and spontaneous loss is shorter in the DM 
patients than in the non-DM patients. Also, the non-DM patients received their 
implants at a younger age. For the patients who lost their implant because of trauma,
the time between implant insertion and implant loss is irrelevant as a trauma on the
implant was assumed to be time independent. However, it is striking that 50% of the 
implants that were lost because of trauma were in DM patients, despite the fact that
DM patients were only 9.4% of the total population. Unstable diabetes leads to less 
solid bone formation, and it can be assumed that the matrix offers less stability for the 
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implant. The trauma needed to breach the stability of the implant in patients with
diabetes might be smaller to patients without diabetes. Unfortunately, conclusive
data concerning the type and impact of trauma could not be retrieved in all cases
from the medical records.
;OLZLYLZ\S[ZHYL[V[OLILZ[VMV\YRUV^SLKNL[OLÄYZ[KH[HYLNHYKPUN[OLPUÅ\LUJL
of DM in patients with an extraoral titanium implant used for BCDs. Given the
outcomes of this study, a prospective analysis might be worthy to investigate the
hypothesis that DM is a prospective risk factor for implant loss.
Figure 3 A Prevalence of diabetes mellitus in male patients. The prevalence of 
diabetes mellitus in the male Dutch population versus the male patients in this study.
B Prevalence of diabetes mellitus in female patients. The prevalence of diabetes 
mellitus in the female Dutch population versus the female patients in this study.
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Conclusion
The prevalence of DM in this large study population was 9.3%, which is two times
higher than the estimated prevalence of 4.5% in the general Dutch population. This
study population presented an increased prevalence of implant loss in the group of 
DM patients aged 40 years or older (14% versus 5.1% in the non-DM group). These
outcomes should be considered in the future as part of individual patient treatment
processes.
80
CHAPTER 2.2
References
1. Håkansson B, Tjellström A, Rosenhall U, et al. The bone-anchored hearing aid. Principal design and a
psychoacoustical evaluation. Acta Otolaryngol 1985;100:229–39.
2. Snik AFM, Mylanus EAM, Proops DW, et al. Consensus statements on the BAHA system: where do we
stand at present? Ann Otol Rhinol Laryngol Suppl 2005;195:2–12.
3. Hobson JC, Roper AJ, Andrew R, et al. Complications of bone-anchored hearing aid implantation. J
Laryngol Otol 2010;124:132–6.
4. Ricci G, Della VA, Faralli M, et al. Results and complications of the BAHA system (Bone-Anchored
Hearing Aid). Eur Arch Otorhinolaryngol 2010;267:1539–45.
5. Burton MJ, Niparko JK, Johansson CB, et al. Titanium-anchored prostheses in otology. Otolaryngol
Clin North Am 1996;29:301–10.
6. Brånemark PI. Osseointegration and its experimental background. J Prosthet Dent 1983;50: 399–410.
7. Granström G. Craniofacial osseointegration. Oral Dis 2007;13:261–9.
8. Dun CAJ, de Wolf MJF, Hol MKS, et al. Stability, survival and tolerability of a novel Baha® implant 
system. Six-month data from a multi-centre clinical investigation. Otol Neurotol 2011; 32:1001–7.
  KL>VSM41-3LPQLUKLJRLYZ144`SHU\Z,(4L[HS(NLYLSH[LK\ZLHUKILULÄ[VM[OLIVULHUJOVYLK
hearing aid compact. Otol Neurotol 2009;30:787–92.
10. Badran K, Arya AK, Bunstone D, et al. Long-term complications of bone-anchored hearing aids: a
14-year experience. J Laryngol Otol 2009;123:170–6.
11. Reyes RA, Tjellström A, Granström G. Evaluation of implant losses and skin reactions around extraoral
bone-anchored implants: A 0- to 8-year follow-up. Otolaryngol Head Neck Surg 2000;122:272–6.
12. Proops DW. The Birmingham bone anchored hearing aid programme: surgical methods and
complications. J Laryngol Otol Suppl 1996;21:7–12.
13. Tjellström A, Granström G, Odersjö M. Survival rate of self-tapping implants for bone-anchored
hearing aids. J Laryngol Otol 2007;121:101–4.
14. Siqueira JT, Cavalher-Machado SC, Rana-Chavez VE, et al. Bone formation around titanium implants 
in the rat tibia: role of insulin. Implant Dent 2003;12:242–51.
15. Kwon PT, Rahman SS, Kim DM, et al. Maintenance of osseointegration utilizing insulin therapy in a
diabetic rat model. J Periodontol 2005;76:621–6.
16. Retzepi M, Donos N. The effect of diabetes mellitus on osseous healing. Clin Oral Implants Res
2010;21:673–81.
17. Wang F, Song YL, Li DH, et al. Type 2 diabetes mellitus impairs bone healing of dental implants in GK 
rats. Diabetes Res Clin Pract 2010;88:e7–e9.
 3P\A(YVUZVU1>HOS,*L[HS(UV]LSYH[TVKLSMVY[OLZ[\K`VMKLÄJP[ZPUIVULMVYTH[PVUPU[`WL
diabetes. Acta Orthop 2007;78:46–55.
19. Cakatay U, Telci A, Kayali R, et al. Changes in bone turnover on deoxypyridinoline levels in diabetic 
patients. Diabetes Res Clin Pract 1998;40:75–9.
20. Rosato MT, Schneider SH, Shapses SA. Bone turnover and insulin-like growth factor I levels increase
after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Int
1998;63:107–11.
21. Isaia GC, Ardissone P, Di SM, et al. Bone metabolism in type 2 diabetes mellitus. Acta Diabetol 1999;36:35–8.
22. Cutrim DM, Pereira FA, de Paula FJ, et al. Lack of relationship between glycemic control and bone
mineral density in type 2 diabetes mellitus. Braz J Med Biol Res 2007;40:221–7.
23. Takizawa M, Suzuki K, Matsubayashi T, et al. Increased bone resorption may play a crucial role in the 
occurrence of osteopenia in patients with type 2 diabetes: Possible involvement of accelerated polyol
pathway in its pathogenesis. Diabetes Res Clin Pract 2008;82:119–26.
24. van de Berg R, Stokroos RJ, Hof JR, et al. Bone-anchored hearing aid: a comparison of surgical
techniques. Otol Neurotol 2010;31:129–35.
25. Baan CA, Schoemaker CG, Jacobs-van der Bruggen MAM, et al.. Diabetes tot 2025. Preventie en zorg
in samenhang. 2009. Available at: http://www.rivm.nl/bibliotheek/rapporten/260322004.html. Accessed
July 2, 2011.
81
TITANIUM FIXTURES AND THE INFLUENCE OF TYPE 2 DIABETES MELLITUS
2.2
26. House JW, Kutz JW Jr. Bone-anchored hearing aids: incidence and management of postoperative 
complications. Otol Neurotol 2007;28:213–7.
27. de Wolf MJF, Hol MKS, Huygen PL, et al. *SPUPJHSV\[JVTLVM [OLZPTWSPÄLKZ\YNPJHS [LJOUPX\L MVY
BAHA implantation. Otol Neurotol 2008;29:1100–8.
28. Unwin N, Gan D, Mbanya JC, et al. International Diabetes Federation. IDF Diabetes Atlas. 2009.
Available at: http://www.diabetesatlas.org/content/global-burden. Accessed July 2, 2011.
29. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type
2 diabetes mellitus. Clin Infect Dis 2005;41:281–8.
30. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care
2003;26:510–3.
31. -VUZLJH=(,HYS`PKLU[PÄJH[PVUHUK[YLH[TLU[VMPUZ\SPUYLZPZ[HUJL!PTWHJ[VUZ\IZLX\LU[WYLKPHIL[LZ
and type 2 diabetes. Clin Cornerstone 2007;8:S7–18.
32. Poortvliet MC, Schrijvers CTM, Baan CA. Diabetes in Nederland. Omvang, risicofactoren en gevolgen,
nu en in de toekomst. 2007. Available at: http://www.rivm.nl/bibliotheek/rapporten/260322001.html. 
Accessed July 2, 2011.

Bone-Anchored Hearing Implant
Loading at 3 Weeks: Stability and
Tolerability After 6 Months
H.T. Faber
C.A.J. Dun
R.C. Nelissen
E.A.M. Mylanus
C.W.R.J. Cremers
M.K.S. Hol
Otology & Neurotology 2013;34:104-110
2.3
84
CHAPTER 2.3
Abstract
Objective: To clinically evaluate the performance of a titanium percutaneous 
bone-anchored hearing implant (BAHI) using a 3-week healing period. Short-term
implant survival, stability changes, and skin reactions are evaluated from the initial
implantation to 6 months post implantation.
Methods: Thirty patients eligible for a BAHI were included in an open, prospective
clinical investigation. Implant stability quotient (ISQ) values were recorded using
resonance frequency analysis (RFA) at the time of implantation and at 10 days; at 3,
6, and 12 weeks; and at 6 months after placement of the implant. Sound processor
Ä[[PUN ^HZ WLYMVYTLK  ^LLRZ HM[LY PTWSHU[H[PVU :RPU YLHJ[PVUZ ^LYL L]HS\H[LK
HJJVYKPUN[V[OL/VSNLYZJSHZZPÄJH[PVU
Results: One implant was lost 3 days after implantation because of poor bone quality.
No implant loss occurred in the remaining 29 patients (96.7%). The mean ISQ value
at the time of implantation was 67.1 (range, 44–71). Compared with baseline, there 
^HZHZPNUPÄJHU[KPWVM0:8\UP[ZH[KH`ZTLHU"W$ ;OLYL^HZ
a positive change in mean ISQ compared with baseline over the subsequent visits.
No reduction in mean ISQ values was observed after implant loading. Skin reactions
were observed incidentally (mean over all visits, 9.7%) and were generally mild 
(Holgers Grade 1; mean 9.0%). An adverse skin reaction (Holgers Grade 2) was 
observed only once (mean, 0.7%).
Conclusion: The current study suggests that loading the implant and 6-mm abutment
with the sound processor at 3 weeks is safe. The stability of the implant as measured
by ISQ values had reached its baseline value within 3 weeks after implantation. The
degree of stability was not affected by implant loading. Only mild skin reactions were
observed incidentally. This study supports the use of early loading at 3 weeks as
current practice in healthy adults with good bone quality; thus, these adults can
ILULÄ[MYVT[OLYLOHIPSP[H[PVUVM[OLPYOLHYPUNH[HULHYSPLYZ[HNL
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Introduction
Percutaneous bone conduction hearing solutions have been used for more than 30
years for the rehabilitation of patients with both conductive and mixed hearing loss.
+Y ;QLSSZ[YT ^HZ [OL ÄYZ[ [V WSHJL H WLYJ\[HULV\Z PTWSHU[ MVY IVULHUJOVYLK
hearing in 1977, using a Brånemark titanium implant.1 Over time, more companies 
have started to produce systems for percutaneous bone conduction hearing, a 
general name for the currently used percutaneous systems is bone-anchored hearing 
implants (BAHIs). The percutaneous BAHI is increasingly popular and is an important 
treatment alternative for patients when conventional air conduction devices are not a 
suitable option or not the best option.2-4
The percutaneous nature of the BAHI involves some drawbacks in terms of stability
and tolerability. Titanium implants can sometimes be lost spontaneously or as a
result of trauma, infection, or problems concerning osseointegration. Implant failure
rates have been reported to vary from 3.4% to 16.7%, with reported mean follow-up
times of 4 to 16 years.5-10 Higher failure rates of approximately 17% have been reported to
occur in children.7,11,12 Patients with diabetes mellitus may experience decreased
bone-implant stability and were recently reported to have a higher rate of implant loss
(14%).13 Granström14 evaluated osseointegrated craniofacial implants in irradiated
patients and found higher implant failures after previous radiotherapy in this group
than in a control group of nonirradiated patients. Furthermore, percutaneous
abutment coupling demands a permanent penetrated skin site that will require
lifelong daily care. Although adverse soft-tissue reactions occur in an average of 4.5%
of cases7 and can typically be easily resolved, some patients may display persistent
skin reactions with recurrent infections and may form granulation tissue that ultimately
requires surgical revision or reimplantation. New developments in implant and surface
design aim to achieve faster and superior osseointegration and to optimize the soft
tissue-implant contact, which may be the key in improving outcomes not only for
patients with compromised bone quality but for all patient groups.
Recently, a new designed titanium implant for percutaneous application was developed
IHZLKVU[LJOUVSVNPJHSRUV^SLKNLHUKYLJLU[KL]LSVWTLU[ZPU[OLÄLSKVMPTWSHU[
dentistry. This implant is designed with a TiOblast surface on the intraosseous portion 
of the implant as well as a wider diameter (4.5 mm compared with 3.75 mm for the 
previous-generation implant) with more and smaller threads at the implant neck. This
implant design is suggested to enhance osseointegration, which leads to stronger 
Ä_H[PVUPU[OLZ\YYV\UKPUNIVULJVTWHYLK^P[O[OLWYL]PV\ZNLULYH[PVUPTWSHU[15,16
Additionally, the abutment was changed from a conical design to a rounded, apically
converging design. The results from an ongoing clinical multicenter study with this
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implant showed higher implant stability quotient (ISQ) values as measured by
resonance frequency analysis (RFA) at the time of implant insertion and during 6
months of follow-up in comparison with the previous-generation implant.17 RFA is a
frequently used tool for obtaining objective measures of implant stability in the dental 
ÄLSKHUKPZPUJYLHZPUNS`\ZLK[VHUHS`aLL_[YHVYHSJYHUPVMHJPHSPTWSHU[Z;OLJSPUPJHS
ZPNUPÄJHUJL VM [OLZL ]HS\LZ Z[PSS YLTHPU [V IL M\Y[OLY LZ[HISPZOLK>P[O YLNHYK [V
HK]LYZLL]LU[ZZPNUPÄJHU[S`ML^LYZRPUYLHJ[PVUZ^LYLYLWVY[LKMVY[OL[LZ[PTWSHU[H[
6 months of follow-up.17 It was suggested that the rounded shape of the test abutment 
may have a positive effect on stabilization of the peri-implant soft tissue.
In the ongoing multi-center study, Dun et al.17 reported about the 6-month results of the 
same implant, which was loaded at 6 weeks after implantation, and RFA values were
not affected by loading the implant with the sound processor at this time point.
Therefore, it was concluded that the level of osseointegration reached 6 weeks after 
implantation is adequate to support the sound processor in healthy adults with good
bone quality. This loading time of 6 weeks after implantation is in accordance with a
JVUZLUZ\ZZ[H[LTLU[WYLZLU[LKPUI`L_WLY[ZPU[OLÄLSK^OPJOYLJVTTLUKLK
a loading time of between 4 and 6 weeks in adults.4 Similarly, the previous-generation 
implant was recently used in association with an earlier loading time.7,187H[PLU[ZILULÄ[
from this reduction in loading time, which may restore their hearing more rapidly.
On the basis on the favorable outcomes reported for this implant (for details, see
Method section) in the ongoing multicenter investigation, it was anticipated that the
[PTLIL[^LLUPTWSHU[H[PVUHUKZV\UKWYVJLZZVYÄ[[PUNTPNO[L]LUILM\Y[OLYYLK\JLK
using this implant. The authors considered it to be safe to reduce the loading time
from 6 weeks, as used in the preceding study by Dun et al.17, to 3 weeks in adult
patients with good bone quality. To clinically evaluate the performance of the implant 
using a 3-week healing period, short-term implant survival, ISQ changes, and skin 
reactions were evaluated from the initial implantation to 6 months post-implantation.
Comparisons were made with outcomes from the preceding study.17 Additionally, the
JOHUNLPUOLHS[OZ[H[\ZHM[LY)(/0Z\YNLY`^HZHZZLZZLK\ZPUN[OL.SHZNV^)LULÄ[
Inventory (GBI) questionnaire.19
Materials and methods
Patients and Procedures
Thirty consecutive patients eligible for receiving the BAHI were asked to participate in
the study. The patients had to be 18 years or older and provide written informed
consent. The criteria to exclude the patients from participation included the following:
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an inability to follow investigational procedures, any factor at the discretion of the
investigator that was considered to contraindicate participation, and any disease or
treatment known to compromise bone quality at the implant site (e.g., radiation
therapy).
Each enrolled subject received 1 Cochlear BAHA BI300 implant with a 6-mm 
abutment placed using the FAST one-stage surgical procedure.20 Soft-tissue
reduction in the area around the implant was performed according to the Nijmegen
linear incision technique.9 The sound processor was installed at least 3 weeks after
surgery. The decision to load the implant was made by the investigator based on a
subjective clinical assessment of the implant site; loading occurred only if the stability
of the implant and soft-tissue status were subjectively judged to be satisfactory.
Follow-up examinations were performed at 10 days; 3, 6, and 12 weeks; and 6
months after the implantation procedure. Any implant loss was recorded. ISQ values
were measured using RFA (Osstell, Göteborg, Sweden). RFA is a tool frequently used 
to monitor implant stability changes over time.21,22 The RFA instrument is used to 
activate a SmartPeg, which is screwed onto the abutment. The technique is
contactless and noninvasive, and patients experience no sensation from the
measurement, which takes 1 to 2 seconds. The RFA measurement reports ISQ
values from 1 to 100 (the higher the number, the higher the stability), as displayed by
the instrument. The highest (ISQ High) and lowest (ISQ Low) values that were obtained
from perpendicular measurements performed at each implant at each visit were
recorded. These values correspond to the directions with the highest and lowest 
stability, which are generally perpendicular to each other. Data analyses were
performed using ISQ High values. In case the abutment was changed from the
standard 6-mm abutment to a longer 9-mm abutment, the RFA data collected with
the longer abutment were not included in the analysis because a change in length of 
the abutment affects the ISQ value.
;OLZ[H[\ZVM[OLZVM[[PZZ\LZ\YYV\UKPUN[OLPTWSHU[ZP[L^ HZTVUP[VYLKHUKJSHZZPÄLK
HJJVYKPUN[V[OL/VSNLYZJSHZZPÄJH[PVU23
([TVU[OZ HM[LY PTWSHU[H[PVUWH[PLU[Z ÄSSLKV\[ [OL.)0X\LZ[PVUUHPYL ;OL.)0
measures the change in health status produced by surgical interventions.19,24 Three
domains are covered by 18 items, 12 related to general improvement, 3 to social
improvement, and 3 to physical improvement. Each question is answered on a
5-point Likert scale ranging from a large change for the worse to a large change for
the better. A summary score is calculated from the individual question scores. This
score is then divided by the number of questions (18) and multiplied by 50 after
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subtracting 3, to produce a score of between -100 (maximum deterioration) and +100
(maximum improvement).
Statistics
An independent statistician performed the statistical analyses. A weighted average of 
ISQ during the period of baseline (time of implantation) to 6 months follow-up was
obtained by determining the mean area under the curve (AUC) using the trapezoid
rule. The mean AUC was calculated for the time the implant was in function. For
implants lost to follow-up, last observation carried forward was used in the mean
AUC calculations. The statistical analyses were performed on the entire study
population as well as the subgroup of patients with loading times of 3 weeks.
The 52 implants that were placed in our center in the preceding study by Dun et al.17
served as a comparison group. Comparisons between the present study and the
preceding study were made using Fisher’s exact test for sex, the Mann-Whitney U
test for age and ISQ values, and the Mantel-Haenszel Chi-square test for the
comparison of Holgers scores between groups. A correction factor was developed
and validated in reference material by Osstell (Osstell, Goteborg, Sweden) to transfer
the ISQ values measured in the present study to corrected ISQ values to address the
use of different SmartPegs. Only these corrected ISQ values are presented throughout 
the study to make it possible to compare ISQ values between the present study and
[OLWYLJLKPUN[YPHSPTWSHU[Z[\K `(ZPNUPÄJHUJLSL]LSVM ^HZHKVW[LK
Results
Patients
Thirty patients were included in the study. The patient demographics are displayed in
Table 1. The study population was comparable to the population that received the
same implant (n = 52) in the preceding multicenter study17 with regard to age and sex.
Implant Survival
(TVUN[OLZLWH[PLU[ZWH[PLU[^ HZMV\UK[VOH]LPUZ\MÄJPLU[IVULX\HSP[`K\YPUN
surgery. At the time of surgery, the bone felt very soft, and the implant could be
moved by manual manipulation. The measured ISQ value at the time of implantation 
was 44. Subsequently, the implant was lost 3 days afterward. In the remaining 29
patients, none of the implants were lost (96.7%).
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2.3Implant LoadingThe implant was loaded with the sound processor in 29 patients. The mean loading
time was 3 weeks and 1.5 days. Loading of the implant occurred in 28 patients (97%)
within the 3-week visit window (mean, 3 wk and 1 d). One patient received the sound
processor at 36 days because of incomplete skin healing at 3 weeks post implantation;
therefore, placement of the sound processor was postponed.
Implant Stability
The mean AUC, which was determined based on ISQ values for the entire study
population, during the period from 0 to 6 months, was 68.1 (SD, 4.8). The mean ISQ
values were as follows: 67.1 (44–71) at the time of implantation (i.e., baseline); 65.8
(56–72) at 10 days; 68.9 (64–73) at 3 weeks; 68.5 (62–72) at 6 weeks; 69.2 (65–72) at 
12 weeks, and 69.6 (63–76) at 6 months (Figure 1). Assessment of the change in ISQ
K\YPUN [OL LHYS` OLHSPUN WLYPVK HM[LY IHZLSPUL ZOV^LK H Z[H[PZ[PJHSS` ZPNUPÄJHU[
decrease in stability from baseline to the next follow-up visit 10 days later. The change
in stability between the 2 initial visits was -2.1 (SD, 4.51; p = 0.0093) ISQ units. The
initial dip was followed by gradually increasing ISQ values. At 21 days, the change in
stability from baseline was 1.04 (SD, 2.27; p = 0.0166) ISQ units. Consecutive changes
from baseline were 0.697 (SD, 2.76; p = 0.1222) at 6 weeks, 1.11 (SD, 2.62; p =
0.0508) at 12 weeks, and 1.57 (SD, 2.35; p = 0.002) at 6 months (Figure 2). Evaluation
of stability changes as a result of implant loading at 3 weeks (n = 28) showed no
ZPNUPÄJHU[ YLK\J[PVU PU 0:8]HS\LZH[HUK ^LLRZHM[LYZV\UKWYVJLZZVYÄ[[PUN
(-0.005 ISQ units [p = 0.3031] and 0.007 ISQ units [p = 0.9192], respectively).
Soft-Tissue Reactions
Most examinations of soft-tissue reactions revealed no irritation (Holgers Grade 0).
:SPNO[YLKULZZ/VSNLYZ.YHKL^HZVIZLY]LKPUJPKLU[HSS `HUKH/VSNLYZJSHZZPÄJH[PVU
of 2 was recorded once, as indicated by the presence of red and slightly moist tissue
(Table 2; Figure 3).
Table 1 Demographics and baseline characteristics
Variable
Present study
(n = 30)
Preceding study17
(n = 52) p
Sex, n (%)
Male
Female
Age, mean (SD), yr
14 (46.7)
16 (53.5)
55.3 (12.3)
23 (44.2)
29 (55.8)
55.5 (13.8)
1.0000
0.9195
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Figure 1 Box plot of implant stability quotient values measured visit BL indicates
intraoperatve baseline measurement. “D” indicates day; ISQ, implant stability quotient; 
“m”, month; “w”, week.
Figure 2 Changes in ISQ based on visit compared with baseline ISQ for the implants 
(blue line) in the present study and the implants (red line) from the preceding study.
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GBI Questionnaire
The GBI displayed a positive change in overall health status with a total score of 
 :,;OLILULÄ[PU[OLNLULYHSKVTHPUILULÄ[^HZ :,"PU[OL
social support domain, this value was +4.2 (SE, 4.6), and in the physical health
KVTHPU [OPZ ]HS\L^HZ :, ;OLZ\IZJHSL ZJVYLVMNLULYHSILULÄ[^HZ
analyzed separately for 3 main subgroups based on cause. The score for each
subgroup was as follows: discharging mastoid cavities +31.3 (SE, 8.5), chronic active
otitis media +32.9 (SE, 4.4), and single-sided deafness +23.6 (SE, 8.2).
Comparison of Outcomes With Values Reported in a
Preceding Study
Mean AUC calculations for ISQ values during the period from 0 to 6 months showed
HZPNUPÄJHU[S`SV^LYTLHU(<*PU[OLWYLZLU[Z[\K`":+JVTWHYLK^ P[O[OL
mean AUC in the preceding study (70.4; SD, 2.1; p = 0.0025). The corrected mean
0:8]HS\LZPU[OLWYLZLU[Z[\K`^LYLZPNUPÄJHU[S`SV^LY[OHU[OVZLYLJVYKLKPU[OL
preceding study at all follow-up visits, except at the 6-week follow-up visit. A 
comparable trend of an initial decrease during the early healing period (10-day
follow-up visit) and a subsequent gradual increase in ISQ values over time was
observed (Figure 2). In the preceding study (Dun et al., 201117), loading at 6 ± 1 week 
occurred in 31 (60.0%) of 52 patients; the other patients received their sound 
Figure 3 Soft-tissue status as measured 
by Holgers' index at the 6-month follow-up
visit represented as the percentage of 
patients. Holgers Grade 0 signifies normal
skin; Holgers Grade 1 indicates slight
redness; and Holgers Grade 2 refers to
red and slightly moist tissue. Mean ISQ
and the 95% confidence interval of the
mean.
93
BONE-ANCHORED HEARING IMPLANT LOADING AT 3 WEEKS
2.3
processor after 7 weeks or later. No reduction in ISQ values after sound processor
Ä[[PUN^HZMV\UKPYYLZWLJ[P]LVMSVHKPUN[PTL
This distribution of local soft-tissue reactions was comparable between the present
study and the preceding study at all time points, except at the 12-week follow-up
]PZP[^OLU SVJHSYLHJ[PVUZ^LYLVIZLY]LKZPNUPÄJHU[S`TVYLVM[LU PU[OLWYLJLKPUN
study (p = 0.0204) (Table 2). This difference was based mainly on the higher incidence
of Holgers Grade 1 reactions, 23.4% versus 3.6%, at the 12-week visit.
Discussion
;OLJ\YYLU[Z[\KPLKPTWSHU[^HZKLZPNULKZWLJPÄJHSS`[VLUOHUJLPTWSHU[Z[HIPSP[`H[
the time of implantation and over time.15,16 Six-month RFA data gathered in a previous 
T\S[PJLU[LY PU]LZ[PNH[PVU MV\UK ZPNUPÄJHU[S` OPNOLY PTWSHU[ Z[HIPSP[` X\V[PLU[ 0:8
values in patients who received this implant compared with the previous-generation
implant at all time points from baseline implantation to 6 months of follow-up.17 Based
on this outcome, the time between implantation and loading the implant with the
sound processor was reduced from 6 weeks, as used in the earlier study17, to 3
weeks in the present study in adult patients with good bone quality. In the present 
investigation, loading the implant at 3 weeks was found to be safe with regard to 
implant loss and skin reactions. Additionally, no deterioration in ISQ values was found 
after loading the implant at 3 weeks from implantation.
The short-term survival rate of 96.7% obtained in this study compares positively with 
survival rates reported in the literature.7,9,10,25-27 A single instance of implant loss
occurred 3 days after implantation in a patient who showed poor bone quality at the 
implant site at the time of implantation. Nevertheless, this implant was placed, and an
ISQ value of 44 was measured. In a dental study by Glauser et al.28, it was noted that
0:8]HS\LZPUL]LU[\HSS`MHPSPUNPTWSHU[Z^LYLZPNUPÄJHU[S`SV^LY[OHU[OVZLVIZLY]LK
for the successful implants. However, reference RFA data for percutaneous titanium
PTWSHU[ZHYLUV[H]HPSHISLHUK[OL]HS\LZ [OH[^V\SK PUKPJH[LZ\MÄJPLU[ PU[LNYH[PVU
remain unknown. Further studies may lead to a minimum baseline ISQ value where 
loading can be considered to be safe.
;OL 0:8]HS\LZZOV^LKHZPNUPÄJHU[KPW PU [OLLHYS`OLHSPUNWLYPVK KH`ZHM[LY
baseline implantation. The level of stability recorded at baseline was regained after
only 3 weeks. This pattern of initial decrease and subsequent increase in ISQ values
was observed in the preceding study as well. In addition, similar temporary decreases
in stability have been reported for dental implants29,30 and have been associated with
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biological changes during early bone healing. Triggered by trauma to the bone
caused by implant surgery, a natural bone remodeling process starts with bone
relaxation and bone resorption. As bone healing proceeds, bone formation and
maturation dominate the bone remodeling process, and increasing stability may be
expected.31 No deterioration in ISQ values after implant loading at 3 weeks was
observed. This result suggests that the level of stability of the implants at 3 weeks 
after implantation of this implant is adequate to support the sound processor.
However, the present study was limited to adult patients with good bone quality. It will 
be of value to focus further research on the performance of the studied percutaneous 
titanium implants for bone conduction hearing in patients (also children) with 
compromised bone quality.
To compare ISQ values between the present study and the preceding study, a 
correction factor (provided by Osstell) was used to address the use of different 
SmartPegs. Although the 2 groups may share many characteristics, we recognize
[OH[[OL`^LYLUV[Z[YH[PÄLKVYPKLU[PJHS0[PZ[OLYLMVYLULJLZZHY`[VILJH\[PV\ZHZ
any differences between groups may be due to group rather than test differences. 
Compared with the preceding study, overall ISQ values of the current study were
ZPNUPÄJHU[S` SV^LY H[ HSS ]PZP[Z L_JLW[ MVY [OL ^LLR ]PZP[ 7VZZPIS ` [OL JVYYLJ[PVU
factor that was validated in reference material was not accurate enough or due to
Z\IQLJ[KPMMLYLUJLZ;OLZLÄUKPUNZLTWOHZPaL[OLPTWVY[HUJLVMM\Y[OLYTLHZ\YLTLU[Z
in other upcoming prospective studies to make comparisons between RFA data 
possible, to allow for further development of an objective and comparable criterion
ISQ value for loading and long-term follow-up in BAHI patients.
Complications in the form of skin reactions were limited in our study, and the skin
reactions that occurred were generally mild. A skin reaction of Holgers Grade 2 was
only observed once over the 6-month follow-up period (during the 6-week visit). The
PUJPKLUJLVMZRPUYLHJ[PVUZ^ HZJVTWHYHISL[V[OH[PU[OLWYLJLKPUNZ[\K `:PNUPÄJHU[S`
more cases of skin reactions were only observed at the 12-week visit were in the
preceding study; however, these cases were mainly mild (Holgers Grade 1) reactions.
Holgers Grade 1 reactions are regarded to be of minor clinical importance because
they do not require treatment. The incidence of skin reactions was unaltered by
implant loading, and it is therefore concluded that earlier loading is also safe
concerning skin reactions. The rounded shape of the abutment is presumed to be a 
decisive factor leading to stabilization of the peri-implant soft tissue and subsequent 
good tissue health.
In terms of quality of life, the GBI questionnaire showed an overall improvement
(mean GBI score, +20.9) in health status for all the patients in our study after 3 months 
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of implantation. A number of studies have reported substantial improvement (mean
GBI score, +28.9) in the experienced health of patients with conductive or mixed
hearing loss who undergo percutaneous titanium implantation.24,32,33 However, the 
L_[LU[VM[OLYLWVY[LKILULÄ[]HYPLZHTVUN[OLYLWVY[Z;HISL;OPZTPNO[ILK\L
to the difference in time at which the questionnaires were completed after BAHI
HWWSPJH[PVU/V^L]LY[OLL_WLYPLUJLKILULÄ[ PU[OLWYLZLU[Z[\K`^HZNYLH[LZ[ PU
the general domain (mean, +29.8). In the social and physical domains, the reported
ILULÄ[^HZT\JOZTHSSLYTLHUHUKYLZWLJ[P]LS`;OPZWH[[LYUPZZPTPSHY
to the results of other BAHI studies24,33 and the results of other otologic procedures19
with good outcomes. In the present study, the general domain of the GBI showed
NYLH[LZ[ PTWYV]LTLU[ PUWH[PLU[Z^P[OJOYVUPJHJ[P]LV[P[PZTLKPH;OPZÄUKPUN^HZ
previously reported by McLarnon et al.32 and Arunachalam et al.24, who also found 
[OH[[OLL_WLYPLUJLKILULÄ[]HYPLKKLWLUKPUNVU[OLPUKPJH[PVUMVYPTWSHU[H[PVU
Conclusion
9LK\JPUN[OLSVHKPUN[PTLPZL_WLJ[LK[VWYV]PKLILULÄJPHSLMMLJ[ZMVYWH[PLU[ZHZ
their hearing can be restored sooner than in previous treatment policy. After a
follow-up period of 6 months, it may be concluded that loading the implant and 6 mm
abutment with the sound processor loaded at 3 weeks was successful. Stability of 
the implant (ISQ) as measured by RFA had reached its baseline value within 3 weeks
Table 3 Results of the GBI questionnaire in the current study compared to those 
reported in the literature (adult patients)
Study Responding/
invited bone-
anchored hearing
implant users
Experience
with bone-
anchored
hearing
implant (m)
Total General Social 
support
Physical
Current 28/29 3 20.9 29.8 4.2 2.4
Arunachalam,
2001 (24)
51/60 >12 31.0 37.0 24.0 14.0
McLarnon,
2004 (32)
69134/168/94 NA 32.7 41.2 21.5 10.0
De Wolf,
2010 (33)
>12 23.0 30.0 13.0 7.0
NA indicates not applicable
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after implantation. No decrease in ISQ values was observed after implant loading. It
will be useful to establish reference ISQ values for deciding to load an implant. Still,
we need more ISQ data to determine these values. Together with positive outcomes
from other BAHI studies that reported short loading times when using the previous-
generation implant, the short-term results of this study encourage us to incorporate 
a 3-week loading time as a current practice in healthy adults with good bone quality.
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Abstract
Objective: This study assesses soft tissue reactions and implant stability of 1132 
percutaneous titanium implants (970 patients) for bone conduction devices (BCD). In
addition, it examines BCD usage and comparisons between different patient groups.
Patients: The surveyed cohort was divided into 3 different age groups (children,
adults, and the elderly). In addition, 4 groups with variable loading times (i.e., the time
between placement of the implant and loading the BCD sound processor) were
PKLU[PÄLKHZ^LSSHZHZ\INYV\WVMWH[PLU[Z^P[OTLU[HSYL[HYKH[PVU
Main Outcome Measures: Soft tissue reactions around the percutaneous implants as
JSHZZPÄLKI`[OL/VSNLYZNYHKPUNZ`Z[LTPTWSHU[MHPS\YLHUKYL]PZPVUZ\YNLY`YH[LZ
Results: In 95.5% of the 7415 observations of 1132 implants, there were no adverse
ZVM[[PZZ\LYLHJ[PVUZ0TWSHU[SVZZ^HZ:PNUPÄJHU[S`TVYLZVM[[PZZ\LYLHJ[PVUZ
and implant failures were observed in children compared to adults and the elderly (p
< 0.05). Implant survival was lower in patients with mental retardation compared with
patients without mental retardation (p $;OLSVHKPUN[PTLKPKUV[PUÅ\LUJL[OL
occurrence of soft tissue reactions and implant survival rates.
Conclusions: Children and patients with mental retardation are the most vulnerable to
soft tissue reactions and implant losses. Additional and more frequent care needs to
be given during outpatient consultations. Because loading as early as 3 to 5 weeks
did not negatively affect skin reactions or implant survival, full BCD installation can
occur earlier without risk.
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Introduction
Since the introduction of percutaneous bone conduction devices (BCDs) by Tjellström
et al.1 in 1977, the surgical procedure for the implantation of the titanium implant and
HI\[TLU[ OHZ ILLU HKQ\Z[LK ZL]LYHS [PTLZ :L]LYHS Z\YNPJHS TVKPÄJH[PVUZ OH]L
subsequently been reported.2-130UNLULYHS[OLHPTVM[OLTVKPÄJH[PVUZPZ[VWYV]PKL
a hairless skin area around the abutment site and provide a maximum reduction of 
subcutaneous tissue. Both of these factors are intended to achieve a solid and close 
attachment of the skin to the bone tissue. Better attachment reduces movement of 
the skin around the implant and debris entrapment.14 The most frequent complication
of a percutaneous implant is a soft tissue reaction around the titanium skin-penetrat-
ing coupling.14 While mild skin reactions can be successfully treated with hygienic
care and the use of medical ointment, severe skin reactions can present more serious
outcomes, such as skin overgrowth, implant extrusion, and chronic wound infections.4,8,9,12
There are several other relevant post-BCD surgery complications, including
permanent hypertrophic skin around the percutaneous abutment, implant loss, and
persistent pain.15,16 Surgical outcomes for a variety of patient groups have been
reported. However, comparisons of the outcomes between patient groups have
HS^H`Z ILLU KPMÄJ\S[ ILJH\ZL [OL Z\YNPJHS [LJOUPX\LZ HUK TL[OVK VM YLNPZ[LYPUN
complications vary among BCD centers. Depending on the BCD center and the
follow-up duration, the rates of implant loss in adults have varied from 3.5% to
17.4%.1,4,7,8,17-20 In children, the rate of implant loss varied from 5.3% to 26%.21-27 It is 
possible that taking good care of the skin surrounding the abutment might be more 
KPMÄJ\S[ MVY JOPSKYLU HUK WH[PLU[Z ^P[O TLU[HS YL[HYKH[PVU YLZ\S[PUN PU OPNOLY
complication rates. Sheehan and Hans described early soft tissue problems in 47% 
of adult BCD patients with Down syndrome; however, implant failure rates were not a 
ZPNUPÄJHU[ WYVISLT28 These differences make a comparison of clinical outcomes 
between different subgroups relevant. 
Good implant osseointegration is the key to success of the BCD system, 
especially before implant loading with the BCD sound device. During the years, the
loading time of the implant has been reduced. In 2005, Snik et al. published an expert 
consensus statement on this topic that was prepared the previous year.29 In this
statement, a loading time of between 4 and 6 weeks was advised for adults, and a
loading time of at least 3 months was advised for children10 years or younger. Later,
in 2007, Wazen et al. reported on 26 cases with an average loading time between 5 
and 9 weeks in adults (average of 6.5 wk).30 After examining the clinical data in
conjunction with laboratory research data, the authors indicated that it would be safe 
to reduce loading times from 3 months to 6 weeks in adults but also concluded that 
HKKP[PVUHS YLZLHYJO IHZLK VU H SHYNLY WH[PLU[ NYV\W^HZ ULLKLK [V JVUÄYT [OLPY
recommendations. On the basis of clinical experience, a 6-weeks loading time is now 
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generally well accepted and practiced.19 However, in Nijmegen, before completion of 
the study of Wazen et al., a loading time between 6 and 8 weeks was already common 
and in practice for years in healthy adults. However, detailed reports on these clinical
outcomes in a larger series comparing variable loading times and the incidence of 
complications and implant failure rates are still not available.
0U5PQTLNLU[OLÄYZ[)*+Z\YNLY`^HZWLYMVYTLKPU1\UL HUKI`[OLLUK
of 2007, more than 1000 BCDs had been implanted. A consistent follow-up of these
patients was performed with the systematic recording of main clinical features using
a standardized checklist. This procedure resulted in a large amount of data and
clinical experience. The current study presents the clinical outcomes of a series of 
more than 1000 implants. The size of the series allows us also to identify variable
groups and compare the outcomes of BCD surgery and usage across different
patient groups. Knowledge of these outcomes might be helpful in preoperative and
postoperative consultation because the outcome data include data gathered during
a 20-year period.
Patients and Methods
The patient cohort consisted of 970 patients who received 1132 titanium BCD
implants between September 1, 1988, and December 31, 2007. Initially, the original 
Tjellström skin graft technique was used. A hairless skin graft was typically derived
from the retro-auricular fold. In 1995, the application of a free skin graft had been
abandoned because that type of graft proved to be more prone to necrosis. A 
ZPTWSPÄLK[LJOUPX\L^HZKL]LSVWLKZ[LWI`Z[LWH[5PQTLNLU;OLLUKYLZ\S[VM[OL
ZPTWSPÄJH[PVU^HZHZPTWSL SVUNP[\KPUHS SPULHY PUJPZPVU;OL [LJOUPX\L MHJPSP[H[LZH
wider subcutaneous tissue reduction while avoiding the need for a thinned skin
ÅHW18,19,31 The clinical reports on the outcomes of the Nijmegen linear incision 
technique have been previously described and included the following patient groups: 
(i) a 3-year follow-up cohort study between January 1997 and December 199919, (ii) 
BCD implantation between 1994 and 2007 in children 16 years and younger32, (iii)
BCD implantation between 1995 and 2007 in adults aged 60 years or older33, and (iv) 
BCD implantation in a random sample of patients34. The data from these clinical
studies formed the basis of the current study. However, over 400 cases have been 
added, and the total cohort was redivided into subgroups. The patients were divided
into groups according to patient age at implantation (children, adults and the elderly). 
-V\Y NYV\WZ^P[O ]HYPHISL SVHKPUN [PTLZ^LYL PKLU[PÄLK HZ^LSS HZ H Z\INYV\W VM
WH[PLU[Z^P[OTLU[HSYL[HYKH[PVU;OLKL[HPSZVMOV^[OLNYV\WZ^LYLJSHZZPÄLKHUK
the group sizes are listed in more detail in the following sections.
105
CLINICAL OUTCOMES OF BCD SURGERY
2.4
Age at implantation
;OLHNLH[ PTWSHU[H[PVU^HZKLÄULKHZ [OLWH[PLU[HNLH[ [OL [PTLVM [OLZ[HNL
Z\YNLY`VY [OLÄYZ[Z[HNL PUJHZLVMHZ[HNLZ\YNLY `;OYLLKPMMLYLU[HNLNYV\WZ
^LYLKLÄULK!JOPSKYLU\W[V`LHYZU$HK\S[ZVM[VU$ HUK[OL
elderly older than 65 years(n = 194).
Mental state
-VY[`ZP_U$PTWSHU[ZPUWH[PLU[Z^P[OTLU[HSYL[HYKH[PVU^LYLPKLU[PÄLK5V
SL]LSVMYL[HYKH[PVU^HZHZJYPILKPU[OLWH[PLU[ÄSLZHUKTLU[HSS`YL[HYKLKWH[PLU[ZVM
varying severities were included in this group.
Loading time
3VHKPUN[PTL^HZKLÄULKHZ[OL[PTLIL[^LLUWSHJLTLU[VM[OLPTWSHU[HUKSVHKPUN
the implant with the BCD sound processor. In recent years, a trend toward reduced
loading time was observable in the series. The loading time varied from 3 to more 
than 12 weeks. Therefore, the cohort was divided into 4 groups: loading at 3 through
5 weeks (n = 88), loading at 6 through 8 weeks (n = 567), loading at 9 through 11
weeks (n = 203) and loading at or after 12 weeks (n = 228). In 46 cases, loading time
JV\SKUV[ILVI[HPULKMYVT[OLWH[PLU[»ZÄSL
Data Collection
0UNLULYHSYL[\YU]PZP[Z^LYLULLKLKIL[^LLU[OLPTWSHU[H[PVUHUK[OLÄ[[PUNVM[OL
BCD sound processor, to evaluate the healing process. In the initial years of BCD
Z\YNLY `HM[LY[OLÄ[[PUNVM[OL)*+ZV\UKWYVJLZZVYWH[PLU[ZULLKLKHJOLJR\WH[
least every 4 months. In later years, this checkup interval was prolonged to 6 months,
and once every year is the current standard. Patients were responsible for scheduling
these outpatient clinic checkups. When problems arose, the physician was able to
set up extra visits, and patients were free to ask for extra visits. Using this follow-up
policy, the number of outpatient visits varied for each implant and depended on the
year of implantation, follow-up time, and the problems that occurred.
At each visit, the degree of soft tissue reaction and the related medical response
^LYL JSHZZPÄLK \ZPUN [OL/VSNLYZ NYHKPUN Z`Z[LT14 A standardized checklist was
\ZLKMVYKH[HLU[Y`PU[V[OLTLKPJHSÄSLZH[[OLV\[WH[PLU[JSPUPJ
;OLWH[PLU[TLKPJHSÄSLZ^LYLYL]PL^LKHUKPUKPJH[PVUZMVY)*+Ä[[PUNZ\YNPJHS
notes, BCD use, revision surgery and implant loss were recorded. For every follow-up visit
PU[OLWH[PLU[ZÄSLKL[HPSZYLNHYKPUNZRPUYLHJ[PVUZZRPUV]LYNYV^[OHUKWHPU^LYLUV[LK
Statistical Analysis
All data were analyzed using SPSS16.0 (SPSS, Inc., Chicago, IL, USA).. The mean
skin reaction scores were calculated by dividing the sum of observed skin reactions
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by the total number of observations performed. A more clinically relevant mean skin
reaction score was calculated by dividing the sum of observed adverse skin reactions
/VSNLYZ I` [OL [V[HS U\TILY VM VIZLY]H[PVUZ ;OPZ ZLJVUK JHSJ\SH[PVU ^HZ
performed because patients with adverse skin reactions needed to be treated in
JVU[YHZ[[VWH[PLU[Z^P[OUVVYTPSKZRPUYLHJ[PVUZ/VSNLYZ;OLJVTWHYPZVUZVM
mean (adverse) skin reaction scores and the number of revision surgeries between
subgroups were performed using a robust analysis of variance test. With different
sample sizes and assuming unequal variances, pairwise comparisons were 
performed using a post-hoc Games-Howell procedure. A Kaplan-Meier curve was 
used to analyze implant survival. Comparisons between the survival curves of 
KPMMLYLU[NYV\WZ^LYLTHKL\ZPUNHSVNYHUR[LZ[;OLSL]LSVMZPNUPÄJHUJLMVYHSS[LZ[Z
was p
Results
Baseline characteristics
Titanium implants (n = 1132) for BCD use were implanted in 970 patients between
September 1988 and December 2007. Forty-eight percent (48%) of the patients were
men, and 52% were women. The mean age at implantation was 47 years (range, 
`Y"Z[HUKHYKKL]PH[PVUZB:+D`Y([V[HSVM  WH[PLU[Z^LYLÄ[[LK^P[O
H)*+VUZPKLHUK  WH[PLU[Z^LYLIPSH[LYHSS`Ä[[LK;OLTLKPHUMVSSV^\W
period was 3.6 years (mean, 4.6 yr; range, 0-22 yr; SD, 4 yr). An overview of the 
PUKPJH[PVUZMVYH)*+Ä[[PUNPZWYLZLU[LKPU;HISL;OLIHZLSPULJOHYHJ[LYPZ[PJZVM[OL
patients groups formed by age and mental state at time of implantation are presented
in Table 2. 
Surgical technique
In 108 of the cases, a skin grafting technique was used to manage the soft tissue
during the implantation. Most of the skin grafts were taken from the retroauricular fold
(n = 87). In 1024 of the cases, various incision techniques that did not make use of a
Table 1 Indications for BCD titanium implants in 970 patients
Indication N (%)
Acquired conductive/mixed hearing loss
Congenital conductive hearing loss
Single-sided deafness
Total
756 (77.9)
117 (12.1)
97 (10.0)
970 (100)
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linear incision technique (986 cases, 87%).
Skin reactions
During the mean follow-up period of 4.6 years, 7415 observations were made for the
total group of 1132 implants. An overview of the skin reaction observations in the
different subgroups is given in Table 3. Statistical analysis indicated statistically
ZPNUPÄJHU[OPNOLYTLHUZRPUYLHJ[PVUZJVYLZPUJOPSKYLUTLHU":+JVTWHYLK
with both adults (mean, 0.19; SD 0.30; p = 0.032) and to elderly patients (mean, 0.15;
SD, 0.35; p = 0.011). In addition, the mean adverseZRPUYLHJ[PVUZZJVYLZ/VSNLYZ
^LYLZPNUPÄJHU[S`OPNOLYPUJOPSKYLUTLHU":+JVTWHYLK^P[OHK\S[ZTLHU
0.05; SD, 0.16; p = 0.042) but not compared with elderly patients (mean, 0.05; SD,
0.20). There was no statistical difference between adults and elderly patients in either
the mean skin reaction scores or the mean adverse skin reaction scores.
Table 2 )HZLSPULJOHYHJ[LYPZ[PJZVMWH[PLU[NYV\WZHZ PKLU[PÄLKI`HNLHUKTLU[HS
Z[H[LH[[OL[PTLVM[P[HUP\TÄ_[\YLPTWSHU[H[PVU
Children Adults Elderly Mental 
retardation
No. implants
No.patients
Age, mean (range), yr
Follow-up, mean (range), mo
145
105
9.5 (3-16)
41 (0-262)
793
692
46.6 (17-65)
61 (0-257)
194
173
72.9 (66-87)
43 (0-156)
46
38
37.7 (3-78)
41 (0-219)
Table 3 Distribution of skin reactions (Holgers grading system) over observations
Holgers
grade
Total 
cohort
Children Adults Elderly Mental 
retardation
n % n % n % n % n %
0
1
2
3
4
6,329
746
253
73
14
85.4
10.1
3.4
1.0
0.2
535
73
33
11
7
81.2
11.1
5.0
1.7
1.1
4,799
604
186
53
7
85.0
10.7
3.3
0.9
0.1
995
69
34
9
0
89.9
6.2
3.1
0.8
0.0
213
42
13
7
2
76.9
15.2
4.7
2.5
0.7
Total
  observations 7,415 100 659 100 5,649 100 1,107 100 277 100
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7H[PLU[Z^P[OTLU[HS YL[HYKH[PVUOHK ZPNUPÄJHU[S` OPNOLY ZRPU YLHJ[PVU ZJVYLZ [OHU
patients without mental retardation (p = 0.33; Table 3). However, the mean adverse
skin reaction scores did not differ between these groups.
In Table 4, the skin reaction observations as a function of loading time are
presented. Both the mean skin reaction scores and the mean adverse skin reaction
scores were comparable among the 4 groups (p > 0.05).
Implant loss
A total of 94 (8.3%) implants were lost or electively removed, with a mean time until 
SVZZVM `LHYZ TLKPHU":+ `Y4VZ[ PTWSHU[Z^LYL SVZ[ PU [OL ÄYZ[
months after implantation (n = 53/94 total lost or electively removed implants, 56%; 
-PN\YL  ,SLJ[P]L YLTV]HS LN ILJH\ZL VM WHPU VY UV )*+ ILULÄ[ VM PTWSHU[Z
VJJ\YYLKVUS`PU[OLÄYZ[TVU[OZHM[LYPTWSHU[H[PVU
Twenty-two implants (15.2%) were lost in children, with a mean age of 11 years. In the
adult group, 58 implants (7.3%) were lost, and 14 implants (7%) were lost in the elderly
group. Spontaneous loss was the most frequent type of implant loss in all age groups.
In children and the elderly, the second most common cause of loss was trauma. In
the adult group, infection and lack of osseointegration were the second most
common cause. In Figure 2, the Kaplan-Meier survival curves for the implants are 
plotted according to the three age categories groups (i.e., children, adults and the
elderly). A comparison of implant survival between groups indicates that there was a
ZPNUPÄJHU[KPMMLYLUJLPUZ\Y]P]HSIL[^LLUHNLNYV\WZp = 0.000). A pairwise analysis
Table 4 Distribution of skin reactions (Holgers grading system) over observations
per loading time group
Holgers grade Loading time (wk)
3-5 6-8 9-11 Ĩ
n % n % n % n %
0
1
2
3
4
710
103
25
5
1
84.1
12.2
3.0
0.6
0.1
2,691
309
106
24
5
85.8
9.8
3.4
0.8
0.2
1,196
135
51
20
0
85.4
9.6
3.6
1.4
0.0
1,556
171
66
22
8
85.4
9.4
3.6
1.2
0.4
Total
   observations 844 100 3,135 100 1,402 100 1,823 100
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YL]LHSLK [OH[ [OPZ Z[H[PZ[PJHSKPMMLYLUJLJVUZPZ[LKVMHZPNUPÄJHU[S` SV^LYZ\Y]P]HS PU
children compared with adults (p = 0.000) and the elderly (p = 0.020). The survival 
curves between adults and the elderly showed no differences.
Figure 1 Time until implant loss and reason of loss. Spontaneous indicates no
known cause of loss; Trauma, loss caused by trauma; Pain, implants that have been
electively removed because of chronic pain; Other, implants removed at the patients’ 
YLX\LZ[ZILJH\ZL[OLYL^HZUV)*+ILULÄ[HM[LYKL[LYPVYH[PVUVMJVJOSLHYM\UJ[PVU
for aesthetic reasons or for re-implantation of implants to achieve a more optimal
placement.
Figure 2 Implant survival analyses for the total cohort, different age groups, and
patients with mental retardation.
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Of the 46 implants in patients with mental retardation, 8 implants (17.4%) were
lost during follow up, and spontaneous loss was the most frequent reason (n = 5). 
Implant survival analyses revealed a statistically lower implant survival in mentally 
retarded patients compared to non-mentally retarded patients (p = 0.001).
Table 5 shows the number of implant losses in the 4 loading time groups within
a given time period after implantation. A comparison of implant survival curves between
[OLKPMMLYLU[SVHKPUN[PTLNYV\WZPUKPJH[LKUVZPNUPÄJHU[KPMMLYLUJLp = 0.550).
Revision surgery
In 68 (6.6%) out of 1032 implants, revision surgery of the implant site was performed
at least once. Overall, soft tissue revision surgery was performed 89 (7.8%) times.
6[OLY PUKPJH[PVUZ MVY YL]PZPVU Z\YNLY` PUJS\KLK [OL Ä[[PUN VM H UL^ VY TT
abutment (n = 12) and exploration of implant site (in cases of pain and problematic
wound healing) (n = 7). Soft tissue revision surgery was performed relatively more
often in children (n = 16/145, 11%) than in adult patients (n = 69/793, 8.7%) and elderly
patients (n= 4/194, 2%). Statistical analyses indicated that soft tissue revision surgery
^HZWLYMVYTLKPUZPNUPÄJHU[S`ML^LYJHZLZPULSKLYS`WH[PLU[Z[OHUPUHK\S[JHZLZp =
Table 5  Implant loss per loading time group
Loading time (wk)
3-5 6-8 9-11 Ĩ
No.cases (% of 
total cases)
88 (7.8) 567 (50.1) 203 (17.9) 228 (20.1)
No.nonelective 
implant extrusions
Within 1 jr
1-2 yr
After 2 yr
0
1 (5)
5 (2x1, 3xS)
12 (2xI, 3xT, 7xS)
1 (T)
20 (4xI, 6xT, 10xS)
3 (S)
0
8 (2xI, 4xS, 2xT)
14 (2xI, 3xT, 9xS)
2 (1xI, 1xT)
5 (1xI, 2xT, 2xS)
No.elective implant 
extrusions
Within 1 jr
1-2 yr
After 2 yr
0
0
1 (P)
1 (P)
3 (2xP, 1xB)
4 (1xP, 2xR, 1xE)
1 (R)
2 (P)
1 (B)
1 (P)
0
3 (1xP, 2xB)
Total no. extruded
implants (% of 
implants in group)
7 (8.0) 41 (7.2) 15 (7.4) 25 (11.0)
Causes of nonelective implant extrusions: I indicates infection; S, spontaneous loss; T, trauma
*H\ZLZVMLSLJ[P]LPTWSHU[L_[Y\ZPVUZ!)PUKPJH[LZUV)*+ILULÄ[!,LZ[OL[PJZ"7WHPU"9YLPTWSHU[H[PVU
of implant to a more optimal position.
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0.001) and child cases (p = 0.016). The difference between children and adults was
UV[ZPNUPÄJHU[ 0UWH[PLU[Z^P[OTLU[HSYL[HYKH[PVUZVM[ [PZZ\LYL]PZPVUZ\YNLY`^HZ
needed 3 times (n= 3/46, 6.5%), but this was not statistically different when compared
with the total cohort.
Discussion
Overall, of the 7415 observations collected for the 1132 implants with a mean follow-up
time of 4.6 years, the soft tissue around the abutment demonstrated no adverse
reaction in 95.5% of implants. Children were more prone to adverse skin reactions.
6M [OL  PTWSHU[LK HUK SVHKLK PTWSHU[Z  ^LYL SVZ[ :PNUPÄJHU[S` SV^LY
implant survival rates were noted for children and patients with mental retardation.
The time between placement of the implant and loading the BCD sound processor
KPK UV[ PUÅ\LUJL PTWSHU[ Z\Y]P]HS 9L]PZPVU Z\YNLY` YH[LZ ^LYL SV^LZ[ PU LSKLYS`
patients and comparable rates were found between the other subgroups.
Since the introduction of the bone-anchored hearing aid technique, several BCD
teams have reported on BCD surgery outcomes. Over time, the implantation
[LJOUPX\LZ OH]L ILLU YLÄULK HUK ZOHYLK HTVUN )*+ Z\YNLVUZ SLHKPUN [V H
reduction in complication rates and surgical time. The Nijmegen bone-anchored 
hearing aid program joined in these developments and has been implanting patients
for more than 20 years. After using several skin grafting techniques, the Nijmegen
linear incision technique was developed. In 1999 and 2008, the Nijmegen BCD team 
reported it to be superior and therefore the preferred technique.18,19 In our center, it
has been the most commonly used technique (87%) in the last 15 years. Van de Berg
et al.16 recently compared the complication rates of four surgical techniques and
found that the use of 2 broad pedicled, local skin envelopes (linear incision technique)
^HZ HZZVJPH[LK ^P[O ZPNUPÄJHU[S` ML^LY THQVY JVTWSPJH[PVUZ JVTWHYLK [V ZRPU
grafting techniques (full-thickness, split-skin and dermal grafts).
In addition to comparing the outcomes of surgical techniques, the outcomes in
various BCD populations are of interest because they can be helpful during pre- and
post-operative consultations with different patient groups. Hobson et al.15 reported 
details of 602 bone-anchored hearing aid implantation procedures. However, none of 
the larger series in literature reported internal comparisons between the outcomes of 
various groups of patients. The present study is the largest BCD population study 
reported to date, with more than 1000 implants examined. The size of the population 
allowed us to identify variable subgroups and to compare the outcomes of BCD 
surgery and BCD usage across different patient groups. 
The main foci of this article were soft tissue reactions (as graded according to 
Holgers grading system), implant loss, and revision surgeries. Using a standardized 
112
CHAPTER 2.4
checklist in the patient chart, this information was made available during every
outpatient clinical observation of the BCD implant site, which was of great value in
enabling a retrospective evaluation of these data. In the majority of observations
(95.5%), no adverse skin reactions were present (Table 3). This result is consistent
with other studies reporting that 97.6% and 97.9% of BCD implants result in no 
adverse skin reactions (Holgers 0 and 1).8,10 More adverse skin reactions were 
observed in the tissue surrounding implants in children. This result is consistent with 
[OLO`WV[OLZPZ[OH[[OPZNYV\WVMWH[PLU[ZOHZNYLH[LYKPMÄJ\S[`JSLHUPUN[OLHI\[TLU[
site. Additionally, developmental growth of the skull might interfere with an immobile
implant site. Reyes et al. 8 also found the highest frequency of skin reactions in a
young age group (<20 ys). However, although more soft tissue problems occurred in 
children, they did not lead to increased soft tissue revision surgery rates (11%). Most
VM[OL[PTL[OL\ZLVMHTLKPJHSVPU[TLU[HUKZWLJPÄJJSLHUPUNHK]PJLJHUZVS]LZVM[
tissue problems. The overall revision surgery rate of 6.6% for skin and soft tissue
problems was comparable with the rate reported by Hobson et al. (6.2%).15  
An implant loss rate of 8.3% was noted for the total cohort. The rate is centered
in the range of implant loss percentages reported in literature. In the literature, both
comparable and lower survival rates are described for children when compared to 
the failure rates for adults. The Nijmegen BCD group reported earlier on outcomes
regarding implant loss in children32, in older adults33 and in a 3-year cohort19. However, 
no statistical comparisons of the survival curves were made. An internal analysis in
[OPZ SHYNL Z[\K` PUKPJH[LK Z[H[PZ[PJHSS` ZPNUPÄJHU[S` SV^LY Z\Y]P]HS YH[LZ PU JOPSKYLU
compared to adults and the elderly (Figure 2). Children are more prone to trauma at
the implant site through activities such as playing or practicing sports. Hypothetically,
osseointegration is sub-optimal or is perhaps more easily disturbed in pediatric
patients. An assessment of implant stability, for example, using non-invasive
resonance frequency analyses, in a pediatric population would be useful in testing
[OLZLO`WV[OLZLZ0UWH[PLU[Z^ P[OTLU[HSYL[HYKH[PVUPTWSHU[Z\Y]P]HS^ HZZPNUPÄJHU[S`
lower than in patients without mental retardation (Figure 2). No evidence was found
that older patients (>65 years of age) had higher implant failure rates compared to
younger patients as has been described previously by Drinias et al.35
The time that an implant was left unloaded to allow for optimal osseointegration
decreased from 12 weeks to an average of 6 weeks over our 20-year BCD program. 
Strikingly, in the earliest loading group (3-5 weeks), none of the 88 implants were lost
PU[OLÄYZ[`LHYMVSSV^PUNSVHKPUN;HISL;OLZLYLZ\S[ZPTWS`[OH[PTWSHU[VZZLVPU-
[LNYH[PVUPZHSYLHK`Z\MÄJPLU[HZLHYS`HZ^LLRZHM[LYPTWSHU[H[PVUMVY[OLSVHKPUNVM
the BCD sound processor.
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Conclusion
This paper presents the clinical outcomes of percutaneous BCD installation in a
series of more than 1000 implants, with a maximum follow-up time of 20 years. The
ZPTWSPÄLKSPULHY PUJPZPVU[LJOUPX\L^HZTHPUS`\ZLKPU[OLWYLJLKPUN`LHYZHUK
demonstrated good outcomes. The results of the study indicate that major
complications following BCD surgery are rare. In 95.5% of cases, there were no
adverse soft tissue reactions. Children appeared to be most vulnerable to adverse
soft tissue reactions. An overall implant failure rate of 8.3% was found and can be
mentioned during preoperative consultation about implant loss. Children and mentally
retarded patients were most vulnerable to implant loss. These results are relevant for
outpatient consultation involving children and mentally retarded patients because
they indicate that extra and more frequent care needs to be given to support the
regular cleansing of skin surrounding the abutment. In addition, the effective treatment
of skin reactions is needed to prevent severe complications such as implant loss.
/V^L]LY [OLTHQVYILULÄ[ZVMOLHYPUNYLOHIPSP[H[PVUNHPULKI`)*+HWWSPJH[PVU PU
these 2 vulnerable groups justify the relatively mild complications of BCD surgery.
The loading of the BCD sound processor 3 to 5 weeks after placement of the implant
in healthy adults was not followed by any implant loss within 12 months. These
outcomes are supportive of a reduction in the currently used standard loading time
VM HYV\UK ^LLRZ ;OL ZPTWSPÄLK SPULHY PUJPZPVU [LJOUPX\L LUHISLZ X\PJR^V\UK
healing and supports the possibility of earlier BCD application.16,36 In adults with
L_WLJ[LKZ\MÄJPLU[IVULX\HSP[ ` SVHKPUNJHUZHMLS`ILWLYMVYTLKH[^LLRZHUK
even be reduced to 3 weeks after an initial 1-stage surgery. A resonance frequency
analysis (RFA) of implant stability in the near future would be helpful in further 
PU]LZ[PNH[PUN[OLZLÄUKPUNZ
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Abstract
;OLVIQLJ[P]LVM[OPZZ[\K`PZ[VKL[LYTPUL[OLILULÄ[ZVMIVULHUJOVYLKOLHYPUNHPK
(Baha) contralateral routing of signal (CROS) in the older adult population with
single-sided deafness. Five questionnaires [general usage questionnaire, Glasgow
ILULÄ[PU]LU[VY`.)0(IIYL]PH[LKWYVÄSLVMOLHYPUNHPKILULÄ[(7/()5PQTLNLU
cochlear implant questionnaire and the hearing handicap inventory for the elderly-
screening version (HHIE-S)] were used to evaluate Baha use. Consecutive patients
V]LY`LHYZVMHNL^P[O::+Ä[[LK^P[OH)HOH*96:IL[^LLU(WYPS  HUK(WYPS
UV[\ZPUNHJVU]LU[PVUHSOLHYPUNHPKPU[OLIL[[LYOLHYPUNLHY^LYLPKLU[PÄLK
Nine out of 11 patients (82%) were still using their Baha CROS, and 7 of the 11
WH[PLU[Z^LYLZ[PSSZH[PZÄLK;OLWH[PLU[ZL_WLYPLUJLKUV[VSP[[SLWYVISLTZ^P[O
OHUKSPUNHUKJSLHUPUNVM[OLKL]PJL;OL.)0ZJVYLZZOV^NVVKILULÄ[PUKVTHPUZ
total (14±11) and general (19±17). The APHAB shows that, overall, 3 out of the 11
WH[PLU[Z  L_WLYPLUJLK ZPNUPÄJHU[ ILULÄ[ ^OPSL HSS V[OLYZ L_WLYPLUJLK UV
ZPNUPÄJHU[ILULÄ[HUKUVKYH^IHJRZ;OL//0,:ZOV^Z[OH[[OLWH[PLU[ZL_WLYPLUJLK
severe (18%), mild to moderate (46%) or no handicap (36%) when using the Baha
*96: 0UJVUJS\ZPVU[OLILULÄ[VMH)HOH*96:MVYLSKLYS`WH[PLU[Z^P[O::+PZ
evident in the majority of patients.
Abbreviations
NCIQ Nijmegen Cochlear Implant Questionnaire
BSP Basic sound perception
ASP Advanced sound perception
SP Speech production
SE Self-esteem
AL Activity limitations
SI Social interactions
(7/() (IIYL]PH[LKWYVÄSLVMOLHYPUNHPKILULÄ[
EC Ease of communication
RV Communication in reverberant rooms
BN Background noise
AV Aversiveness of sounds
.)0 .SHZNV^ILULÄ[PU]LU[VY`
HHIE-S Hearing handicap inventory for the elderly-screening version
PTAac Pure tone average at frequencies of 0.5, 1, 2 and 4 kHz for air conduction
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Introduction
Brånemark et al.1 ÄYZ[PUJVYWVYH[LK[P[HUP\TPTWSHU[ZPU[VIVULPU[OLKLU[HSYLNPVUPU
1965. This led to the development and use of titanium implants for prostheses. In 
1982, Tjellström et al.2^LYL [OLÄYZ[ [V PTWSHU[WH[PLU[Z^P[OHIVULHUJOVYLK
hearing aid (Baha), a new type of bone conduction hearing device. The Baha has
now become a widely accepted hearing aid for patients with conductive or mixed
hearing loss as an alternative to a conventional air-conduction hearing aid.
The indications for Baha surgery have been extended over the years.3,4 In 
addition to the bilateral Baha application, indications for Baha surgery have been 
extended and proven to be successful in children or in persons with a moderate 
mental retardation with an acquired or congenital unilateral conductive hearing
loss.5-10 In the same period, the notion spread that the Baha could also be successfully
applied in cases of single-sided inner ear deafness, applying the Baha in the deaf ear
and having the sound transmitted transcranially to the normal-hearing ear.11,12
Vaneecloo et al.13 described the indication for single-sided deafness (SSD) in 2000 by
applying the Baha as a transcranial contralateral routing of signal (CROS) device.
9LWVY[ZOH]LZPUJLZOV^UZOVY[HUKSVUN[LYTLMÄJHJ`MVY[OL)HOH*96:PUHK\S[Z
with SSD in terms of recognition of speech in noisy environments and subjective
TLHZ\YLTLU[Z VM ILULÄ[14,15 Although directional hearing remains a problem for
Baha patients with SSD, its application has become more popular in general surgical
departments in comparison to other hearing aid options. For SSD, the Baha CROS is
the most preferred option.11
Initially, the Baha CROS application for SSD was evaluated primarily in patients
with a hearing impairment in the best ear up to 25 dB HL. However, recent studies
have shown that the Baha CROS is effective in patients with mild hearing loss (PTAac
<40 dB HL, averaged over the frequencies of 0.5, 1, 2 and 4 kHz) in their better-hearing
ear.16,17 Older patients, in particular, are expected to have a more pronounced hearing
impairment in their best ear as a result of presbycusis and, in cases of SSD, are
[OLYLMVYLL]LUTVYL\YNLU[S`PUULLKVMOLHYPUNHTWSPÄJH[PVU
/LHYPUNSVZZZ[YVUNS`PUÅ\LUJLZWZ`JOVZVJPHSZ[H[\ZPU[OLLSKLYS `;OL`JHUILJVTL
more isolated by their hearing impairment, and hearing aids often provide a
UVUVW[PTHSYLZ[VYH[PVU4HU`LSKLYS`PUKP]PK\HSZHYLUV[[YLH[LKZ\MÄJPLU[S`MVY[OLPY
hearing loss.18,19
Follow-up studies have shown that Baha CROS application in patients with SSD
is effective in reducing psychosocial consequences in the long term.12,20,21 Elderly 
Baha CROS patients with SSD and possibly presbycusis in the better-hearing ear are 
presumed to be a special group within this group of SSD because they might need 
OLHYPUNHTWSPÄJH[PVUL]LUTVYL[OHU[OVZL^P[OV\[WYLZI`J\ZPZPU[OLIL[[LYOLHYPUN
ear. On the other hand, the opportunities for a successful outcome of hearing aid 
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HTWSPÄJH[PVUMVYZWLLJO\UKLYZ[HUKPUNPULSKLYS`WH[PLU[ZHIV]L[OLHNLVMKLWLUK
not only on their hearing loss but also on their cognitive function. This paper analyses
^OL[OLY [OL LSKLYS`)HOHWVW\SH[PVU^P[O::+L_WLYPLUJL Z\Z[HPULKILULÄ[ MYVT
Baha CROS. For this analysis, several quality-of-life instruments were used.
Patients
(SSJVUZLJ\[P]LWH[PLU[ZÄ[[LK^P[OH)HOH*96:IL[^LLU(WYPS  HUK(WYPS
^LYL PKLU[PÄLK 7H[PLU[Z ^OV OHK WHZZLK H^H` PU [OLTLHU[PTL ^LYL L_JS\KLK
Inclusion criteria were age 60 years or older and proven SSD. Two persons were
excluded from the study because they used a hearing aid in the better-hearing ear,
which would make it impossible to determine the effect of the Baha CROS device.
Questionnaires were sent to the remaining 11 patients, and all questionnaires were
returned. The follow-up time ranged from 2 to 6 years. The mean age of implantation 
was 66 (±6) (Table 1).
Methods
(X\LZ[PVUUHPYL^HZNLULYH[LK MYVTÄ]LKPMMLYLU[WH[PLU[V\[JVTL PUZ[Y\TLU[Z [V
evaluate daily Baha use, the disability experienced in the daily use, the level of handicap,
the disability imposed and the quality of life as described by the Baha users.
;OL ÄYZ[ WHY[^HZ H NLULYHS5PQTLNLUX\LZ[PVUUHPYL [V L]HS\H[L [OL WH[PLU[Z»
satisfaction with the Baha CROS and the ease and amount of daily use.22 Satisfaction
Table 1 Descriptive data of the population (n=11)
Variable Mean (SD, range)
Gender
Male 6 (55%)
Female 5 (45%)
Age 71 (SD±7, 62–86)
Age at implantation 66 (SD±6, 60–79)
Duration of Baha CROS use 4 years (SD±1, 2–6)
PTAac for better-hearing ear 31 (SD±19, 9–54)
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^HZ KLÄULK HZ H WVZP[P]L YLZWVUZL [V [^V VM [OL [OYLL MVSSV^PUN HZWLJ[Z!
recommendation to a peer, being prepared to pay for the Baha CROS themselves
and choosing the Baha CROS again. The other four questionnaires were well-estab-
lished measures of the quality of life. Two questionnaires were used to evaluate
Z\IQLJ[P]LILULÄ[![OL.SHZNV^ILULÄ[PU]LU[VY`.)0HUK[OLHIIYL]PH[LKWYVÄSLVM
OLHYPUNHPKILULÄ[ (7/();OYLLX\LZ[PVUUHPYLZWYV]PKLK PUZPNO[VU [OLJ\YYLU[
Z[H[\ZHUKILULÄ[VM)HOH*96:\ZL![OL5PQTLNLUJVJOSLHYPTWSHU[X\LZ[PVUUHPYL
(NCIQ), the APHAB and the hearing handicap inventory for the elderly-screening
version (HHIE-S).
.)0 PZ HTLHZ\YLVMWH[PLU[ILULÄ[KL]LSVWLKLZWLJPHSS` MVY V[VYOPUVSHY`UNV-
logical interventions.23 It is validated to measure outcomes on health status after
otorhinolaryngological procedures such as Baha surgery.24 It measures quality of life
PU[OYLLKVTHPUZ!ZVJPHSNLULYHSHUKWO`ZPJHS;OLKVTHPUZZJVYLVUHZJHSLVMò
TH_PT\TKYH^IHJR[VTH_PT\TILULÄ[
APHAB is a 24-item, self-assessment, disability-based inventory to document
[OLV\[JVTLVMHOLHYPUNHPKÄ[[PUNHUKL]HS\H[L[OLÄ[[PUNV]LY[PTL25 It was used to
quantify the disability and the reduction in disability after Baha surgery. The inventory
yields scores on subscales for ease of communication (EC), listening under
reverberant conditions (RV), listening in background noise (BN) and aversiveness of 
sounds (AV). Scores were noted for both the aided and the unaided situations after
Baha surgery on a seven-point scale.
NCIQ was initially developed by Hinderink et al.26 to quantify the quality of life in
cochlear implant (CI) users. It focuses on three domains, describing physical,
psychosocial and social aspects. Its subdomains are basic sound perception (BSP), 
advanced sound perception (ASP), speech production (SP), self-esteem (SE), activity 
limitations (AL) and social interactions (SI). The former three subdomains are disabil-
P[`ZWLJPÄJ" [OL SH[[LY [OYLL HYL OHUKPJHWZWLJPÄJ ;OPZ X\LZ[PVUUHPYL JVU[HPUZ 
items, is validated for patients with CIs, is also used for and is sensitive for Baha
CROS users.22 The answer categories were transformed to a score of 0 for an
extremely poor to 100 for a perfect situation.
//0,:KL]LSVWLKI`=LU[Y`HUK>LPUZ[LPU PZHOHUKPJHWZWLJPÄJZJYLLUPUN
tool for elderly subjects with hearing loss.27 It is designed to assess the effects of 
hearing impairment on two domains: emotional consequences and social/situational 
effects. Total scores can range between 0 (no handicap) and 40 (maximum handicap). 
The HHIE-S was adapted by de Wolf et al.22 for use in the Baha CROS-aided situation
by adding questions concerning the patient’s hearing prior to Baha surgery.
Demographic characteristics of the patients (age, years of Baha CROS use, age
at implantation) and the most recent measured pure tone average (PTA) at frequencies 
of 500, 1,000, 2,000 and 4,000 Hz for air conduction (PTAac) in the better-hearing ear
were used to analyse statistical correlations.
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Statistics
The statistical analyses were performed using SPSS 16.0 (SPSS, Inc., Chicago,
USA). Spearman’s rho was used to correlate the variables to the outcomes of the
questionnaires. Only Spearman’s rho values of 0.4 or greater were regarded as
JSPUPJHSS`ZPNUPÄJHU[(UHS`ZPZVM [OL(7/()KVTHPUZ,*9=HUK)5 PZZPNUPÄJHU[
when there is a 10-point difference within each domain between the aided and the
unaided situation.27(KPMMLYLUJLVMWVPU[ZPZZPNUPÄJHU[^OLUJVUZPKLYPUNHZPUNSL
domain.27
Results
The population contained 11 Baha CROS users with SSD aged 60 or older. The
mean age was 71 years at the time of the study. Table 1 describes the patient char-
acteristics concerning gender, age, age at implantation, years of Baha CROS
experience and PTAac.
Daily use
;OLYLZ\S[ZMYVT[OLÄYZ[X\LZ[PVUUHPYLZOV^LK[OH[VM[OLWH[PLU[Z V\[VM
were still using their Baha CROS. One patient had stopped wearing the device after
4 years because of recurrent infection around the abutment. The other patient
stopped using the Baha CROS after 2 years because of a lack of directional hearing.
The devices used are the Baha Compact (n=6), the Baha Classic (n=4) and one Baha
Cordell. The duration of daily use in Baha CROS users was variable, with four patients
(36%) using their Baha CROS for more than 8 h a day.
;OLX\LZ[PVUUHPYLZOV^LK[OLWH[PLU[Z[VILTVKLYH[LS`[V]LY`ZH[PZÄLK^ P[O[OL
)HOH *96:  ;OL` ZOV^LK SP[[SL [V UV KPMÄJ\S[PLZ ^P[O [OL HWWSPJH[PVU HUK
THPU[LUHUJLVM[OLKL]PJL"UVULVM[OLWH[PLU[ZOHKKPMÄJ\S[PLZPUWSHJPUN[OL)HOH
CROS (100%). All could handle the controls well (100%) and experienced only a few
problems cleaning the abutment (64%). Patient satisfaction was also displayed by the
positive responses to whether they would recommend the Baha CROS to a peer
(82%) and choose the Baha CROS again (82%). An overview of the results is shown
in Table 2.
Current status and benefit of Baha use
.)0 ^HZ \ZLK [V HZZLZZ [OL X\HSP[`VMSPML ILULÄ[Z VM [OL )HOH *96: ;OYLL
questionnaires provided information on the current status regarding Baha use: NCIQ,
APHAB and HHIE-S.
In the GBI, all patients reported an increase in quality of life in total and on a
general and a social level. The average total score was 14 (±11), the general score 19 
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Table 2 Results of the questionnaire daily use
Question Response
Are you still using the Baha? Yes 9 (82%)
No 2 (18%)
How many hours per day have you been using
the Baha on a regular basis over the past
2 weeks?
Not worn the BAHA 2 (18%)
Less than 1 h a day 0
1-4 h a day 4 (36%0
4-8 h a day 1 (9%)
More than 8 h a day 4 (36%)
In general, is your current Baha worth the
effort?
No 1 (9%)
A little 3 (27%)
Moderately 3 (27%)
Much 3 (27%)
Very much 1 (9%)
Do you have difficulties placing the Baha? Yes 0
No 11 (100%)
Can you handle the Baha controls well? Yes 11 (100%)
No 0
Are you familiar with the extra application
options?
Yes 4 (36%)
No 7 (63%)
Do you have difficulties cleaning skin around
the implant site?
Yes 1 (9%)
Sometimes 3 (27%)
No 7 7(64%)
How do you judge the sound of the Baha? Very good 1 (9%)
Good 3 (27%)
Reasonable 6 (55%)
Bad 1 (9%)
Very bad 0
Would you recommend the Baha to a friend
with the same hearing loss as yours?
Yes 9 (82%)
No 2 (18%)
Would you, based on your experience with the
Baha, choose the Baha again?
Yes 9 (82%)
No 2 (18%)
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[OLZVJPHSZJVYLHUK[OLWO`ZPJHSZJVYLò ;^VWH[PLU[ZYLWVY[LK
some type of a physical drawback; they were using more medication since the Baha 
CROS application.
;OL(7/()^HZ\ZLK[VX\HU[PM`[OLKPZHIPSP[`HUK[OLILULÄ[VM)HOHÄ[[PUN
Overall, the APHAB showed a decrease in disability of 7% from the unaided situation
VM [VMVY[OLHPKLKZP[\H[PVUIV[OZ[\KPLKHM[LY[OL)HOHÄ[[PUN
The results show an improvement in the ease of communication (10%), reverberation
HUKIHJRNYV\UKUVPZL ;HISLKPZWSH`Z [OLILULÄ[HJX\PYLKI`)HOH
CROS in these domains; lower scores mean less disability. AV increased after Baha
*96: HWWSPJH[PVU  <ZPUN [OL NSVIHS ILULÄ[ ZJVYL [OYLL Z\IZJHSLZ ^P[O H
ILULÄ[ZJVYLWVPU[Z[OYLLWH[PLU[ZL_WLYPLUJLKZPNUPÄJHU[ILULÄ[MYVT[OL)HOH
CROS, but there was no difference for the remaining patients.27 Considering the
ZPUNSLKVTHPUZZPNUPÄJHU[PTWYV]LTLU[Z^ LYLVIZLY]LKPUSPZ[LUPUN^ P[OIHJRNYV\UK
UVPZLMVYMV\YWH[PLU[ZKPMMLYLUJLWVPU[ZSPZ[LUPUNPUYL]LYILYHU[YVVTZMVY
four patients (36%) and ease of communication for two patients (18%). The four 
WH[PLU[Z^P[OZPNUPÄJHU[ PTWYV]LTLU[Z PU SPZ[LUPUN^P[OIHJRNYV\UKUVPZL^LYLUV[
[OLZHTLWH[PLU[Z^P[OZPNUPÄJHU[YLZ\S[ZPUSPZ[LUPUNPUYL]LYILYHU[YVVTZ
;OL5*08 YLÅLJ[ZX\HSP[`VM SPML PUWO`ZPJHSWZ`JOVZVJPHSHUKZVJPHSHZWLJ[Z;OL
NCIQ results show high scores in all of these domains, meaning better outcomes
(Table 4). The hearing prior to the use of Baha CROS was poor in 77% of the patients. 
One patient found his hearing to be bad and two patients judged their hearing to be 
good before Baha CROS use. Ten patients (90%) deemed their hearing better with 
Baha CROS use, with an average improvement of 27%. One patient, who stopped
using the Baha CROS because of a lack of directional hearing, found the hearing to
be similar. Patients ranked questions about self-esteem, social interactions and
activity limitations as the most important.
Table 3 Results of the APHAB (%)
Unaided Aided Benefit
Mean SD Mean SD Mean SD
Ease of communication 33 ±11 23 ±13 10 ±16
Background noise 66 ±17 53 ±20 13 ±27
Reverberation 62 ±19 48 ±25 15 ±22
Aversiveness 34 ±34 44 ±25 -10 ±18
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The HHIE-S displayed the level of handicap for emotional consequences and social/
situational effects. Lower scores mean less disability in a range of 0–40; the average
LTV[PVUHSZJVYL^ HZHUK[OLZVJPHSZP[\H[PVUHSZJVYL;HISL7H[PLU[ZJSHZZPÄLK
their level of handicap with the use of the Baha CROS as severe (18 %), mild to
moderate (46 %) or non-existent (36 %).
Mean PTAac in the contralateral ear was 28 dB (±15) and the PTAac^ HZUV[ZPNUPÄJHU[S`
correlated with any domain or total score of any questionnaire. A trend can be seen
in the relationship between the PTAac and the APHAB score for listening in reverberant
rooms (Figure 1). A lower PTAac trended towards correlation with better hearing in
YL]LYILYHU[ YVVTZ 7LYOHWZ H SHYNLY WVW\SH[PVU ^V\SK OH]L ZOV^U H ZPNUPÄJHU[
correlation.
Table 4 Results of the NCIQ (range 0–100)
NCIQ Mean SD
Physical function
Basic sound perception 75 ±11
Speech production 81 ±16
Advanced sound perception 74 ±15
Psychosocial function
Self-esteem 72 ±16
Activity limitations 76 ±15
Social function
Social interactions 72 ±12
Table 5 Results of the HHIE-S (range 0–40)
Outcome Mean SD
Total 16 ±9
Emotional 5 ±4
Situational and social 11 ±7
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Discussion
This study describes the changes in quality of life with the use of a Baha CROS for
the elderly with SSD. A general questionnaire addressed the daily use and practicality
of the Baha CROS. Willingness to recommend the Baha CROS to a peer and to
choose the Baha CROS again indicate a high level of satisfaction of the Baha CROS
device in this group of elderly with SSD.
In the evaluation of daily use, it is notable that the users had little to no problems
with placing and cleaning the device and operating the controls. These results show
that our group of older adults, who generally have more problems adapting to
operating new devices, have no problems with use of the Baha. Two users had
stopped using the Baha CROS and would not choose it again. The reason for this 
limited use and satisfaction was because of the placement of the implant. The
location intervened with the use of a hat, which was a burden for one patient. Their
improvement in quality of life was on par with the other users. It has been suggested
that the degree of success depends on non-audiological aspects such as lifestyle
and working environment.28 It seems reasonable to assume that the elderly population
only apply the Baha CROS in situations with high listening demands, which can
explain the relatively limited duration of daily use.
;OL J\YYLU[ Z[H[\Z HUK ILULÄ[ VM )HOH*96: \ZL^LYL L]HS\H[LK \ZPUN [OL
(7/()5*08HUK//0,:;OLILULÄ[PUX\HSP[`VMSPML^HZYLÅLJ[LKI`[OL.)0;OL
current study made use of these four instruments, specially developed for otorhino-
laryngology, each with its own merits, and all have been previously used to evaluate 
quality of life with the Baha.
Figure 1 7\YL [VULH]LYHNL]LYZ\ZILULÄ[ PU YL]LYILYHU[ YVVTZHJJVYKPUN [V [OL
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;OL.)0^HZ\ZLK[VHZZLZZWH[PLU[ILULÄ[HM[LY)HOH*96:Z\YNLY `;OL.)0
^HZZWLJPHSS`KL]LSVWLK[VL]HS\H[LWH[PLU[ILULÄ[HM[LYHU`V[VYOPUVSHY`UNVSVNPJHS
surgery or therapy. It is sensitive to any change in health status brought about by a
ZWLJPÄJL]LU[!PU[OPZJHZL[OLWYV]PZPVUVMH)HOH*96:(SSWH[PLU[ZYLWVY[LKHU
increase in quality of life in total and on general and social levels, while the physical 
KVTHPUZOV^LKHULNH[P]LILULÄ[)LULÄ[ZVU[OLZVJPHSHUKNLULYHSSL]LSZTLHZ\YLK
with the GBI were comparable to other studies.22,29
The APHAB was developed to quantify the disability associated with a hearing
loss and the reduction of disability that is achieved with a hearing aid.25 The APHAB
showed improvement in the ease of communication, listening in background noise
and listening in reverberated rooms. A difference of 10% or more favouring the same
hearing aid for the domains EC, RV and BN can be interpreted with a high level of 
certainty to indicate the superiority of the favoured instrument.27 0[ PZ KPMÄJ\S[ [V
compare our group of elderly with SSD to a group of Baha users of varied indications
and ages. Results of other research with the APHAB show a similar improvement in
the quality of life after Baha surgery. Our results are comparable with results in SSD
WH[PLU[Z^P[OH)HOH^OLYL[OL)(/(*96:WYV]PKLKZPNUPÄJHU[Z\IQLJ[P]LILULÄ[Z
and improved speech understanding in noise.14,15,20 The data from this study are
comparable to elderly patients using the Baha with a unilateral conductive or mixed
hearing loss, as shown in Table 6.22 An increase of aversiveness to sound can be
L_WLJ[LKILJH\ZLVMHTWSPÄJH[PVUVMHSSZV\UKZ;OLZTHSSPUJYLHZLPU[OLH]LYZP]LULZZ
to sound was not a reason for the patients not to recommend it to a peer or not to
choose the device again. The patients who would recommend the device valued the
KL]PJL TVYL MVY P[Z ILULÄ[Z YLSH[LK [V JVTT\UPJH[PVU IHJRNYV\UK UVPZL HUK
YL]LYILYHU[YVVTZ;OVZL^ OVNHPULKSP[[SLILULÄ[^ V\SKUV[YLJVTTLUKP[[VHWLLY
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0TWYV]LTLU[ PU SPZ[LUPUN ^P[O IHJRNYV\UK UVPZL ^HZ ZPNUPÄJHU[ MVY MV\Y WH[PLU[Z
(36%), listening in reverberant rooms for four patients and ease of communication for
two patients. An improvement in the ease of communication is not to be expected
when the patients have a normal-hearing ear. The greatest improvement is seen in 
situations with background noise or reverberation. This result is comparable to
WYL]PV\ZÄUKPUNZYLNHYKPUN)HOH*96:\ZHNLPU::+WH[PLU[Z11,14,15,30
The NCIQ provided information on the effects of the disability and handicap on
the quality of life in physical, psychosocial and social aspects. The NCIQ is an
LZ[HISPZOLKPUZ[Y\TLU[[OH[JHUKL[LJ[^OL[OLYH*0OHZZPNUPÄJHU[LMMLJ[ZVUZL]LYHS
health-related quality of life aspects, and it has proven valuable for Baha. The quality
of life was higher in our group of elderly with SSD in comparison to a previously
reported group of Baha users with a conventional application and thus conductive or 
Table 6 Questionnaire comparison for elderly with SSD and elderly with a
conventional application
SSD Conventional
application
Mean SD
Current status of Baha CROS use
Basic sound perception
Speech production
Advanced sound perception
Self-esteem
Activity limitations
Social interactions
75
74
72
76
72
+11
+16
+15
+16
+15
+12
49
58
65
59
59
64
APHAB (aided)
Ease of communication
Background noise
Reverberation
Aversiveness
HHIE-S Total
Emotional
Situational and social
23
53
48
44
16
5
11
+13
+20
+25
+25
+9
+4
+7
39
58
57
42
18
7
11
Benefit in the Baha CROS-aided situation
GBI
Total
General
Social
Physical
14
19
8
-2
11
+17
+12
+9
23
30
13
7
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mixed hearing loss (Table 6).22 This difference is substantial and cannot be explained 
as yet. A possible explanation might be a bias to please. As we cannot explain the 
difference, we cannot generalise the results. The domains most valuable for the
patients were self-esteem, activity limitations and social interactions. The quality of 
life was rated highly in these domains.
Sensorineural hearing loss increases after the age of 60. Presbycusis affects 
25–40% of the population aged 65 or older. Patients above the age of 60 were 
included in this study. It is, however, impossible to state whether the included patients 
above the age of 60 all had presbycusis. Looking at their respective hearing loss in 
the better-hearing ear provided a more detailed view of the potential for presbycusis 
in these elderly patients.
An established treatment for a patient with little or no hearing on one side and 
with some hearing loss in their better ear is the BICROS. The device is a fully capable
hearing aid that enables the patient to hear sounds from the good side and is capable 
of receiving the sound transmitted from the CROS aid on the other side. Three 
patients in the study population were given the option of a BICROS but declined 
ILJH\ZLVMHSYLHK`Z\MÄJPLU[OLHYPUNYLOHIPSP[H[PVU
Another possible form of hearing rehabilitation is possible with a cochlear
implantation. Heyning et al.31 describe improved hearing in patients with unilateral
sensorineural deafness and tinnitus. Cochlear implantation can be considered an
option for the elderly population but was not an option for the patients in this study 
given the hearing loss on the better ear was not within the criteria for cochlear
implantation.
Previous studies and our paper suggest that the Baha CROS can substantially 
relieve a hearing handicap in patients with SSD in comparison to other CROS hearing
aids.32 0U5PQTLNLUVUS`VM [OLWH[PLU[ZÄ[[LK^P[OHIVULJVUK\J[PVUKL]PJL
show signs of SSD. Though CROS devices have problems with restoring sound 
localisation, the Baha CROS seems a viable solution for patients with SSD.
0UJVUJS\ZPVU[OLILULÄ[VMH)HOH*96:MVYLSKLYS`WH[PLU[Z^P[O::+PZL]PKLU[PU
[OLTHQVYP[`VMWH[PLU[Z 0U[LYLZ[PUNS ` [OLNYLH[LZ[ILULÄ[ PZZLLU PUZP[\H[PVUZ^P[O
background noise.
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Abstract
Objective: To determine factors predicting whether patients with single-sided deafness
(SSD) opt for a bone conduction device (BCD) for the contralateral routing of sound
(CROS) after a regular trial with a BCD on a headband.
Design: Retrospective case-control study.
Setting: Nijmegen, the Netherlands.
Patients: Thirty consecutive patients with SSD.
Interventions: Patients received a trial with a BCD headband as part of the regular
workup for SSD. The patients were divided into 2 groups according to their decision 
[VVW[MVYH)*+)*+VYUV[)*+ò
Main Outcome Measures: Patients completed a questionnaire on satisfaction with
[OL)*+OLHKIHUKWH[PLU[HUK)*+YLSH[LKMHJ[VYZHUKILULÄ[PUSPZ[LUPUNZP[\H[PVUZ
Results: Fourteen patients (47%) chose a percutaneous BCD application after the
)*+OLHKIHUK[YPHS/LHYPUNSVZZVM[OLJVU[YHSH[LYHSLHYH[R/a^HZZPNUPÄJHU[S`
larger in the BCD+ group for bone and air conduction (P=.05 and P=.02, respectively). 
Patients in the BCD+ group experienced more problems in several listening situations
HUK\ZLK[OL)*+OLHKIHUKTVYLMYLX\LU[S`[OHUWH[PLU[ZKPKPU[OL)*+òNYV\W
Conclusions!:L]LYHSPUKP]PK\HSMHJ[VYZPUÅ\LUJL[OLKLJPZPVUVMWH[PLU[Z^P[O::+[V
opt for a BCD. Hearing loss in the contralateral ear at high frequencies seems to be
a relevant factor to predict the success of the BCD headband trial. It is advisable to
offer all patients with SSD the option to participate in the BCD headband trial for at
least 1 week and create a realistic expectation for patients based on their unaided
subjective hearing handicaps.
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Introduction
For several years, bone conduction devices (BCDs), including both the Cochlear Ltd
bone-anchored hearing aid (BAHA) and, more recently, the Oticon Medical devices 
(Ponto) have been used as contralateral routing of sound (CROS) devices. A group of 
WH[PLU[Z^ OVILULÄ[MYVT[OPZYLOHIPSP[H[PVUOH]L\UPSH[LYHSZLUZVYPUL\YHSOLHYPUNSVZZ
commonly known as single-sided deafness (SSD). The BCD CROS achieves 
ZPNUPÄJHU[ PTWYV]LTLU[ JVUJLYUPUN ZVTLWYVISLTZ JH\ZLKI` [OL OLHK ZOHKV^
effect, which plays a substantial role in the hearing impairment of patients with SSD.1,2
:\IQLJ[P]LILULÄ[HUHS`ZPZI`TLHUZVM[OL(IIYL]PH[LK7YVÄSLVM/LHYPUN(PK)LULÄ[
(APHAB).3 ZOV^Z H ZPNUPÄJHU[ PTWYV]LTLU[ PU [OL LHZL VM JVTT\UPJH[PVU
conversation in background noise, and conversations with reverberation.4-6 However, 
P[ YLTHPUZKPMÄJ\S[[VWYLKPJ[^OPJOWH[PLU[Z^P[O::+^PSSILULÄ[MYVT)*+*96:
treatment. All patients receiving the standard workup for BCD CROS treatment have 
the opportunity to try a BCD headband to help them decide whether to proceed to 
BCD surgery. According to studies by Andersen et al7 and Schrøder et al,8 only 20%
to 25% of the patients with SSD caused by acoustic neuroma surgery opt for a 
percutaneous BCD CROS. Desmet et al9 evaluated 196 patients with SSD for several
factors (Fletcher index of ipsilateral and contralateral ear, bone conduction threshold
BHUKR/aDL[PVSVN `HNLHUKK\YH[PVUVMKLHMULZZ[VKL[LYTPUL[OLPYPUÅ\LUJL
on the decision of a patient to opt for a BCD or not. Eighty-seven patients (44%) opted
MVY H )*+ I\[ UV Z[H[PZ[PJHSS` ZPNUPÄJHU[ MHJ[VYZ ^LYL MV\UK 2VTWPZ L[ HS10 also 
searched for predicting factors such as age, sex, transcranial attenuation, and 
duration of deafness in 46 patients with SSD. The decision of the 29 patients who 
opted for a BCD (63%) was based on subjective factors.
Martin et al11MV\UKZPNUPÄJHU[S`OPNOLYZH[PZMHJ[PVU^P[O[OL)*+*96:HTVUN
patients with SSD with a longer duration of deafness (>10 years) using the Glasgow 
)LULÄ[ 0U]LU[VY` .)0" OV^L]LY H UVUZPNUPÄJHU[ [YLUK^HZ ZLLU \ZPUN [OL ::+
questionnaire. Hol et al2 showed that there is a tendency for speech recognition to
improve more with the BCD CROS in patients with congenital SSD compared with
patients with acquired deafness. However, sound localization in the unaided condition
^HZIL[[LYMVYJVUNLUP[HSS`KLHMWH[PLU[Z^P[OHZL_WLJ[LKUVZ[H[PZ[PJHSS`ZPNUPÄJHU[
KPMMLYLUJLZPUPTWYV]LTLU[HM[LY)*+Ä[[PUN2 This effect leads to the hypothesis that
congenital SSD could be a valuable predictor in the success of the BCD after the
OLHKIHUK[YPHS;OLHPTVM[OPZZ[\K`PZ[VÄUKTVYLWYLJPZLKL[LYTPUHU[Z[VWYLKPJ[
whether patients would opt for a BCD CROS after a trial with a BCD headband.
;OLZL KL[LYTPUHU[Z JHU SLHK [V HU HZZLZZTLU[ VM [OL ILULÄ[ VM H )*+ PU [OL
counseling of the patient following a headband trial. The determinants might serve as
an alternative for the headband trial for selected patient groups.
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Methods
Patients
Thirty consecutive patients with SSD were included in this study from May 2009 to
August 2010. All of the patients received a BCD headband trial as part of their workup 
for the treatment of SSD. The inclusion criteria were profound or total unilateral
sensorineural hearing loss, pure-tone bone conduction threshold on the contralateral
side of 25 dB or lower and an air-bone gap of 20 dB or lower averaged over 0.5, 1,
and 2 kHz. An air-bone gap of 25 dB was allowed if the bone-conduction threshold
was lower than 5 dB; the trial with the BCD headband lasted at least 1 week.
Questionnaire
The questionnaire administered for this study was derived from elements of validated
questionnaires to answer the research question. These questionnaires were the
(7/()[OL.SHZNV^/LHYPUN(PK)LULÄ[7YVÄSL./()7HUK[OL::+X\LZ[PVUUHPYL
and Speech Spatial Qualities of Hearing scale (SSQ). The APHAB consists of 4
subdomains: ease of communication, background noise, reverberation, and
aversiveness of sounds. The APHAB gives an indication of the improvement achieved
with a hearing aid by comparing baseline and postintervention outcomes.3 The 
./()7TLHZ\YLZ PUP[PHS KPZHIPSP[ ` OHUKPJHW OLHYPUN HPK \ZL OLHYPUN HPK ILULÄ[
residual disability, and patient satisfaction.12 The SSD questionnaire concerns use,
aesthetics, handling of the BCD, satisfaction, and several listening situations.13 The
SSQ measures disabilities of speech hearing in different listening situations,
disabilities of spatial hearing, and quality of hearing.14 The questionnaire used in the
current study was completed with a number of other questions based on clinical
experience and contained questions about satisfaction, patient-related factors
(duration of deafness, fear of operation, cosmetics, visibility of deafness), BCD-related 
factors (sound quality, intensity of the BCD, annoyance in use), and listening situations
in an unaided situation and with the BCD headband. The patients were also asked if 
they wanted to proceed to placement of a BCD and to explain their choice.
Statistical analysis
The r2 test or Fisher exact test, in cases of small subgroups, was applied to compare 
the determinants for both groups. P#^HZJVUZPKLYLK[VILZPNUPÄJHU[6^PUN[V
the small group of patients, the 5-point scales were converted to 3-point scales for 
HUHS`ZPZL_JLW[MVY[OLSPZ[LUPUNZP[\H[PVUZ;OPZWVPU[ZJHSLYLWYLZLU[ZHJVUÄYTPUN
answer, neutral answer, and denying answer. The results were computed using
version 16 of the SPSS software package (SPSS Inc).
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Table 1 Patient characteristics.
Pure-tone
Averageb
Pure-tone
4.0 kHzc
Patient no
Sex/age ya
Cause of deafness BCD Air 
con-
duction
Bone
con-
duction
Air 
con-
duction
Bone
con-
duction
1/M/25
2/F/44
3/F/44
4/F/38
5/M/56
6/F/35
7/F/35
5/M21
9/F/42
10/M/22
11/F/55
12/M/65
13/M/65
14/M/41
15/M/42
16/M/49
17/F/57
18/M/77
19fF/61
20/M/56
21/M/61
22/M/53
23/M/50
24/F/55
25/M/51
26/F/63
27/M/29
28/M/57
29/M/72
30/F/19
Congenital
Congenital
Congenital
Congenital
Congenital
Congenital
Congenital
Congenital
Congenital Congenital
Congenital
Sudden deafness
Sudden deafness
Sudden deafness
Sudden deafness
Sudden deafness
Sudden deafness
Sudden deafness
Acoustic neuroma
Acoustic neuroma
Acoustic neuroma
Acoustic neuroma
Acoustic neuroma
Surgery for meningioma
Surgery for metastases
of acinic cell carcinoma
in the cerebellopontine
region
Cholesteatoma surgery
Trauma
Noise trauma/labyrinthitis
Meningitis
Morbus Ménière
Sensorineural hearing
loss. Early childhood
intervention, unknown
origin
+
+
+
+
-
-
-
-
-
-
-
+
+
+
+
-
-
-
+
+
-
-
+
-
-
+
-
+
+
-
8
28
13
3
2
12
18
0
20
7
12
12
8
2
12
12
7
8
8
18
5
7
23
13
17
27
19
13
10
7
5
3
13
7
23
10
0
0
13
7
18
12
8
2
12
5
7
13
13
20
5
5
25
13
17
8
10
18
20
5
10
45
7
10
20
10
20
0
15
55
10
55
40
0
40
30
10
15
25
45
10
10
35
5
40
35
20
45
45
0
0
10
0
0
5
5
20
0
10
35
0
55
25
0
43
0
5
15
25
40
10
0
20
5
30
10
15
35
50
0
Abbreviations: BCD, bone conduction device; +, used a BCD headband; -, did not use a BCD headband.
a Age, years, at time of BCD headband trial.
b Of thresholds at 0.5, 1, and 2 kHz in contralateral ear (in decibels of hearing level).
c Pure-tone threshold at 4.0 kHz in contralateral ear (in decibels of hearing level).
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Results
After the BCD headband trial, the group of 30 patients was divided into 2 groups 
IHZLKVU[OLWH[PLU[Z»KLJPZPVU[VJOVVZLH)*+*96:)*+NYV\WVYUV[)*+ò
group). The BCD+ group consisted of 14 patients (47%), including 9 men and 5
^VTLU ^P[O H TLHU HNL VM  `LHYZ YHUNL  `LHYZ ;OL )*+ò NYV\W
consisted of 16 patients (53%), including 9 men and 7 women, with a mean age of 
44.8 years (range, 19-77 years). Table 1 gives an overview of the etiologies of hearing 
loss. Twenty-two patients (74%) were provided with a BAHA Intenso, 3 patients (10%)
with a BAHA Classic, and 1 patient (3%) with a BAHA Divino during this trial with the
headband (all, Cochear Ltd). In 4 cases (13%), the type of BCD was not registered.
All of the patients received the questionnaire at the time of the headband trial. Nine
patients fully completed the questionnaire at once; 6 patients completed a part of the
questionnaire and were asked to complete it at a later stage. Another 15 patients who
had tried the BCD headband without answering the questionnaire were phoned in 
September 2010 to participate in our study. These patients all agreed to participate
and received the questionnaire by mail. All patients returned the questionnaire,
resulting in a response rate of 100%.
As described herein, the time between BCD headband trial and questionnaire
varied per patient. The mean time difference was 27.1 weeks (range, 2-73 weeks) in 
the BCD+ group and 20.6 weeks (range, 2-59 weeks) in the BCD–group (P=.42). As
a result of the time that elapsed between the headband trial and questionnaire, not
all questions could be answered by some patients. Other questions were not
Figure 1 Satisfaction with a bone-anchored hearing aid (BAHA) headband in both
groups (n=30). A plus sign indicates that the patient used a headband; a minus sign 
indicates that the patient did not.
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applicable to all patients because they did not have a job or had not tested all listening
situations. The minimum number of patients who were applicable for analysis was 23.
,PNO[WH[PLU[ZPU[OL)*+NYV\W^LYLZH[PZÄLK^P[O[OL)*+OLHKIHUK
JVTWHYLK^P[O PU[OL)*+òNYV\W-PN\YL-V\YWH[PLU[ZMYVT[OL)*+
NYV\W ^LYLKPZZH[PZÄLK^P[O[OL)*+OLHKIHUKI\[JOVZLH)*+7H[PLU[ZPU
the BCD+ group used the BCD headband in the trial period more often than did
WH[PLU[ZPU[OL)*+òNYV\W0U[OL)*+NYV\WWH[PLU[Z\ZLK[OLOLHKIHUK
every day, and 8 patients (57%) used it for more than 7 hours a day. In the BCD–
group, 11 patients used the BCD headband 1 to 4 hours a day (69%), and no patient 
used it for more than 7 hours a day (Figure 2).
Figure 2 Use of a bone-anchored hearing aid (BAHA) headband during the trial in
both groups (n=30). A Hours per day. B Days per week.
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7H[PLU[Z^P[OJVUNLUP[HSKLHMULZZ^LYLTVYLJVTTVUPU[OL)*+òNYV\W,SL]LUVM
30 patients (37%) were diagnosed as having congenital SSD; 7 of these patients
(64%) did not select a BCD after the headband trial, while 4 (36%) did so. Of the
remaining 19 patients (63%) with acquired deafness, 9 patients (47%) did not choose
a BCD (r2 test; P=.39). In the small subgroup of patients with acoustic neuroma or
other tumors in the cerebellopontine region, 3 of 6 patients opted for a BCD (50%).
Comparing the mean air conduction and bone conduction thresholds at 1, 2,
and 4 kHz of the contralateral ear of both groups, there was no difference for the
MYLX\LUJPLZVMHUKR/a/V^L]LY[OLTLHUOLHYPUNSVZZH[R/a^ HZZPNUPÄJHU[S`
greater in the BCD+ group. The mean air conduction threshold was 31.2 dB (range,
K)PU[OL)*+NYV\WJVTWHYLK^P[O K)YHUNLK)PU[OL)*+ò
group (P=.02). The mean bone-conduction threshold was 22.4 dB (range, 0-55 dB)
PU[OL)*+NYV\WHUK K)YHUNLK)PU[OL)*+òNYV\WP=.05).
Patients were asked about their hearing abilities without the BCD headband in
different listening situations. Answers were given on a 5-point Likert scale, which
ranged from always to never. Table 2 shows the number of patients who answered
[OLX\LZ[PVU^P[O¸HS^H`Z¹PUZWLJPÄJSPZ[LUPUNZP[\H[PVUZ7H[PLU[ZPU[OL)*+òNYV\W
scored their hearing abilities higher than patients in the BCD+ group for most of the 
SPZ[LUPUNZP[\H[PVUZ:PNUPÄJHU[S`TVYLWH[PLU[ZPU[OL)*+òNYV\W^LYLHS^H`ZHISL
to understand speech in a conversation with 1 (P=.05) or several (P=.02) people in a
X\PL[LU]PYVUTLU[4VYLWH[PLU[ZPU[OL)*+òNYV\W^ LYLHISL[VOH]LHJVU]LYZH[PVU
Table 2 Listening situations before Bone Conduction Device (BCD) headband
test.
No. (%)
Situation BCD+ BCD- P Value a
Always able to understand speech in
a conversation with one person in a quiet environment
Always able to understand speech in
a conversation with one persone in a noisy environment
Always able to understand speech in
a conversation with several people in a quiet
environment
Always able to understand speech in
a conversation with several people in a noisy
environment
Always hear the doorbell or telephone when it rings
Always able to have aon on the telephone
7 (50)
1 (7)
1 (7)
0 (0)
1 (7)
8 (57)
14 (88)
1 (6)
8 (50)
0 (0)
9 (56)
15 (94)
.05
NA
0.1
NA
0.007
.03
Abbreviations: NA, not available; +, used a BCD headband; -, did not use a BCD headband. 
aTwo-sided, Fisher exact test.
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on the phone (P=.03) and hear the doorbell or telephone when it rang (P=.007).
9LNHYKPUNHJVU]LYZH[PVUPUUVPZ`LU]PYVUTLU[Z[OLYL^HZUVZPNUPÄJHU[KPMMLYLUJL
IL[^LLUNYV\WZ/V^L]LYWH[PLU[ZPU[OL)*+òNYV\WJVTWHYLK^P[O
patients (14%) in the BCD+ group were almost always able to understand a
conversation with 1 person in a noisy environment (Fisher exact test; P=.01).
Table 3 shows possible factors explaining the choice to refrain from using a BCD. The
cosmetic aspects of the BCD and the fact that patients have to wear a device behind
[OLLHY^LYLIV[OZ[H[PZ[PJHSS`ZPNUPÄJHU[YLHZVUZ[VYLMYHPUMYVT\ZPUNH)*+MVYVM
WH[PLU[ZPU[OL)*+òNYV\WJVTWHYLK^P[OUVWH[PLU[ZPU[OL)*+NYV\W
(P=.02 and P=.01, respectively). The visible indication of deafness was not a relevant
factor for 26 patients (13 in both groups). Surgery was not a reason to refrain from
\ZPUNH)*+ PUWH[PLU[Z  VM [OL)*+NYV\W-V\YWH[PLU[Z PU [OL)*+ò
group (n=16) refrained from using a BCD because surgery was required. There was
UVZPNUPÄJHU[KPMMLYLUJL^OLUJVTWHYPUNWH[PLU[Z^P[OJVUNLUP[HS::+HUKWH[PLU[Z
with acquired SSD for these factors. Of 5 patients who refrained from using a BCD
because of the cosmetic aspects and the fact that they had to wear a device behind
the ear, 2 patients had congenital SSD (18% of all patients had congenital SSD) and
3 patients had acquired SSD (16% of all patients had acquired SSD). The visible
indication of deafness was a reason to refrain from using a BCD in 1 patient with
acquired SSD; no patients with congenital SSD mentioned it as a reason to refrain.
Table 3 Possible factors to refrain from using a Bone Conduction Device (BCD)
in a group of 30 patients.
No. (%)
Reason to refrain from using
a definitive BCD
Yes Neutral No P valuea
Surgery required
BCD+
BCD-
1 (7.0)
4 (25.0)
0
6 (37.0)
13 (93.0)
6 (37.0) NA
Wearing a device behind the ear
BCD+
BCD-
0
5 (31.0)
1 (7.0)
5 (31.0)
13 (93.0)
6 (38.0)
.01
Cosmetic aspects
BCD+
BCD-
.05 (0)
5 (31.0)
1 (7.1)
4 (25.0)
13 (92.9)
7 (44.0)
.02
Visibility of deafness
BCD+
BCD-
0
2 (6.0
1 (7.1.0)
2 (13.0)
13 (92.9)
13 (81.0) NA
144
CHAPTER 3.2
Before the BCD headband trial, 9 patients (64%) in the BCD+ group and 3
WH[PLU[Z PU[OL)*+òNYV\WL_WLYPLUJLK[PUUP[\ZH[SLHZ[OHSMVM[OL[PTLMYVT
[PUUP[\Z ;OPZ KPMMLYLUJL ^HZ ZPNUPÄJHU[ P=.02). The tinnitus, if present, was not
affected by wearing the BCD.
Most patients used the BCD headband on intensity 1 or 2. In the BCD+ group, 
more patients used the BCD headband on intensity 1, and, in the BCD–group, 
PU[LUZP[`^HZ\ZLKTVYLVM[LU;OPZKPMMLYLUJL^HZUV[ZPNUPÄJHU[P=.12). Only 2 
WH[PLU[Z PU [OL)*+òNYV\W\ZLK PU[LUZP[`-V\YVMWH[PLU[Z JV\SKUV[
remember which intensity they had used.
Comment
Most studies show a positive effect in satisfaction and improvement of quality of life
in patients with SSD who use BCDs, formerly referred to as BAHAs, as a CROS
system.2,11,13 These studies included only those patients who had chosen a BCD after
a headband trial. The current study describes characteristics of patients with SSD in 
both groups, that is, those who elected to use a BCD and those who refrained from 
using a BCD. These characteristics included listening situations, reasons to refrain
from using a BCD, such as wearing a device behind the ear or cosmetic aspects of 
the BCD, tinnitus before headband trial, and the etiology of SSD.
>P[OV\[[OL)*+OLHKIHUKTVYLWH[PLU[ZPU[OL)*+òNYV\WJVTWHYLK^P[O
the BCD+ group were always able to hear in several listening situations, such as a
conversation with 1 or more persons in a quiet environment (P=.05 and P=.02,
respectively), during a phone call (P=.03), or when the doorbell or telephone is ringing
(P=.01). This suggests that patients with subjectively good hearing abilities in the
unaided situation are less likely to opt for a BCD. Therefore, it is important to be aware
of a patient’s hearing capabilities and subjective handicap estimation in the counseling
of patients with SSD to create a realistic expectation of the BCD headband test.
The mean hearing loss of the better-hearing contralateral ear at 4.0 kHz was
ZPNUPÄJHU[S` SHYNLY PU [OL )*+ NYV\W MVY IV[O IVUL JVUK\J[PVU P=.05) and air
conduction (P=.02). This result might suggest that patients with less function of the 
JVU[YHSH[LYHSLHYILULÄ[TVYLMYVT[OL)*+OLHKIHUK/V^L]LYILJH\ZLVM
patients in the BCD+ group had pure-tone thresholds of 0 to10 dB at a frequency of 
4 kHz and 3 patients with hearing loss of 30 to 55 dB at 4.0 kHz did not choose a
BCD, this is not a straightforward suggestion.
The cosmetic aspects of the BCD and the fact that patients have to wear a
KL]PJLILOPUK[OLLHY^LYLIV[OZ[H[PZ[PJHSS`ZPNUPÄJHU[YLHZVUZ[VYLMYHPUMYVT\ZPUN
H)*+ MVY WH[PLU[Z  PU [OL)*+òNYV\WJVTWHYLK^P[O UVWH[PLU[Z PU [OL
BCD+ group (P=.02 and P=.01, respectively). A possible explanation might be that
145
HEADBAND TRIAL IN PATIENTS WITH SINGLE-SIDED DEAFNESS
3.2
WH[PLU[Z^OVL_WLYPLUJLKZ[YVUNILULÄ[ZMYVT[OL)*+[HRL[OLJVZTL[PJHZWLJ[Z
MVYNYHU[LK7H[PLU[Z^P[O::+^OVOHKHSYLHK`YLJLP]LKH)*+^LYLZH[PZÄLK^P[O
the aesthetics of the BCD, reporting scores of 7.7 to 8.8 out of 102,5,13
For 4 of 16 patients in the BCD–group, surgery was a reason to decline a BCD.
All patients were informed about the option of conventional CROS hearing aids.
These 4 patients declining a BCD were offered this trial period as well, and all of them
KLJSPULK7H[PLU[Z PU[OL)*+NYV\WL_WLYPLUJLKZPNUPÄJHU[S`P=.02) more 
[PUUP[\Z [OHU WH[PLU[Z PU [OL )*+ò NYV\W   6US`  WH[PLU[ ^OV OHK HSYLHK`
received a percutaneous BCD experienced a reduction in tinnitus once she started
using the BCD. The other patients in the BCD+ group who experienced tinnitus did
not experience any reduction of tinnitus with the BCD headband or percutaneous
BCD system. Holgers and Håkansson15 reported a reduction of tinnitus after a 
percutaneous BCD application in 9 of 47 patients (19%) with conductive or mixed 
hearing loss. To our knowledge, these data are not available for unilateral sensorineural
hearing loss. These results indicate that tinnitus is not a predictor in the choice for a 
BCD. The severity of tinnitus was not a subject of this questionnaire; it can be 
speculated, however, that a high level of tinnitus might be a negative predictor. This 
could be an interesting option for further research.
In the current study population of with patients with SSD, almost half of the 
patients (47%) chose a BCD after the BCD headband trial compared with rates of 
37.5% to 63.0% reported in the literature.5,7-10,16 The patients in the current study tried 
the headband because they experienced a handicap owing to their SSD. Probably 
most patients with SSD will never visit a physician because they are not aware of the
opportunities of BCD application or are able to cope with the situation unaided. It is 
[OLYLMVYL PTWVY[HU[ [V YLHSPaL [OH[ [OL J\YYLU[ Z[\K` YLÅLJ[Z VUS` [OL WVW\SH[PVU
]PZP[PUNHWO`ZPJPHU^P[OOLHYPUNYLSH[LKKPMÄJ\S[PLZV^PUN[V[OLPY::+0UHWPSV[Z[\K`
by Hol et al,2 even 3 of 10 persons with SSD without complaints concerning their 
hearing loss did opt for a BCD after headband trial. Therefore, the fact remains that a
NYLH[U\TILYVMWH[PLU[Z^P[O::+TPNO[ILULÄ[MYVTH)*+
Seven of 11 patients with congenital SSD (64%) refrained from using a BCD compared
with 9 (47%) of 19 patients whose SSD had other causes (P=.39). This outcome 
Z\WWVY[Z I\[ JHUUV[ JVUÄYT [OL O`WV[OLZPZ [OH[ [OLYL PZ H KPMMLYLUJL IL[^LLU
patients with congenital SSD and patients whose SSD has other causes as described 
by Hol et al.2 It is conceivable that patients who have been used to monaural hearing
since birth and have never experienced binaural hearing develop better monaural
hearing abilities than patients who become deaf after experiencing binaural hearing.
Possibly, congenitally deaf patients might develop the ability to use spectral (pinna)
cues for directional hearing in the horizontal plane.17 Slattery and Middelbrooks17
reported fairly good monaural sound localization abilities in patients with congenital
SSD.
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The time between the BCD headband trial and the time in which patients
completed the questionnaire might have biased the results. However, a recall bias
^HZUV[JVUÄYTLKI` [OLWH[PLU[Z [OLTZLS]LZ"VUS`H ML^X\LZ[PVUZJV\SKUV[IL
HUZ^LYLK-\Y[OLYTVYL[OLYL^ HZUVZPNUPÄJHU[[PTLKPMMLYLUJLIL[^LLU[OLNYV\WZ"
therefore, we assumed that the possible bias for both groups was comparable. By
accepting the extension of time that elapsed between the trial and the questionnaire,
15 extra patients could be included.
9LTHYRHIS ` WH[PLU[Z^LYLKPZZH[PZÄLK^P[O [OLOLHKIHUKI\[ UL]LY[OLSLZZ
chose a BCD. One of the patients did so only because his wife and children
L_WLYPLUJLKHUV[HISLILULÄ[^OLUOL^HZ\ZPUN[OL)*+OLHKIHUK;OLV[OLY
WH[PLU[ZZH[PZÄLK^P[OTVZ[HZWLJ[ZVM[OL)*+Z`Z[LTTLU[PVULK[OLWHPUJH\ZLK
by the headband as their main reason for dissatisfaction with the headband trial,
though not with the device itself.
However, 3 patients refrained from using a BCD after the headband trial despite
satisfaction with the headband trial. One patient mentioned the cosmetic aspects as
a reason to refrain from using a BCD, and another patient experienced dizziness with
the BCD headband. For the third patient, who has an acquired SSD, the visible
indication of deafness was the reason to refrain from using a BCD. He was afraid to
be treated differently when his handicap became apparent. For 26 of 30 patients
(87%), visible indication of their unilateral deafness was not a reason to refrain from
using a BCD. Rather, a number of patients considered BCD usage to be an advantage.
When deafness is apparent, people can take that into account.
Aside from a role for hearing loss in the contralateral ear on high frequencies and
worse pretesting hearing abilities, no relevant factors were found to predict the success of 
the BCD headband trial. However, 47% of the patients with SSD opted for a BCD after the 
headband trial. Furthermore, most of these patients used the BCD headband every day
for more than 7 hours a day. According to the literature, they will use the percutaneous
BCD system even more often.8,13 An improvement ranging from 5 to 20 dB can be
expected with a percutaneous BCD application compared with transcutaneous BCD
application by means of the headband.18 It might be interesting to apply a more powerful
device for headband testing to provide a more realistic test situation.
We concur with the results of Desmet et al9 and Kompis et al10 that no factors
have yet been established to determine the success of a BCD. Snapp et al19 found
[OH[ZWLLJOPUUVPZL[LZ[PUNTPNO[ILHUHJJ\YH[LWYLKPJ[VYVMV]LYHSSILULÄ[PU[OL
preoperative evaluation of the BAHA device in patients with SSD. Overall, currently no 
ZWLJPÄJPUZ[Y\TLU[L_PZ[Z[OH[WYLKPJ[Z[OLV\[JVTLHUK[OLYLMVYLHOLHKIHUK[YPHS
cannot be replaced yet. The headband trial prior to implantation best resembles the 
effect of the BCD and is the assessment of choice in determining the effect of a BCD
in patients with SSD. However, additional assessment of preoperative subjective 
OLHYPUNOHUKPJHWJHUILILULÄJPHSPUJYLH[PUNYLHSPZ[PJL_WLJ[H[PVUZ
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In conclusion, in the population of patients with SSD in Nijmegen, the Netherlands,
47% opted for a BCD after an extended BCD headband trial. Patients with hearing
loss in the contralateral ear, especially at high frequencies and with subjectively
^VYZLOLHYPUNHIPSP[PLZTPNO[ILULÄ[TVYL MYVTH)*+5VV[OLY YLSL]HU[ MHJ[VYZ
were found to predict the success of the BCD headband. It is, therefore, advisable to
continue offering all patients with SSD the BCD headband trial, which is proposed to
last for at least 1 week, and create a realistic expectation for patients based on their
unaided subjective hearing handicap.
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CHAPTER 3.3
Abstract
Objective: To examine the long-term satisfaction of hearing rehabilitation and the
WVZZPISLPUÅ\LUJLZVMNLUKLYPU::+WH[PLU[Z[OH[\UKLY^LU[IVULHUJOVYLKOLHYPUN
implant (BAHI) surgery in our clinic. 
Methods!(SSU$JVUZLJ\[P]L::+WH[PLU[ZÄ[[LK^P[OH)(/0IL[^LLU1HU\HY`
HUK6J[VILY^LYLHZRLK[VÄSSV\[HWVZ[HSIHZLKX\LZ[PVUUHPYLJVUZPZ[PUN
VM[OYLLPUZ[Y\TLU[Z![OLÄYZ[[VL_HTPULOLHYPUNKPZHIPSP[`(7/()[OLZLJVUK[V
examine coping behaviour (CPHI) and the third to measure daily use and satisfaction
with the BAHI (SSD questionnaire). The APHAB scores were compared for 29
patients, studied in 2005 who were implanted between 2001 and 2003.
Results: A total of 23 of the 135 contacted patients (17%) reported discontinuation 
V]LYHUH]LYHNL MVSSV^\W [PTLVMTVU[OZ `LHYZTVU[OZ5VZPNUPÄJHU[
statistical differences were found in the degree of disability between men and women
according to the APHAB. Men and women with a BAHI for SSD seem to cope equally,
according to the CHPI. Improvement in quality of life or the appreciation of the BAHI
^HZUV[PUÅ\LUJLKI`[OLMVSSV^PUNMHJ[VYZ!NLUKLYHNLKPYLJ[PVUHSOLHYPUNHIPSP[ `
the appearance of the device and handling the device.
A total of 3 of the 29 patients implanted between 2001-2003 were lost to follow
up, while 18 of 26 patients were still using their BAHI (69.2%) at the mean follow up
time of 117 months (9 years, 9 months). In all domains, the mean APHAB scores were
UV[ZPNUPÄJHU[S`JOHUNLKH[TVU[OZ`LHYHUK`LHYZHM[LYPTWSHU[H[PVU
Conclusion: Our study showed the results of BAHI use in SSD patients over a relatively 
long follow up period, with an average of 5 years (spread 2-129 months) and a
YLWVY[LKKPZJVU[PU\H[PVUYH[LVM5VZPNUPÄJHU[NLUKLYKPMMLYLUJLZ^LYLMV\UK
in patients with SSD in terms of reported disability or coping with a BAHI.
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3.3
Introduction
Since 1977, titanium temporal bone anchored hearing implants (BAHI) have been
used in hearing rehabilitation by means of bone conduction. This indication has been
established for a variety of unilateral and bilateral types of hearing loss, including
conductive hearing loss, mixed hearing loss, and profound unilateral sensorineural
hearing loss, which is also known as single-sided deafness (SSD). Strictly, SSD is
KLÄULK HZ ZLUZVYPUL\YHS OLHYPUN SVZZ PU VUL LHY ^P[O ULHY UVYTHS JVU[YHSH[LYHS
hearing function. Patients with SSD have functional hearing for speech, education
HUK ]VJH[PVUHS ZRPSSZ I\[ [OL` L_WLYPLUJL KPMÄJ\S[PLZ ^OLU [OL ZV\UK ZV\YJL PZ
positioned on the impaired side.1,2
In the past, the audiological rehabilitation of individuals with SSD was limited to the
use of air-conduction contralateral routing of sound (CROS) hearing aids that had a
^PYLHYV\UK[OLULJR*96:KL]PJLZOH]LPTWYV]LKZPNUPÄJHU[S `HUK[OL[YLH[TLU[
options for patients with SSD have expanded with the application of BAHI as a
transcranial CROS device, as described by Wazen et al. in 2003.1 A hearing handicap
JHUILKPMÄJ\S[[VKLÄULHZ[OLWLYJLW[PVUVMHU`OHUKPJHWJHUKPMMLY^PKLS`HTVUN
patients.3 Not only do the reactions to minimal hearing impairment vary greatly among 
patients, but the perceived communication and psychosocial handicap cannot easily 
be determined from an audiogram alone. Several quality of life (QoL) instruments 
OH]LILLU\ZLK[VHZZLZZ[OLKLNYLLVMH\KPVSVNPJHSOHUKPJHWHUK[OLILULÄ[ZVM
surgical rehabilitation of SSD by BAHI CROS. 
Patients with single-sided deafness are a subset of all patients with hearing handicaps. To 
HJJ\YH[LS`L]HS\H[L[OLOLHYPUNOHUKPJHWHUK[OLZH[PZMHJ[PVUVMH)(/0PU[OLZLZWLJPÄJ
patients, one needs to understand the general perspective of patients with hearing 
handicaps. Age-related symmetric sensorineural hearing loss is a widely occurring
WYVISLTHUKP[PZHZZ\TLK[VJH\ZLHZPNUPÄJHU[OLHYPUNOHUKPJHW/V^L]LYVUS`VM
PUKP]PK\HSZ^OVJV\SKILULÄ[MYVTOLHYPUNHPKZHJ[\HSS`W\YJOHZL[OLT4 In addition, of 
those who have purchased hearing aids, not all wear them. Of those who have and wear
[OLPYOLHYPUNHPKZVUS`HYLZH[PZÄLK^P[O[OLT4 In the process of acquiring a
hearing aid, the four following elements are involved: seeking help, uptake (acquiring a
OLHYPUNHPK\ZPUN[OLOLHYPUNHPKHUKÄUHSS `ILPUNZH[PZÄLK^P[O[OLKL]PJL5 Several 
MHJ[VYZZ\JOHZWYLÄ[[PUNOLHYPUNHPKL_WLJ[H[PVUZJV\UZLSSPUNHUKWLYZVUHSP[`HZWLJ[Z
[OH[PUJS\KLJVWPUNHUKHJJLW[HUJLVMOLHYPUNSVZZ^ PSSPUÅ\LUJL[OLZLLSLTLU[Z1LYLT`
L[HSVIZLY]LK[OH[[OVZL^ P[OIL[[LYHJJLW[HUJLVM[OLPYOLHYPUNWYPVY[VOLHYPUNHPKÄ[[PUN
used their hearing aid more frequently than those with lower acceptance.6 Satisfaction
with a hearing aid can vary over time, for instance, as habituation takes place. Another 
MHJ[VY[OH[TH`PUÅ\LUJLZH[PZMHJ[PVU^P[O[OLKL]PJLPZNLUKLY7
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+PZ[PUJ[V\[JVTLZ[OH[HZZLZZ[OLILULÄ[ZVMHIVULJVUK\J[PVUZ`Z[LTPU::+
patients are still lacking.8 To create a realistic expectation in patients with SSD, a
pre-operative headband trial of 1-2 weeks is recommended.9 In patients with SSD
^OVOH]LOHK)(/0Z\YNLY `[OLYLPZH[LUKLUJ`MVYZH[PZMHJ[PVUHUKILULÄ[WLYJLW[PVU
outcomes to regress over time when compared with the initial short-term outcomes.10,11
(S[OV\NO[PTLZLLTZ[VPUÅ\LUJL[OLZH[PZMHJ[PVU^P[OH)(/0PUWH[PLU[Z^P[O::+
SVUN[LYTZ[\KPLZVUWH[PLU[Z»Z\IQLJ[P]LILULÄ[HYLYHYL10-14
The aim of the present study was to examine the long-term satisfaction of hearing 
YLOHIPSP[H[PVUHUK[OLWVZZPISLPUÅ\LUJLZVMNLUKLYPUHSS::+WH[PLU[Z[OH[\UKLY^LU[
BAHI surgery in our clinic.
Patients and Methods
(SSJVUZLJ\[P]L::+WH[PLU[ZÄ[[LK^P[OH)(/0IL[^LLU1HU\HY`HUK6J[VILY
^LYL PKLU[PÄLK7H[PLU[Z^OVOHKWHZZLKH^H` PU [OLTLHU[PTLVY OHK [OL
abutment or implant removed were excluded. The inclusion criteria were an age of 18 
years or older and SSD.
Questionnaires
( WVZ[HSIHZLK X\LZ[PVUUHPYL ^HZ KL]LSVWLK ^P[O [OYLL PUZ[Y\TLU[Z! [OL ÄYZ[ [V
examine hearing disability, the second to examine coping behaviour and the third to
measure daily use and satisfaction with the BAHI. All patients who did not return the
questionnaire were contacted by telephone to evaluate whether they were still using
their BAHI.
;OLHIIYL]PH[LKWYVÄSLVMOLHYPUNHPK(7/()PZHZLSMYLWVY[X\LZ[PVUUHPYLKPZLHZL
ZWLJPÄJ PUZ[Y\TLU[[OH[ PZ\ZLK[VX\HU[PM`[OL PTWHJ[VMHOLHYPUNWYVISLTVUHU
individual’s daily life.15 Multiple domains of hearing are examined, including hearing in 
Background Noise (BN), Reverberant conditions (RV), Ease of Communication (EC)
and Aversiveness to sound (AV). These scores quantify the hearing disability after
)(/0Ä[[PUNHUKSV^LYZJVYLZJVYYLZWVUK[VSV^LYKPZHIPSP[ `;OL(7/()ZJVYLZJHU
be related to norm data and data from other studies.
;OL*VTT\UPJH[PVU7YVÄSLMVY[OL/LHYPUN0TWHPYLK*7/0^HZKL]LSVWLKI`+LTVYLZ[
and Erdman (1987) to provide a comprehensive assessment of the rehabilitation needs
of hearing-impaired adults. The primary goal of the CPHI is to differentiate between
adequate and inadequate coping behaviour in patients with a hearing handicap.
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Examples of inadequate coping behaviour are the denial of hearing loss, avoidance
behaviour and dominating conversations. The Dutch translation, generated by Mokkink 
et al., was used in this study.16 The Dutch version comprises the Communication 
Strategies and Personal Adjustment scales. The scale for Communication Strategies
has been subdivided into the three following subscales to examine coping in
communicative situations: Maladaptive Behaviours, Verbal Strategies and Non-verbal
Strategies. The scale for Personal Adjustment also consists of three subscales, as
follows: Self-Acceptance, Acceptance of Loss and Stress & Withdrawal. These scales
are aimed at the feelings, attitudes and self-image of individuals, which impact the
interpersonal relationships of the patients. The scores can range from 0-5 and patients
with lower scores potentially have more problems with coping in comparison to
patients with higher scores.
;OL::+X\LZ[PVUUHPYL^HZÄYZ[\ZLKPUHJSPUPJHSZ[\K`PU1HUK^HZZWLJPÄJHSS`
designed to be administered after BAHI implantation for SSD. It was developed by
[OL MVYTLY,U[PÄJ4LKPJHS:`Z[LTZ*VTWHU`HUK^HZW\ISPZOLK PU [OLWYVK\J[»Z
audiology manual.17 This questionnaire has been used in our clinic over the years to
assess daily use and satisfaction with the BAHI; therefore, it was added for comparison
reasons.10,18
A sub comparison of APHAB scores was performed with 29 patients implanted in the
same clinic between 2001 and 2003, as previously described by Hol et al. in 2005.10
The study described the administration of the APHAB after implantation and after
one year follow up. Using a paired samples t test, these data can be compared with
the data from the present study, which has a much longer period of follow up.
Statistics
The statistical analyses were performed using IBM SPSS Statistics 20 (SPSS, Inc.,
Chicago, U.S.A.).
Results
General
The questionnaire was sent out to 145 patients. Of the 145 patients, 102 (70.3%)
returned the questionnaire, and we were able to contact 33 of the remaining 43 by
[LSLWOVUL:LLÅV^JOHY[PU[HISL;OLJVU[HJ[KL[HPSZVM[OLYLTHPUPUNWH[PLU[Z
were no longer up to date and could not be retrieved. As such, these patients were
lost to follow up. Nine out of the 102 patients (8.8%) who responded to the questionnaire 
reported discontinuation of the BAHI. Fourteen out of the 33 contacted non-responders
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(42.4%) had stopped using the BAHI. In total, 23 patients (17%) out of 135 patients 
with SSD had stopped using their BAHI. The reason most patients reported was 
SPTP[LKHKKP[PVUHSILULÄ[UL_[[V[OLPYUVYTHSOLHYPUNLHY
The group of BAHI users that responded to the questionnaires consisted of 41 men 
(44.1%) and 52 women (55.9%). The mean age in this group was 56.1 years (SD ± 10.3),
and the average time of follow up was 61.7 months (5 years, 1.7 months) (SD ± 39.3
2-129 months). Table 2 displays the percentage of non-users in the group of patients
with SSD who received a BAHI. The distribution of gender in the population of non-
users showed that 56.5% were male and 43.5% were female. The mean age in the 
group of non-users was 58.7 years (SD ± 15.8).
APHAB
;OL(7/()^HZ\ZLK[VX\HU[PM`[OLOLHYPUNKPZHIPSP[`HM[LY)(/0Ä[[PUN;OLSL]LSVM
disability was acquired in several domains for the aided situation, and lower scores
indicate less disability. The mean score was 18.6 (SD ± 14.0) for Ease of Communication,
57.2 (SD ± 20.7) for hearing in Background Noise, 46.3 (SD ± 22.6) for Reverberation
and 39.6 (SD ± 24.7) for Aversiveness to sounds. The global APHAB score for the
aided situation of the domains, EC, BN and AV, was 40.7 (SD ± 15.7).
CPHI
The Communication Strategies scale, which examines coping in communicative 
situations, was divided into the Maladaptive Behaviours, Verbal Strategies and
Non-verbal Strategies subscales. The mean score was 4.1 (SD ± 0.7) for Maladaptive 
Behaviours, 2.8 (SD ± 0.6) for Verbal Strategies and 4.1 (SD ± 0.7) for non-verbal
strategies. The Personal Adjustment scale comprised the subscales, Self-Accept-
ance, Acceptance of Loss and Stress & Withdrawal. The mean score was 3.9 (SD ±
0.9) for Self-Acceptance, 3.4 (SD ± 1.0) for Acceptance of Loss and 3.1 (SD ± 0.9) for
Stress & Withdrawal. For matters of comparison, data of studies in groups of patients
with hearing impairment are presented as well in the table.
SSD questionnaire
The responders to the questionnaire that were still using the BAHI, used their BAHI 
for an average of 44.4 hours (SD ± 22.9) per week, which equates to a mean of 6.3
hours of use per day. Almost half of the patients (53.8%) used the BAHI 63 hours or 
TVYLPUH^LLRÄN\YL
4VZ[WH[PLU[ZL_WLYPLUJLKPTWYV]LKX\HSP[`VM SPML ÄN\YL;OL)(/0
^HZNYHKLKHZ:+VUHWVPU[3PRLY[ZJHSLÄN\YL+PYLJ[PVUHSOLHYPUN
was subjectively improved in 8 patients (8.6%), 27 patients had differing results
(29.0%) and 57 patients reported no difference (60.3%). The physical appearance of 
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the BAHI was graded as 6.8 (SD ± 1.5). Handling the device was easy (52.7%) or very
easy (32.3%) for the majority of patients. Fourteen patients (15.1%) found it acceptable
to handle, and no patients found it very hard to handle.
Figure 1 BI use in hours per week. 
BI use is calculated by multiplying the amount of use in hours per day times the 
number of days in the week patients use their BI. Maximum use is 65 hours per week.
Figure 2 Improvement on quality of life with a BI.
The majority of patients reported improvement on quality of life in the SSD questionnaire.
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Gender in BAHI usage group
The average age of the men was 58 years, and the average age of the women was
54 years (p = 0.17). The mean weekly BAHI use in men was 43.6 hours and 45.0 
hours in women (p = 0.77). There was no difference in improvement in quality of life,
with 26 of the 41 men (45.6%) reporting improvement versus 31 of the 52 women
(54.4%) (p = 0.52). The appreciation of the BAHI was scored on a range of 0-10, with
a value of 7.2 for men and 7.0 for women (p = 0.51). The improvement in quality of life 
VY[OLHWWYLJPH[PVUVM[OL)(/0^HZUV[PUÅ\LUJLKI`MHJ[VYZZ\JOHZHNLKPYLJ[PVUHS
hearing ability, device appearance or device handling.
5VZPNUPÄJHU[Z[H[PZ[PJHSKPMMLYLUJLZ PUKPZHIPSP[`^LYLMV\UKIL[^LLUTLUHUK
^VTLUHJJVYKPUN[V[OL(7/()ÄN\YL;OL,*MVY[OLHPKLKZP[\H[PVU^HZ
for men and 19.3 for women (p = 0.57), the BN for the aided situation was 54.3 for
men and 59.4 for women (p = 0.24), and the RV for the aided situation was 42.7 for
men and 49.2 for women (p = 0.16). The global APHAB score for the three domains
showed slightly less disability in men and was 38.2 for men and 42.7 in women (p =
0.17).
Men and women with a BAHI for SSD seemed to cope equally, according to the
*/70ÄN\YL;OLZJVYLZMVYTLUHUK^VTLU^LYLHUKYLZWLJ[P]LS `MVY
Maladaptive Behaviours, 2.8 and 2.8, respectively, for Verbal Strategies, 4.2 and 4.2,
respectively, for Non-verbal Strategies, 4.2 and 3.7, respectively, for Self-Acceptance,
3.4 and 3.5, respectively, for Acceptance of Loss and 3.2 and 3.1, respectively, for
Stress & Withdrawal.
Figure 3 Appreciation of the Bone Implant.
Patients rated their BI with an overall grade (0-10) in the SSD questionnaire.
Appreciation of the Bone Implant
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0U[OLWLYPVKIL[^LLUHUK[OLÄYZ[ WH[PLU[Z^P[O::+^LYLPTWSHU[LK
with a BAHI and intensively evaluated (Hol). Of these 29 patients, 3 were lost to follow
up. Of the remaining 26 patients, 18 patients were still using their BAHI (69.2%). The
mean follow up time was 117 months (9 years, 9 months) and ranged from 105 to 129 
Figure 4 Global disability in APHAB scores.
Global disability (0-100) over all APHAB domains where a higher score relates to
more disability.
Figure 5 Coping by means of the CPHI.
Coping in SSD patients with a BI (0-5). A high CPHI score indicates an adequate 
coping behaviour.
MB = Maladaptive Behaviours, VS = Verbal Strategies and NVS = Non-verbal Strategies. SA = Self-Accept-
ance, AoL = Acceptance of Loss, STWD = Stress & Withdrawal.
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months. Gender was equally distributed, with a 50-50 distribution over the group of 
users and non-users.
The mean APHAB scores were compared as obtained at 10-14 weeks post
KL]PJLÄ[[PUNVUL` LHYHUKHUH]LYHNLVMTVU[OZHM[LYKL]PJLÄ[[PUNHZKPZWSH`LK
PUÄN\YL6M[OLWH[PLU[Z[OH[Z[PSS^LYL\ZPUN[OLPY)(/0*96:[OLTLHUZJVYLZ
for the EC were 15.1, 13.6 and 15.6, respectively. The mean scores for BN domain 
were 36.6, 47.2 and 53.7, respectively. The mean scores for the RV domain were 
28.9, 31.9 and 42.9, respectively. The mean scores for the AV domain at the
comparison time points were 27.4, 29.3 and 38.9, respectively. The differences in
ZJVYLZV]LY[PTL^LYLUV[ZPNUPÄJHU[S`KPMMLYLU[
Discussion
The purpose of the present study was to assess hearing disability and long term use
among men and women with SSD that underwent BAHI surgery for hearing
rehabilitation in the period between January 2001 and October 2011.
In our study of patients with SSD using a BAHI CROS, we have found no
Z[H[PZ[PJHSS`ZPNUPÄJHU[KPMMLYLUJLIL[^LLU[OLNLUKLYZPUYLWVY[LKKPZHIPSP[ `OHUKPJHW
VYJVWPUNILOH]PV\Y:PTPSHYS ` UV ZPNUPÄJHU[KPMMLYLUJLIL[^LLU [OLNLUKLYZ^HZ
found for discontinuation of BAHI use. The presented data are unique as data were
Figure 6 Disability by APHAB scores in time.
Disability in the APHAB domains in the same group of patients over time. A higher 
score relates to more disability (0-100).
EC = Ease of Communication, BN = Background Noise, RV = Reverberant conditions, AV = Aversiveness to
sound.
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gathered in a relatively large group of patients with a relatively long follow up (average 
of 5 years; spread 2-129 months). Discontinuation of BAHI use was 17%. When
JVUZPKLYPUNVUS` [OL ÄYZ[NYV\WVM  PTWSHU[LKWH[PLU[Z [OLKPZJVU[PU\H[PVU^HZ
30%.
The APHAB gives an indication of the improvement achieved with a hearing aid
by comparing baseline and post-intervention outcomes. A higher score post-inter-
vention for the domains EC, RV and BN is likely to be associated with satisfaction. In
our study, we could only retrospectively judge the hearing disability in the aided
situation. For the interpretation of the disability data, we compared our results to 
other studies where the APHAB was used to evaluate disability for patients with SSD 
^OV^LYLÄ[[LK^P[OH)(/010 Hol et al. described 29 patients with SSD implanted
with a BAHI. Most of their patients in that study also participated in the present study.
0U[OLÄYZ[Z[\K`I`/VSL[HS[OLTLHUMVSSV^\W[PTL^HZ`LHYHUKTVU[OZ;OL
current APHAB scores were compared to those reported in the previous study, the
TLHUZJVYLZMVY[OLKVTHPUZ,*)5HUK9=UV[ZPNUPÄJHU[S`PUJYLHZLKHM[LY`LHYZ
in comparison to 3 months and 1 year. This result implies a perceived increase of 
disability after 5 years in comparison to 1 year after BAHI surgery. An explanation for
[OPZPUJYLHZLPUKPZHIPSP[`TH`ILHKHW[H[PVUHUKHUHKQ\Z[TLU[[V[OLILULÄ[VM[OL
new hearing situation. Additionally, the initial values might have been biased because 
of enthusiasm or gratitude. The patients’ perception may have been biased because 
they felt lucky to receive a new and expensive hearing aid, which could have resulted
in a moral obligation to like the device. After several years of everyday use, they may
have come to terms with the other aspects of their hearing rehabilitation. This 
suggests that the present data are the best estimates of perceived disability.
The norm for APHAB data at the 50th percentile for hearing aid users with symmetric
sensorineural hearing loss in the aided situation is 23 for EC, 37 for RV, 40 for BN and
38 for AV.19 In our study, the patients experienced less disability in the domain EC
(18.6) and more handicap in RV (46.3), BN (57.2) and AV (39.6). It makes sense that 
scores for listening in background noise and reverberant rooms generated more
handicap in patients with SSD, as they have serious problems with spatial hearing.
The CPHI results in our study were compared to those of other studies, as shown in
table 3.16,20,21 The Dutch translation of the CPHI has been applied before in a clinical
sample of adults with hearing impairment.16 Demorest and Erdman also conducted a
large, multicentre study to investigate the psychometric characteristics of the CPHI in
an adult population. This population included not just patients with SSD but also
others with varying aetiologies of hearing loss and hearing aid use.20 The CPHI scores 
of the present study are similar to those of other studies, suggesting no aberrant
coping strategies in our study population.
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The SSD questionnaire revealed positive results, with 54% using the BAHI fulltime
and 61% reporting improved quality of life, leading to an overall score of 7.1 on a scale
VM/HUKSPUNVM[OLKL]PJL^HZUV[HWYVISLT^P[OÄUKPUNP[HJJLW[HISL[V
OHUKSL HUK HSS V[OLY WH[PLU[Z ÄUKPUN P[ ]LY` LHZ` [V OHUKSL +PYLJ[PVUHS OLHYPUN
YLTHPULKHU PZZ\LMVYKLIH[LHZL_WLYPLUJLKUVZ\IQLJ[P]LILULÄ[7H[PLU[Z
with SSD lack the ability to use interaural differences in time and loudness to localise
sound, therefore directional hearing is poor.10,22
0[ZOV\SKILUV[LK[OH[ZH[PZMHJ[PVU^ P[O[OL)(/0JHUILPUÅ\LUJLKI`[OLKL]PJL
related factors like sound quality, handling of the device and skin reactions around
the implant. Over the years, the development of the processor has led to better
hearing, especially in patients with SSD. SSD patients with mild to moderate hearing
SVZZ PU [OL JVU[YHSH[LYHS LHY ZOV^LK H Z[H[PZ[PJHSS` ZPNUPÄJHU[ PTWYV]LTLU[ PU HSS
measures with the use of the Divino or Intenso processors compared with the
\UHPKLK ZP[\H[PVU 7YL]PV\Z Z[\KPLZ \ZPUN [OL .SHZNV^ )LULÄ[ 0U]LU[VY` .)0
revealed that 91% of SSD patients with a BAHI CROS device reported improvements
in their quality of life.23 The GBI is a retrospective questionnaire that assesses the
effects of interventions on the health status of patients. With long follow-up as in the
present study, such questionnaires cannot be used.
-VY[OLTHQVYP[`VMLSKLYS`WH[PLU[Z^P[O::+H)(/0OHZL]PKLU[ILULÄ[Z24 It can be
argued that differences in hearing between patients of different ages in the studied
population could have affected the results. Pearson et al. described age-related
Table 3 The CPHI scores in comparison to other studies.
Demorest et al.a
(n = 1226)
Erdman et al.a
(n = 1004)
Mokkink et al.b
(n = 399)
Our studyb
(n = 102)
MB 4.0 4.0 4.0 4.1
VS 3.0 2.9 2.8 2.8
NVS 3.7 3.5 3.6 4.1
SA 3.5 3.5 4.0 3.9
AoL 3.7 3.7 3.3 3.4
ST 3.1 3.2 2.9c 3.1c
WD 3.3 3.3
a English language paper, b Dutch language paper, c The combined results of the Stress and Withdrawal
Scale. MB = Maladaptive Behaviours, VS = Verbal Strategies and NVS = Non-verbal Strategies. SA = 
Self-Acceptance, AoL = Acceptance of Loss, ST = Stress and WD = Withdrawal.
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differences in gender, where hearing sensitivity declined more than twice as fast in
men as in women at most ages. Additionally, they found that women had more
sensitive hearing than men at frequencies above 1000 Hz.25 Better word recognition 
has also been reported among older women compared to men.26 There is evidence 
to suggest that, on average, the cumulative effects of aging on the auditory system
differ by gender.
In our study, we did not examine other physical conditions that may have affected
everyday life or mental status. Health conditions and general life circumstances for
men and women impact their ability to manage hearing loss. Although sensory,
physical, and social differences between women and men have been documented,
little is known about how these differences impact hearing handicaps.
Another variability in hearing rehabilitation for patients with SSD is the effect of 
transcranial attenuation. In 1981, transcranial attenuation of BC sound was measured
at a few audiometric frequencies, with stimulation at the mastoid.27 More frequencies
and locations were investigated by Stenfelt et al., who reported an average of 5 to 10 
dB of attenuation with large intersubject variability.28 The median transcranial 
attenuation depends on stimulation position and frequency. However, for adjacent
frequencies, the variability is great, both between individuals and within subjects.
This is considered to be a result of variability in skull bone thickness. Pre-operative
measures in the form of the individual patient’s actual bone conduction thresholds
JHUPUJYLHZL[OLWYLKPJ[HIPSP[`VM)HOHÄ[[PUNZ29
It is important to establish expectations and preconceptions before BAHI surgery,
especially in patients with SSD. We belief that preoperative counselling helped our
WH[PLU[ZTHUHNL[OLPY\UKLYZ[HUKPUNVMSPRLS`ILULÄ[PUJS\KPUNH[YPHS^P[O)(/0VUH
OLHKIHUK>OPSL[OL)(/0OHZILULÄ[ZP[HSZVOHZSPTP[H[PVUZMVYWH[PLU[Z^P[O::+
as indicated by a discontinuation rate of 30% after an average of ten years follow up.
;OLWVZZPISLPUÅ\LUJLVMNLUKLYVUWH[PLU[Z»ZH[PZMHJ[PVU^P[O[OLKL]PJLJV\SKUV[
be established. Counselling that acknowledges the limits of the device whilst also 
WYVTV[PUN[OLILULÄ[Z^P[OYLHSPZ[PJL_WLJ[H[PVUZPZPTWVY[HU[([YPHSWLYPVK^P[OH
headband can show each individual patient what to expect.
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Discussion
The bone anchored hearing implant (BAHI) has established its place over the years in
the hearing rehabilitation for a growing selection of patients. Indications have been
L_[LUKLKZ\YNPJHS[LJOUPX\LZYLÄULKHUK[OLTHU\MHJ[\YLYZOH]LKL]LSVWLKIL[[LY
implants and sound processors to improve the overall quality and satisfaction of the
BAHI. Research has supported this development and ongoing studies will hopefully
JYLH[L H IL[[LY \UKLYZ[HUKPUN VM [OL ILULÄ[ PU UL^ WH[PLU[ NYV\WZ ;OPZ [OLZPZ
describes characteristics and optimisations of the BAHI implant and the consequences
for the patient in terms of medical complications and best moment for loading the
implant. Patients’ opinion is assessed and satisfaction for BAHI users with single
sided deafness.
Chapter 2 presents clinical aspects of the BAHI implant. Chapter 2.1 describes the
effect of the implant location and skin thickness on the frequency and severity of skin
reactions around the abutment. No correlations were found between the distances
from the superior part of the external auditory ear canal to the implant or between the
horizontal and vertical positions of the implant and the type and number of skin
reactions. Implant loss was not correlated with the described distance, or the position
of the implant. Several other factors should be taken into consideration when
surgically placing the implant. The optimum point for sound transmission is as close
as possible to the cochlea which would bring the implant closer to the pinna. Aesthetic
factors dictate a position further from the pinna so it can be covered by hair and the
hearing handicap won’t be visible. Although a reduction of skin is performed before
positioning of the implant, a relatively high skin can touch the sound processor when
gravity creates a sagging motion of the cranial skin and subsequent subcutaneous
tissue. This might lead to discomfort and eventual underuse of an audiological good
working hearing aid. The surgeon will have to make a decision for placement based 
on these factors. An alternative surgical approach is suggested by Hultcrantz in 2011,
evaluating BAHI surgery without thinning of the surrounding skin in adults.1;OLÄYZ[
YLZ\S[ZHYLWYVTPZPUNHUKJVUÄYTLKPUJOPSKYLUPU2 Further research in larger
groups of patients and in a controlled setting is advocated to really establish the
WV[LU[PHSILULÄ[
Chapter 2.2 evaluates whether diabetes mellitus (DM) is a risk factor for titanium
Ä_[\YL SVZZ PU IVULJVUK\J[PVU KL]PJLZ ILJH\ZL VM VZZLVPU[LNYH[PVU MHPS\YL ;OL
hypothesis was that among patients with DM, implant failure rate was higher
compared with non-DM patients. Because of a change in physiological processes in 
patients with DM, skin reactions and the formation of bone matrix can be inhibited.
The group of patients with DM showed increased implant loss and a reduced time
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between implantation and loss. Half of the implants lost because of trauma were in
DM patients, despite the fact that DM patients were only 9.4% of the total population.
In the Type 2 DM patients 14% of the implants were lost, compared with the 5.1% of 
[OLPTWSHU[ZPUUVU+4WH[PLU[Z7YLVWLYH[P]LZJYLLUPUNMVY+4TPNO[ILILULÄJPHS
in the workup for BAHI surgery. A minor invasive test will show signs of DM or pre-DM
in patients without clinical DM symptoms. A stable DM with adequate medication can 
counter the physiological processes associated with DM and might lead to reduced
PTWSHU[SVZZ9LZLHYJOULLKZ[VL]HS\H[LPMZRPUYLHJ[PVUZTPNO[ILPUÅ\LUJLKI`HU
unstable DM too.
In chapter 2.3 the results are described of loading the implant with the sound
processor at three weeks. The performance was evaluated by short-term implant
survival, stability changes, and skin reactions from the initial implantation to 6 months
post implantation. Of the 30 patients, one implant was lost just 3 days after
implantation. Poor bone quality was observed during surgery and is the reason for
the implant loss. No implant loss occurred in the remaining 29 patients (96.7%). It was
concluded that loading the Cochlear BI300 implant and 6-mm abutment with the
sound processor at 3 weeks is safe. Only mild skin reactions were observed
incidentally (in 9.7% of the visits). A clinical relevant Holgers grade of 2 or higher was
observed only once (0.7%).
Implants stability quotient (ISQ) values were obtained to evaluate how they would
alter over time. The mean ISQ value at the time of implantation was 67.1 with a 
ZPNUPÄJHU[KPWVM0:8\UP[ZH[KH`Z;OLYL^HZHWVZP[P]LJOHUNLPUTLHU0:8
compared with baseline over the subsequent visits and the ISQ values had reached
its baseline value within 3 weeks after implantation. The ISQ was not affected by
implant loading. At present it is still not clear whether there are minimal ISQ-outcomes
to prevent loading of the implant with the sound processor. It is also unclear at which
ISQ-value the implant should not be loaded after, for example, head trauma; or when
soft tissue around the implant is infected or other clinical threatening situations that 
might lead to implant loss.
In the next years, ISQ outcomes will be published more and more and they will be
JVYYLSH[LK ^P[O ZWLJPÄJ PTWSHU[ ZPaLZ HUK Z\YMHJLZ Z[Y\J[\YLZ ([ [OL ZHTL [PTL
clinicians will start to analyse ISQ outcomes in favourable and unfavourable situations.
By doing so they will be looking for ISQ values that can be considered as safe for
loading. In the end, ISQ values might be most helpful for the follow up in an individual
patient.
Chapter 2.4 creates an overview of clinical outcomes of a series of more than 1000 
implants. The outcomes in various BAHI populations are of interest because they can
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be helpful during pre- and post-operative consultations with different patient groups. 
+PMMLYLU[WH[PLU[NYV\WZJV\SKILPKLU[PÄLKHUKV\[JVTLZVM)(/0Z\YNLY`HUK\ZHNL
could be compared. Soft tissue reactions according to the Holgers grading system,
implant loss, and revision surgery was assessed in 7415 observations for the total
group of 1132 implants. These outcomes were compared for children, adults, elderly
and patients with a mental retardation.
Relatively, more adverse skin reactions were observed in children than in adults. The
Z[\K` ZOV^LKZ[H[PZ[PJHSS` ZPNUPÄJHU[ OPNOLYTLHU ZRPU YLHJ[PVU ZJVYLZ PU JOPSKYLU
compared with both adults and elderly patients. This result is consistent with the
O`WV[OLZPZ[OH[JOPSKYLUOH]LNYLH[LYKPMÄJ\S[`JSLHUPUN[OLHI\[TLU[ZP[L0[OHZILLU
suggested that more frequent care needs to be given to cleansing of the skin around
the abutment. Children are more prone to trauma at the implant site through activities
such as playing or practicing sports. Hypothetically, osseointegration is sub-optimal
or is perhaps more easily disturbed in pediatric patients. Twenty-two implants (15.2%)
were lost in children, whereas in the adult group 58 implants (7.3%) were lost, and 14
implants (7%) were lost in the elderly group. An assessment of implant stability, for
example, using resonance frequency analysis in the pediatric population might be
useful in testing this hypothesis.
An alternative to a percutaneous implant with abutment is transcutaneous coupling.
Transcutaneous bone conductors, if powerful enough, can provide a solution that
minimises adverse events and implant loss. Siegert et al. has described the principle
of a transcutaneous device with magnetic coupling.3,4 This bone conducting hearing
device needs one operation, has a low risk for complication, and a hearing gain
similar to other transcutaneous bone conducting devices. Sylvester et al. have
WYLZLU[LKÄYZ[YLZ\S[ZVM[OL:VWOVUV)VUL*VUK\J[PVU0TWSHU[PUH\KPVSVNPJHSNHPU
and increase in quality of life, however only in patients with conductive hearing loss,
not in patients with mixed hearing loss.5 Hol et al. have compared the Sophono to the
percutaneous Baha.6;OL:VWOVUVVMMLYZHWWLHSPUNJSPUPJHSILULÄ[ZHZH\KPVSVNPJHS
challenges remain; the Baha device had an output of 10 to 15 dB higher than the
Sophono device. For children with congenital conductive hearing loss, in which a
sensorineural hearing loss component in not uncommon, (10-15 dB lower output
might hinder the children in teaching situations. Denoyelle et al. has published results
of 6 children with conductive hearing loss because of ear atresia and their preliminary
results show satisfactory functional gain.7 ;OLZL YLZ\S[Z OH]L [V IL JVUÄYTLK VU
larger series of patients focusing on both auditory results and quality of life. The
optimal hearing level for children in teaching conditions is 15 dB or less but the mean
air conduction PTA with transcutaneous Sophono device in these studies was around 
30 dB HL.8
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Chapter 3 presents an assessment of patients’ opinion and satisfaction with the a 
BAHI CROS (contralateral routing of sound ) in patients with single sided deafness
(SSD). Chapter 3.1 analyses the changes in quality of life in the elderly BAHI CROS
population, studied by several quality-of-life instruments. It was shown that the elderly
patients would choose the BAHI again and would recommend them to others,
implying a high level of satisfaction. GBI, APHAB and NCIQ scores shows a general
increase in quality of life because of BAHI CROS use. Nine out of 11 patients were still
using their BAHI CROS. Although it can be speculated that elderly can have more
problems with relative small controls, they experienced none to little problems with
handling and cleaning of the device.
The amount of time that the elderly SSD patients use the BAHI CROS can roughly
be divided into two groups. One group that uses the BAHI CROS the entire day and 
a group that uses it 1 to 4 hours a day. Many patients, not just elderly, use the BAHI 
*96:MVYZWLJPÄJSPZ[LUPUNZP[\H[PVUZ;OL(7/()ZOV^LKZPNUPÄJHU[PTWYV]LTLU[Z
in listening in background noise, listening in reverberant conditions and the ease of 
communication. The limited amount of hours of BAHI CROS use in elderly might be
explained by a reduced amount of challenging listening situations. Although the
amount of hours use might be reduced, the importance for good hearing might
actually increase. The questions in the NCIQ concerning social interactions and 
activity limitations were rated as the most important. The NCIQ results in physical,
psychosocial and social aspects also show better outcomes in all of these domains.
The level of hearing impairment of the better hearing ear is relevant for
rehabilitation. In patients with a sensorineural hearing loss in the better hearing air, a
BICROS might be more suitable that can only be achieved with a conventional
air-conduction device. Consultation in the outpatient clinic should focus on the needs
and expectations of the elderly patient and the hearing levels in the better hearing ear
should be taken into account.
Chapter 3.2 describes characteristics of patients with SSD who have tested the BAHI 
as a CROS device on a headband. Characteristics were presented for two groups,
^OV ÄUHSS` LSLJ[LK MVY )(/0 *96: PTWSHU[H[PVU HUK [OVZL ^OV YLMYHPULK MYVT
implantation. These characteristics included listening situations, reasons to refrain
from a BAHI CROS, such as wearing a device behind the ear or cosmetic aspects of 
the BAHI CROS, tinnitus before headband trial and the aetiology of SSD. Such 
information can help with counselling.
Aside from hearing loss in the contralateral ear in the high frequencies and worse
pretesting hearing abilities, no relevant factors were found to predict the success of 
the BAHI CROS headband trial.
175
DISCUSSION
4
Patients with congenital SSD and patients with acquired SSD seem to form two
separate groups. Seven out of 11 patients with congenital SSD (64%) refrained from
a BAHI CROS, compared to 9 out of 19 patients (47%) with acquired SSD. This
V\[JVTLZ\WWVY[ZI\[JHUUV[JVUÄYT [OLO`WV[OLZPZ [OH[ [OLYL PZHKPMMLYLUJL PU
BAHI CROS appraisal between congenital and acquired SSD patients, as suggested
by Hol et al.9 It is conceivable that patients who are used to monaural hearing since
birth and never experienced binaural hearing have learned to cope with that situation 
TVYLLMMLJ[P]LS`[OHUWH[PLU[Z^OVKL]LSVWLK::+SH[LY PU SPML(\KPVSVNPJHSILULÄ[
might therefore be less in patients with congenital SSD opposed to patients with 
acquired SSD.
All the patients with subjectively good hearing abilities in the unaided situation 
seem less likely to opt for a BAHI CROS. The patients who did not choose the BAHI 
CROS reported little problems understanding people in a quiet or noisy environment. 
:V[OLH\KPVSVNPJHSILULÄ[VM[OL)(/0*96:HWWSPJH[PVU^V\SKOH]LILLUSPTP[LK
*VUZPKLYPUN[OLIHSHUJLVMILULÄ[ZHUKKYH^IHJRZHZPNUPÄJHU[YLWVY[LKKYH^IHJR
is the cosmetic aspect. Although a lot of development has gone in creating a smaller,
more aesthetic sound processor, the visibility of a handicap is often a reason to 
YLMYHPUMYVTOLHYPUNYLOHIPSP[H[PVU6US`^OLU[OLHTV\U[VMH\KPVSVNPJHSILULÄ[JHU
exceed the drawbacks, patients with SSD seem to choose a BAHI. The BAHI CROS 
ZVTL[PTLZSLHK[VILULÄ[PUV[OLYTVTLU[Z[VKPZ[\YIHUJLVMZWLLJOWLYJLW[PVU
Chapter 3.3 presents results of the long-term satisfaction of hearing intervention in 
patients with SSD that have had surgery for BAHI CROS application. About 20% of 
the SSD users stopped using their device. In the long term follow up of 29 patients, 
the APHAB showed a perceived increase of disability after 10 years in comparison to 
1 year after BAHI surgery. An enthusiasm bias at the 1 year evaluation might explain
the deterioration; patients were selected for a new sophisticated hearing device
which, initially, might have led to a moral obligation to like the device. A possible 
gradually adaptation to the hearing situation with the BAHI CROS might also play a 
role. 
7VZZPISL PUÅ\LUJL VM NLUKLY PU WH[PLU[Z» ZH[PZMHJ[PVU ^HZ PU]LZ[PNH[LK 5V
ZPNUPÄJHU[NLUKLYLMMLJ[Z^LYLMV\UK>LOH]LUV[L_HTPULKV[OLYJVUKP[PVUZ[OH[
may have affected the outcomes. Transcranial attenuation is a factor that we have not
[HRLUPU[VHJJV\U[I\[^ OPJOTPNO[OH]LWSH`LKHYVSLPUILULÄ[0[YLTHPUZPU[LYLZ[PUN
[V RUV^ MHJ[VYZ [OH[ PUÅ\LUJL ZH[PZMHJ[PVU^P[O [OL )(/0 *96:^OLU JVUZ\S[PUN
patients. As patients can have doubts about surgery and the idea of a visible hearing 
HPK P[ PZ PTWVY[HU[ [VTHRL HWH[PLU[ ZWLJPÄJ LZ[PTH[L VU [OLILULÄ[ :V MHY [OL
Z[\KPLZKPKU»[PKLU[PM`THQVYMHJ[VYZYLSH[LK[VILULÄ[
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In summary, this thesis evaluates the long term results of multiple years of BAHI
implant stability. In a large series of more than 1000 implants the BAHI proved to be
a safe and reliable implant with no adverse soft tissue reactions in the majority of 
patients (95.5%). In the early days of BAHI surgery, the abutment consisted of dead 
spaces which may have lead to an easy accumulation of bacteria. A new abutment 
without any dead space might bring this already low percentage of skin reactions
KV^U;OLZRPUYLHJ[PVUZ^LYLUV[PUÅ\LUJLKI`[OLWVZP[PVUVM[OLPTWSHU[VU[OL
skull. Recent research has shown that reducing the thickness of the skin around the 
implant might not be necessary. With the reduction of soft tissue, the reaction on
pathogens around the abutment might actually be reduced.
Studies on newly developed transcutaneous BAHIs have to prove if they indeed
HYL MYLL VM ZRPU YLHJ[PVUZ ^OPSL VMMLYPUN Z\MÄJPLU[ HTWSPÄJH[PVU ;OL V]LYHSS )(/0
implant failure rate was 8.3% with the highest results in children and mentally retarded
WH[PLU[Z 0TWSHU[KLZPNUOHZ PTWYV]LKZPNUPÄJHU[S`V]LY [OL`LHYZ9LJLU[S` P[^HZ
suggested using nanotechnology to create a grooved surface of the implant, what
might create better osseointegration. Diabetes mellitus seems to be an unfavourable
condition with respect to implant loss and future research may focus on the value of 
WYLVWLYH[P]LZJYLLUPUNMVY+44LHZ\YLTLU[VM0:8]HS\LZTH`ILOLSWM\S[VÄUK[OL
best loading moment. It cannot be excluded that the innovations in implant technology
might lead to immediate loading of the implant after surgery if the ISQ value exceeds
a certain value. This implant research has already reduced loading time to three 
weeks. The cone beam CT scan can perhaps support the research in creating an
image of the level of osseointegration.
;OPZ [OLZPZOHZZOV^U[OLILULÄ[VM)(/0*96:HWWSPJH[PVU PU ZLSLJ[LKWH[PLU[Z
^P[O ::+ (SZV PU [OL LSKLYS` WVW\SH[PVU WH[PLU[Z L_WLYPLUJL ILULÄ[ VM [OL )(/0
CROS. Once patients underwent implant surgery, long term results are good with a
KPZJVU[PU\H[PVUVM Q\Z[  -HJ[VYZ [OH[ PUÅ\LUJL [OLKLJPZPVU [V VW[ MVY H)(/0
could not be established with certainty. Patients with congenital SSD seem to be less
easy to convince than patients with acquired SSD. New studies should focus on and
evaluate this difference and others factors like the hearing thresholds in the better
hearing ear. 
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Summary
The bone anchored hearing implant (BAHI) is a well established option for hearing
rehabilitation by means of bone conduction. The three main components of the BAHI
are a screw shaped implant, surgically placed in the mastoid portion of the temporal
IVULVU^OPJOHWLYJ\[HULV\ZHI\[TLU[PZÄ_H[LK(ZV\UKWYVJLZZVYPZZUHWWLK
on to the abutment and enables sound vibrations to be transmitted to the cochlea via
bone conduction.
)HZPJYLZLHYJOHUKJSPUPJHS^VYROH]LHK]HUJLKJVUZPKLYHIS`ZPUJL[OLÄYZ[WH[PLU[
^HZÄ[[LK^P[OH)(/0 PU 4VYLRUV^SLKNL PZH]HPSHISL [OHUL]LYILMVYL^P[O
better implants, more sophisticated signal processing and several designs from
different manufacturers are available today. Audiological outcomes and quality of life
results have shown the effectiveness of BAHI treatment. However, the BAHI has
some drawbacks like skin reactions around the abutment and loss of the implant;
WVVYIVULX\HSP[`TPNO[ULNH[P]LS`PUÅ\LUJLVZZLVPU[LNYH[PVUHUK[OLZRPUWLUL[YH[PUN
abutment is prone to infections. Characteristics of the implant and skin reactions are
described in chapter 2.
:L]LYHSMHJ[VYZHYLRUV^U[VPUÅ\LUJL[OLJVUKP[PVUVMZRPUHUKIVUL+H[HHIV\[[OL
implant location and skin thickness was gathered to evaluate their effect on the
frequency and degree of skin reactions around the abutment. The average implant
location in a random sample of 248 implants was 48 mm from the external ear canal
and the mean skin thickness was 5.5 mm. No relation was established between
implant location or skin thickness and the frequency and severity of skin reactions or
implant loss.
0TWSHU[ SVZZTPNO[ VJJ\Y ^OLU [OL PTWSHU[ PZ UV[ Z\MÄJPLU[S` PU JVU[HJ[ ^P[O
bone, called osseointegration. Diabetes mellitus (DM) leads to an altered process of 
bone remodelling and the osseointegration might be suboptimal. A large series of 
  PTWSHU[ZPU[OLÄYZ[`LHYZVM)(/0PTWSHU[H[PVUPU5PQTLNLU^HZKP]PKLKPU[V
two groups; patients with established DM and patients without DM. An overall implant
survival rate of 90% was found,  the prevalence of DM was 9.3%. A statistical
difference in implant loss was found in a subpopulation of 739 implants in patients
over 40 years of age; in the group without DM, 5.1% of the implants were lost versus
14% in the group of diagnosed DM patients. In the workup of candidates for BAHI
implantation, their blood glucose level may be helpful for counseling purposes.
To optimise osseointegration, new implant designs have been introduced. Owing
to better bone-implant interaction, loading the implant as early as three weeks after
surgery is considered as safe. Short-term implant survival, stability changes, and skin
reactions from the initial implantation to 6 months post implantation are described in
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29 patients. Implant stability quotient (ISQ) values were recorded periodically in order
[VOH]LHTVYLVIQLJ[P]LTLHZ\YLVM PTWSHU[ Ä_H[PVU PU [OLIVUL;OL 0:8]HS\LZ
YLHJOLKP[ZIHZLSPUL]HS\L^P[OPU[OYLL^LLRZHUKÄ[[PUNVM[OLZV\UKWYVJLZZVYKPK
not affect the ISQ values.
An analysis of 1132 implants placed in the period between 1988and 2007
showed an overall amount of implant loss of 8.3% and absence of an adverse skin
YLHJ[PVUPU VM[OLV\[WH[PLU[JSPUPJ]PZP[Z:PNUPÄJHU[S`TVYLZVM[[PZZ\LYLHJ[PVUZ
and implant failures were observed in children and implant survival was lower in
patients with mental retardation. Special care needs to be taken in consultation and
cleaning of the skin in these groups.
The indication for the BAHI has been established for a variety of unilateral and bilateral
types of hearing loss, including conductive hearing loss, mixed hearing loss, and
profound unilateral sensorineural hearing loss, which is also known as single-sided
deafness (SSD). SSD is sensorineural hearing loss in one ear with (near) normal
contralateral hearing function. Patients with SSD may have adapted to one sided
OLHYPUNI\[[OL`L_WLYPLUJLKPMÄJ\S[PLZ^OLU[OLZV\UKZV\YJLPZWVZP[PVULKVU[OL
impaired side. Chapter 3 presents the results of satisfaction in SSD patients
rehabilitated with the BAHI as a contralateral routing of sound (CROS) device.
Elderly BAHI CROS patients with SSD and possibly presbycusis in the better-hearing 
ear are presumed to be a special group within this group of SSD because they might
ULLK OLHYPUN HTWSPÄJH[PVU L]LU TVYL [OHU [OVZL ^P[OV\[ WYLZI`J\ZPZ PU [OL
better-hearing ear. Eleven SSD patients over 60 years of age were evaluated, 9 were
Z[PSS\ZPUN[OLKL]PJLHUKVM[OLT^LYLZ[PSSZH[PZÄLK;OL`L_WLYPLUJLKUV[VSP[[SL
problems with handling and cleaning of the device and the outcomes of quality of life
questionnaires indicated a high level of satisfaction.
;VKL[LYTPUL [OL SL]LSVMILULÄ[HUKZH[PZMHJ[PVU^P[O [OLKL]PJLILMVYL)(/0
surgery, a headband trial is conducted where the patient uses the BAHI CROS for at 
least a week. Factors determining the success of the headband are not well
established. The evaluation of the factors; listening situations, cosmetic aspects of 
[OLKL]PJL[PUUP[\ZHUK[OLHL[PVSVN`VM::+KPKUV[YL]LHSHUPUÅ\LUJLPU[OLKLJPZPVU
to opt for a BAHI CROS. Patients with subjectively good hearing abilities in the
unaided situation are less likely to opt for a BAHI CROS. Therefore, it is important to
be aware of patients hearing capabilities and subjective hearing handicap estimation
in the counselling of SSD patients to create a realistic expectation of the BAHI
headband trial.
The long term results of satisfaction of the BAHI in SSD patients were analysed
in 135 patients. For the entire group, 112 patients (83,0%) were still using the device
HM[LYHUH]LYHNLVM`LHYZMVSSV^\W0U[OLNYV\WVM[OLÄYZ[ PTWSHU[LKWH[PLU[Z
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18 of the contacted 26 patients (69,2%) were using the BAHI on a daily basis after a
follow-up period of 10 years. This suggests an effect of the time of device use on
discontinuation of BAHI use. Quality of life and satisfaction was evaluated too,
OV^L]LYVUS`PU[OLNYV\WVM)(/0\ZLYZ5VZ[H[PZ[PJHSKPMMLYLUJLPUWYVÄ[^HZMV\UK
H[ZL]LYHSWVPU[Z PU[PTL;OLZH[PZMHJ[PVU^P[O[OL)(/0^HZUV[ PUÅ\LUJLKI`[OL
factor gender, age, directional hearing ability, the appearance of the device and
handling of the device.
In general this thesis describes the basic characteristics of the BAHI implant and
attempt to optimise them. The consequences for the patient are described in terms
of complications and best loading moment of the implant. Another objective is to
assess patients’ opinion and satisfaction with the BAHI CROS for patients with single
sided deafness.
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Samenvatting
Het botverankerd hoortoestel, waarvoor momenteel de overkoepelende term Bone
Anchored Hearing Implant (BAHI) wordt gebruikt, is een welbekende manier van ge-
hoorrevalidatie voor patiënten met conductief of gemengd gehoorverlies en patiënten
met eenzijdige doofheid, ook wel single-sided deafness (SSD) genoemd. De BAHI
bestaat uit drie elementen; het implantaat welke operatief in het schedelbot achter
OL[VVYVZ[LTWVYHSL^VYK[NLWSHH[Z["OL[HI\[TLU[LLURVWWLSZ[\R^H[NLÄ_LLYK
wordt op het implantaat en door de huid steekt; en de geluidsprocessor welke op het
abutment wordt geklikt en zorgt voor de geluidstransductie via beengeleiding naar
het slakkenhuis.
In de afgelopen 25 jaar heeft de BAHI zijn effectiviteit meer dan bewezen. De 
audiologische voordelen voor de patiënt en toegenomen kwaliteit van leven zijn 
bekend, toch zijn er ook enige nadelen van de BAHI te noemen. Het feit dat
huidreacties zich voor kunnen doen en het implantaat los van het bot kan komen, zijn
belangrijke complicaties om te vermelden. Onderzoek naar verschillende factoren die
hierop van invloed zouden kunnen zijn, is om die reden erg relevant en heeft
bijvoorbeeld al aangetoond dat huidziekten in de vorm van psoriasis en eczeem hier
een negatieve invloed op hebben. In hoofdstuk 2.1 van dit proefschrift is gekeken
naar de locatie van het implantaat achter het oor en de dikte van de huid waarbij geen
relatie is gevonden tussen deze factoren en de mate van huidreacties of verlies van
het implantaat. Diabetes Mellitus (DM) daarentegen blijkt wel een verhoogde kans op
implantaat verlies te geven. In hoofdstuk 2.2 wordt een grote retrospectieve groep
van 739 implantaten beschreven. Er wordt een implantaatverlies van 5,1% gevonden
bij patiënten met DM tegenover 14% bij patiënten zonder DM. Dit zou verklaard
kunnen worden door een verminderde verankering van het implantaat in het bot,
aangezien DM tot een veranderde botopbouw leidt en zo verminderde botkwaliteit en
verminderde stabiliteit van het implantaat kan geven. Om een maat voor deze bot – 
implantaat interactie te verkrijgen is het mogelijk een implantaat stabiliteit quotiënt
(ISQ) te meten. Hoofdstuk 2.3 beschrijft analyses van de ISQ-waarden, waarbij de
sound processor drie weken na implantatie, in plaats van de gebruikelijke 6-12 weken
wordt geplaatst. Dit blijkt geen problemen te geven in de vorm van implantaatverlies 
of huidreacties, in elk geval tot 6 maanden na implantatie.
Een grote analyse van 1.132 implantaten, geplaatst in de afgelopen 20 jaar in
Nijmegen, toont in hoofdstuk 2.4 een totaal implantaatverlies van 8,3% en een
ernstige huidreactie werd gevonden in slechts 4,5% van de polikliniekbezoeken. Er
^LYKLUZPNUPÄJHU[TLLYO\PKYLHJ[PLZNL]VUKLUIPQRPUKLYLULUTLLYPTWSHU[HH[]LY-
lies bij kinderen en patiënten met een mentale retardatie. Deze groepen zouden
gebaat zijn bijbetere voorlichting en meer aandacht aan reiniging van de huid.
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Naast klinische aspecten van het implantaat worden resultaten en opinie over de
BAHI bij patiënten met SSD beschreven. Bij deze groep patiënten kan adaptatie
optreden in het omgaan met hun eenzijdige doofheid. Een aantal blijkt in staat om
een functioneel gehoor te creëren om te kunnen verstaan in groepen en hun beroep
uit te oefenen, anderen hebben hier meer moeite mee. Voor gehoorrevalidatie wordt
de BAHI toegepast om het geluid aan de aangedane zijde om te leiden naar het beter
horende oor. Oudere patiënten met SSD zouden wellicht meer versterking van het
NLS\PKUVKPNOLIILUVT]VSKVLUKLWYVÄQ[[LLY]HYLU]HULLU)(/0THHYLLUHUHS`ZL
in hoofdstuk 3.1 toont een hoge mate van kwaliteit van leven aan zonder dat er
problemen werden aangegeven met het hanteren van het toestel of schoonmaken
van de huid.
Het is van belang preoperatief een realistisch beeld te kunnen schetsen van het
te verwachten effect van de BAHI. Heden ten dage wordt een hoofdband test
uitgevoerd, waarbij patiënten de BAHI ten minste een week op proef hebben.
Hoofdstuk 3.2 beschrijft een evaluatie van deze test welke aantoont dat patiënten
met SSD en een relatief goed gehoor aan het enig horende oor minder snel voor de
BAHI kiezen. Het cosmetische aspect speelde geen rol, noch oorsuizen of de
oorzaak van de SSD. Indien SSD-patiënten voor een BAHI kiezen, blijven de meeste
gebruikers enthousiast. Het percentage SSD-patiënten dat is gestopt de BAHI te
gebruiken is 83% na gemiddeld 5 jaar en 69% na gemiddeld 10 jaar. In hoofdstuk 3.3
wordt een grote groep van 135 patiënten over 20 jaar beschreven met op verschillende
momenten in de tijd een vergelijkbare tevredenheid. De mate van tevredenheid werd 
niet beïnvloed door het geslacht, leeftijd, de mate van richtinghoren of het uiterlijk en
hantering van het apparaat.
Samenvattend beschrijft dit proefschrift de klinische aspecten van de BAHI in de
vorm van complicaties en implantaatkarakteristieken, Daarnaast wordt de mate van 
tevredenheid op de lange termijn beschreven bij SSD patiënten.
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Dankwoord
Het dankwoord kan ik gebruiken om de vele mensen te kunnen bedanken die direct
of indirect bij dit proefschrift zijn betrokken. Een wijs man heeft mij eens verteld dat
promoveren bestaat uit 1% inspiratie en 99% transpiratie. Die inspiratie en transpiratie
zijn niet alleen van mij afkomstig, maar van meerderen van wie ik een aantal mensen
via deze weg graag wil bedanken.
Allereerst de patiënten die belangeloos hun tijd en moeite hebben gestoken in het
meewerken bij de onderzoeken met betrekking tot hun BAHI. Door het invullen van
de vragenlijsten en bezoeken aan de polikliniek hebben we waardevolle data kunnen 
verzamelen die nieuwe patiënten met een BAHI kunnen en zullen helpen.
Grote dank ben ik verschuldigd aan professor Cremers. Met name bij het schrijven
van de inleiding van dit proefschrift heb ik een kijkje in uw keuken gekregen van het
LMÄJPwU[LUIL]SVNLUZJOYPQ]LU]HUZ[\RRLU,LU]HRHU[PLTL[ RSLPURPUKLYLU^LYK
moeiteloos afgewisseld met het beoordelen en aanvullen van stukken die ik uw kant
op zond. Het lijkt me fair om te stellen dat zonder uw bezielende begeleiding dit
proefschrift er nog niet zou hebben gelegen. Het feit dat er reeds meer dan 50
promovendi mij voor zijn gegaan zegt voldoende over de daadkracht en het 
enthousiasme waar u mee werkt. 
Beste Ad, professor Snik, de manier waarop je naar door mij geschreven tekst hebt
gekeken kan ik bewonderen. Je hebt een totale overview over de stof en je hebt me
daarmee regelmatig aan het denken gezet over nieuwe inzichten in de materie die ik 
nog niet had gezien. Jouw kritische blik heeft menig stuk meer diepgang gegeven. 
Dit alles weet je op een zeer prettige manier over te brengen en ik ben erg dankbaar
dat je zo nauw betrokken bent bij mijn promotie.
Beste Myrthe, de meeste tekst in mijn dankwoord moet ik eigenlijk aan jou besteden,
aangezien ik de meeste dank aan jou ben verschuldigd. Als we het hebben over
inspiratie en transpiratie dan heb je beide facetten ten volste in mijn proefschrift
verwerkt. Je bent een uitmuntende begeleidster: je inspireert met nieuwe onderzoeken
en jouw bevlogenheid voor onderzoek werkt aanstekelijk. Je bent te allen tijde
bereikbaar voor overleg en naar jou opgestuurde stukken werden regelmatig dezelfde
avond nog kritisch beoordeeld. Dank Sander, dat ik je vrouw hiervoor af en toe kon
JVUÄZX\LYLU 0R KLUR KH[ KL JVTIPUH[PL ]HU QV\^ VYNHUPZH[PLR\UKL LU WSHUUPUN
goed aansluit op mijn manier van werken naar deadlines, waardoor er nu een boekje 
ligt. Maar ik zou je tekort doen door alleen de vakinhoudelijke kanten te benoemen. 
Naast een organisator en planner ben je namelijk een warm en begripvol mens die op 
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de momenten dat het onderzoek minder vlotte mij op een aanmoedigende manier 
mijn weg liet gaan om uiteindelijk tot een mooi resultaat te komen, het proefschrift. 
Zeer veel dank.
De eerste onderzoeksstappen heb ik gezet bij Emmanuel Mylanus. Nog als medisch 
student uit Utrecht hebben we samen mijn eerste artikel geschreven en daarmee
werden een aantal zaken mij duidelijk. Namelijk dat onderzoek toch wel erg leuk is, 
^HU[ PR]VUKOL[OLLYSPQR]VSSLKPN PULLUZWLJPÄLRVUKLY^LYW[LK\PRLU=LYKLYKH[
KNO in Nijmegen inderdaad zo goed is als ik erover gehoord had. Dank voor die 
eerste stappen in Nijmegen en in het onderzoek. Je hebt destijds mijn goede gevoel
bij Nijmegen volledig bevestigd door me warm te ontvangen en enthousiast te begeleiden. 
Ik had destijds niet kunnen voorzien dat die stapel statussen en röntgenfoto’s zouden 
uitmonden in een volledig proefschrift.
Leden van de manuscriptcommissie, prof. dr. de Groot, prof. dr. Dhooge en prof. dr.
Meijer, hartelijk dank dat u het manuscript hebt willen beoordelen.
Mooi dat jullie, Maarten en Jacolien hebben toegezegd als paranimfen voor bij de 
promotie. Jullie zijn twee mensen die verstrengeld zitten in dit proefschrift. Maarten,
toen ik hier zat als 'onderzoeksgroentje' kon ik bij jou de vragen stellen over SPSS en
RVUQLTLKL^LN^PQaLUUHHYZPNUPÄJHU[PL4HHYUHHZ[KL]LSL)(/0NLZWYLRRLUPZ
het af en toe ook gelukt om de weg naar de golfbaan te vinden. De volgende keer
hopelijk alleen zonder regen en onweer, dat speelt wat lekkerder. Jacolien, jouw 
ondersteuning voor dit proefschrift is ongekend. Naast jouw eigen onderzoek en
vervolgens opleiding wist je tijd vrij te maken om mee te schrijven aan stukken die in 
dit boekje staan gedrukt. Ik wil je daar ontzettend voor bedanken en vind het erg leuk 
dat je als mede BAHI-onderzoeker mijn promotie dag meebeleeft.
Waar het onderzoek met de BAHI wordt voortgezet komt Rik in beeld. Dank voor je
betrokkenheid bij enkele publicaties en ik wens je veel succes met de volgende serie 
aan publicaties over de BAHI.
Op deze plek ook dank aan Laura en Hanneke, met wie twee leuke stukken zijn 
geschreven. Het was prettig om met jullie samen te werken en hopelijk vinden jullie 
een mooie specialisatie waar jullie talenten goed benut kunnen worden. Hanneke, ik 
ben benieuwd of er van jou ook een boekje komt, maar dan in de longziekten.
De ondersteunende rol van het VAC kan ik nu ook mooi bedanken en dan met name
Mieki, Herman en Teja die zich bezig houden met patiënten met een BAHI. Natuurlijk 
dan ook dank aan Carine Hendriks voor het regelen van de vele organisatorische
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zaken die af en toe onbelicht blijven. Zo ook de secretaresses, verpleging, balie- en
archiefmedewerkers voor het ophalen van statussen en ondersteuning op de poli.
Dank aan Diny Helsper voor het vervaardigen van een manuscript wat naar de ma-
nuscriptcommissie kon worden gestuurd. Dat dit samen viel samen met werken in 
weekenden en zelfs de vierdaagse maakt dat extra bijzonder.
Hierbij kan ik ook mijn dank opschrijven aan de staf van de Keel-, Neus-, en Oorheel-
kunde van het UMC St Radboud voor de mogelijkheid en het vertrouwen om de opleiding
tot KNO-arts te kunnen volgen. Speciale dank gaat daarbij uit naar prof. dr. Marres
en dr. van den Hoogen voor de geboden tijd om het onderzoek af te kunnen ronden.
Zo vlak na de KNO-lympische spelen waar we als AIOS uit Nijmegen weer een
klinkende overwinning hebben bijgeschreven op de bokaal is één ding weer duidelijk.
Niet zozeer dat we ‘sporhef’ zijn en willen winnen, maar dat we een hechte groep 
mensen zijn die gezelligheid niet bepaald uit de weg gaat. In de overstap naar
Nijmegen zijn Inge en ik in een warm nest beland waarbij ik iedereen van de
assistenten kan bedanken. Ferdinand, Robert Jan, Godelieve, Jan-Willem, Olivier,
Bart, George, Stijn, Veronique, Hans,  Louise, Rabia, Jimmie, Maarten, Erik, Arthur,
Richard, Joost, Annemarie, Eline, Caroline, Ingrid, Rik, Henrieke, Ruud, Jasmijn,
Anne, Saskia, Josephine, Thijs en Lisette dank voor een goede tijd!
Lieve Jeroen, ik ben blij dat we samen dingen kunnen doen die we allebei mooi 
vinden. De eerste stappen werden achter jou aan gezet de kroeg in bij Bu in Utrecht.
Van de racerij tot aan het golfen hebben we mooie ervaringen gehad en ik kijk er naar
uit er nog een aantal bij te schrijven. Ik geniet er van samen met jou op pad te gaan
en kijk er naar uit dit nog veel te gaan blijven doen. Dat Otis jouw naam heeft  gekregen
is een kleine geste voor een groot gevoel wat er voor jou is.
Lieve Quirine, qua gevoelens en gedachten over vele zaken zitten we vaak op één lijn.
Ik wil je bedanken voor je luisterend oor en goede adviezen die je me hebt gegeven
zodat ik met frisse zin weer verder kon gaan met schrijven. 
Lieve papa en mama, ik ben jullie dankbaar voor het gezin waarin jullie mij hebben
laten opgroeien. Ik kan niet  anders zeggen dan dat ik een onbezorgde jeugd heb
gehad en dat heb ik grotendeels aan jullie te danken. Mam, dank voor al je medeleven 
met ons gezin en je vaak attente kaartjes om me succes te wensen voor onder
andere het afschrijven van het proefschrift.
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Lieve Inge, jouw rust in huis en ons gezinnetje heeft mij de ruimte gegeven om in 
de avonden en weekenden door te kunnen werken aan dit proefschrift. Ik heb
bewondering voor hoe je voor Mauk en Otis zorgt en ondertussen alles zo regelt dat
ik daardoor vrij in mijn hoofd kan zijn voor de promotie. We kennen elkaar al vanaf de 
schooltijd en dat zal nog lang zo zijn. Dank lieverd dat we nog steeds samen zijn en ik 
geniet nog elke dag van je.
Mauk, Otis en jullie nieuwe broertje. Wat zijn jullie waanzinnig lekkere mannetjes! Het
duurt nog wel even voordat jullie dit überhaupt kunnen lezen (en dan wordt ‘überhaupt’ 
een lastig woord bedenk ik me nu), maar jullie geven me zoveel lol als ik weer thuis
ben. Door met jullie met de treintjes en autootjes te spelen kunnen jullie me heerlijk 
HÅLPKLU]HUOL[NLLULYOPLY]VVYTLSPN[6VRQ\SSPLILKHUR[]VVYQ\SSPLYVSPUKP[IVLRQL
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Hubert Thiadrik Faber werd als jongste van 3 kinderen op 10 augustus 1979 geboren
te De Bilt. Na het behalen van het eindexamen aan het Christelijk Gymnasium Utrecht
in 1997 heeft hij gedurende driekwart jaar in Australië, Nieuw-Zeeland en Indonesië
gewerkt en rondgereisd. De wens om geneeskunde te studeren leidde door numerus
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werd behaald. Hij heeft twee jaar Geneeskunde gestudeerd aan de Katholieke
Universiteit te Leuven. De studie geneeskunde is vervolgd in Utrecht waarbij tijdens
de studie een keuze co-schap op de afdeling KNO-heelkunde is gevolgd in het UMC 
Utrecht begeleid door prof. dr. W. Grolman. Onderzoek is gedaan op de afdeling
KNO-heelkunde van het Universitair Medisch Centrum St. Radboud te Nijmegen 
naar de locatie van het BAHI implantaat en de invloed hiervan op het voorkomen van
complicaties onder begeleiding van dr. E.A.M. Mylanus en prof. dr. C.W.R.J. Cremers.
Het artsexamen werd in 2010 behaald, waarna aansluitend gestart werd met de
opleiding tot keel- neus- en oorarts in het UMC St. Radboud. Thans is hij in opleiding
onder prof. dr. H.A.M. Marres en opleider F.J.A. van den Hoogen. Zijn perifere stage
werd gelopen in het CWZ te Nijmegen onder leiding van J.A.M. Engel. Daarnaast is 
het BAHI-onderzoek voortgezet onder leiding van prof. dr. C.W.R.J. Cremers en prof.
ir. A.F.M. Snik wat heeft geresulteerd in dit proefschrift.
Hubert Faber woont samen met Inge Hoeve en samen hebben zij twee kinderen,
Mauk Louis (18-12-2009) en Otis Tjibbe Jeroen (22-6-2011).
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List of abbreviations
AC Air conduction
AL Activity limitations
(7/() (IIYL]PH[LKWYVÄSLVMOLHYPUNHPKILULÄ[
ASP Advanced sound perception
AV Aversiveness of sounds
Baha Bone anchored hearing aid
BAHI Bone Anchored Hearing Implant
BC Bone conduction
BCD Bone Conduction Device
BN Background noise
BSP Basic sound perception
*7/0 *VTT\UPJH[PVU7YVÄSLMVY[OL/LHYPUN0TWHPYLK
CROS Contralateral Routing of Signal
CT Computed Tomography
DM Diabetes Mellitus
EC Ease of communication
FHP Frankfurter Horizontal Plane
.)0 .SHZNV^ILULÄ[PU]LU[VY`
./()7 .SHZNV^/LHYPUN(PK)LULÄ[7YVÄSL
HHIE-S Hearing handicap inventory for the elderly-screening version
HL Hearing Loss
ISQ Implant Stability Quotient
NAL-N-L National Acoustics Laboratory-Non-Linear
NCIQ Nijmegen Cochlear Implant Questionnaire
PTAac Pure tone average at frequencies of 0.5, 1, 2 and 4 kHz for air conduction
QoL Quality of Life
RFA Resonance Frequency Analysis
RV Communication in reverberant rooms
SD standard deviation
SE Self-esteem
SI Social interactions
SP Speech production
SSQ Speech, Spatial and Qualities of hearing
UCHL Unilateral Conductive Hearing Loss
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